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ABSTRACT 
 
Duchenne muscular dystrophy (DMD) is a muscle-wasting disease caused by the loss of 
sarcolemmal protein dystrophin. In DMD and the mouse model of the disease mdx, there 
is an increase in an associated protein, caveolin-3. In this study, mdx mice with 
deficiencies in caveolin-3 were generated to allow a distinction to be made between the 
pathology caused by the loss of dystrophin and that caused by an excess of caveolin-3.   
 
It was found that in late gestation embryos, there were perturbations in skeletal muscle 
stem cell populations and depletion of respiratory muscles in mdx and mdx/cav3+/-, both 
of which were more severe in mdx/cav3+/- embryos. In post natal skeletal muscles, there 
was a trend in that the level of regeneration, believed to be indicative of previous 
degeneration, was consistently greater in mdx than mdx/cav3-/-. Taken together it would 
appear whereas increased caveolin-3 may compensate for the lack of dystrophin in 
embryonic mdx muscle; post natally, it may contribute to the muscle regeneration 
observed in mdx.  
 
The data presented in this thesis should help towards clarifying the contribution of 
caveolin-3 in the pathogenesis of DMD and in doing so expand on the understanding of 
the molecular aetiology of the disease.         
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CHAPTER 1 – INTRODUCTION 
 
This thesis focuses on the muscle-specific protein caveolin-3 and the histological 
pathogenesis of the mdx mouse, an animal model for Duchenne muscular dystrophy 
(DMD).  It has been known for more than a decade that caveolin-3 is upregulated in both 
mdx mouse and males’ suffering with DMD and was suggested the upregulation of 
caveolin-3 contributed to the observed pathogenesis. In order to investigate this further, 
mdx mice with hypophysiological levels of caveolin-3 and mdx mice deficient in caveolin-
3 were generated and analyses made using haematoxylin and eosin staining, 
immunohistochemistry and immunoblotting (which shall be referred to as western 
blotting throughout this thesis) on embryonic and adult tissues. The analyses of 
embryonic tissue in a disease that is generally believed to initially present with the 
dystrophic phenotype postnatally is justified in light of recent data, that suggests the 
dystrophic phenotype has an embryonic origin.   
 
1.1 - Muscular dystrophy 
The muscular dystrophies are a group of around seventy inheritable skeletal muscle-
specific diseases distinct from other myopathies in that there is no associated neuro-
degeneration, they are characterised by progressive muscle degeneration and 
subsequent loss of strength. Like other myopathies, there is usually an increase in serum 
creatine kinase. Histologically, dystrophic muscle tissue contains areas of 
degeneration/regeneration and necrosis with fibres of varying sizes and areas of 
connective and adipose tissue. Many muscular dystrophies are the result of genetic 
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mutations of the genes encoding proteins of the dystrophin-associated glycoprotein 
complex (DGC). Muscular dystrophies were initially classified into three principal 
groups; Duchenne – the most common and severe type (section 1.1.1), limb-girdle and 
facioscapulohumeral and three rarer groups; distal, oculopharyngeal and congenital, 
depending on the anatomical location of the affected muscles. They are classified today 
following histological, molecular and genetic analysis of the patient  (Edmondson and 
Olson, 1989). 
 
 Image from - http://www.patient.co.uk/health/Muscular-Dystrophies-An-Overview.htm 
Figure 1.1 - Illustration showing five different types of muscular dystrophy.   
DMD, the most severe of all the muscular dystrophies affects most of the muscles in the 
body, while others affect specific areas. Many present with cardiomyopathy also. 
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1.1.1 - Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is the most common and debilitating of all 
muscular dystrophies, it is characterised by progressive global muscle degeneration 
resulting in subsequent loss of strength and impaired mobility (Meryon, 1851). 
Although eponymously named after Guillaume-Benjamin Amand Duchenne de Boulogne 
following his report in 1861, the disease was initially described by Edward Meryon ten 
years previously. Prior to the disease being known as Duchenne dystrophy or Meryon’s 
disease, it was referred to as pseudohypertrophic muscular dystrophy due to the 
pronounced calf enlargement exhibited by many with the disease; this name however 
was not accurate as not all displayed the pseudohypertrophic phenotype and this 
particular phenotype was also seen in other types of muscular dystrophy (Walton, 
1956). DMD occurs as a result of a mutation of the dystrophin (DMD) gene, located on 
chromosome Xp21, which results in the absence of sarcolemmal protein dystrophin 
(section 1.3.1). Dystrophin is an integral protein of the DGC (section 1.3) and its 
absence results in the breakdown of the DGC. There is also a concomitant increase in 
DGC associated protein caveolin-3 (section 1.3.2) (Repetto et al., 1999). Microarray 
analysis has provided data showing that many genes are differentially expressed in DMD 
muscle compared to healthy muscle and that there is a correlation between pathological 
severity and the degree of differential gene expression (Haslett et al., 2002; Porter et al., 
2002; Noguchi et al., 2003). DMD effects 1/3,500 live male births, making it the second 
most common single gene disorder thus far identified next to cystic fibrosis (Repetto et 
al., 1999). Although an inheritable genetic disorder, one third of all cases arise via 
spontaneous mutations within the DMD gene. As the disease is X-linked, far more males 
than females are affected by the disease however, between 1993 and 1999, four of the 
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three hundred and fifty-five deaths due to DMD in England and Wales were female 
(Calvert et al., 2006). This figure represents 1.1 % of mortalities recorded. Symptoms 
usually manifest when the infant exhibits difficulty with ambulation and in the absence 
of any familial history of the disease, a diagnosis given between the ages of three and 
five; by which time the disease has had a profound effect on the child’s mobility. Disease 
progression is such that loss of independent ambulation occurs at an average age of nine 
(Eagle et al., 2002). If left untreated death usually occurs in the mid-to-late teens, 56 % 
of mortalities due to respiratory failure although in 95 % of cases there is also 
cardiomyopathy (Walton and Nattrass, 1954; Cox and Kunkel, 1997; Calvert et al., 2006). 
Though the general consensus that the malady of DMD becomes symptomatic during the 
child’s early ambulatory years, knowledge of increased serum creatine kinase levels in 
DMD neonates has been known for many years and more efficient means of identifying 
the disease developed, with a view to earlier treatments (Zellweger and Antonik, 1975). 
 
One aspect of DMD that has received far less research is the effect the loss of dystrophin 
has on brain physiology. Studies evaluating cognitive function have shown that DMD 
boys have cognitive impairment and a lower average IQ than healthy subjects; 
moreover, incidents of autism spectrum disorder/persuasive developmental disorder 
are far more prevalent in DMD boys than in the general population (Anderson et al., 
2002; Wu et al., 2005).  
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Figure 1.2 - Two signs synonymous with DMD. (A) To rise from the floor, ambulatory 
DMD boys must use what is referred to as the ‘Gower’s sign’, a manoeuvre whereby the 
arms are used to help straighten the legs and trunk until an upright position is achieved. 
(B) Enlarged calf muscles are a common feature of DMD, but as the enlargement is due 
to an accumulation of adipose and connective tissue rather than muscular hypertrophy, 
the condition is referred to as ‘pseudohypertophy’.     
 
1.1.2 - Limb-girdle muscular dystrophy  
The limb-girdle muscular dystrophies (LGMD) are a heterogeneous group of muscular 
dystrophies that affect skeletal muscles of the shoulders, hips and proximal limbs. As 
A 
B 
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with all muscular dystrophies this manifests in the degeneration of effected muscles and 
subsequent loss of strength; cardiomyopathy may or may not accompany the disease 
(Mathews and Moore, 2003). There are a total of twenty-two limb-girdle muscular 
dystrophies thus far identified, which are sub-divided into types 1 and 2; type-1 are 
inherited in an autosomal dominant manner and includes the caveolinopathy LGMD type 
1C (LGMD-1C) whereas type-2 are inherited in an autosomal recessive manner and 
includes the sarcoglycanopathies (LGMD-2C-F) (Gordon et al., revised 2009). 
Cardiomyopathy is often present in all sarcoglycanopathies, with the exception of 
LGMD-2D (α-sarcoglycanopathy), perhaps due to the substitution of α-sarcoglycan with 
ε-sarcoglycan in smooth muscle and as a consequence no loss of sarcoglycan complex 
integrity in the plasma membrane of the coronary artery endothelium (Straub et al., 
1999).   
 
1.1.3 - Limb-girdle muscular dystrophy type 1C (LGMD-1C) 
LGMD-1C was the third of the autosomal dominant limb-girdle muscular dystrophies to 
be recognised and is caused by the absence of sarcolemmal protein caveolin-3 (McNally 
et al., 1998; Minetti et al., 1998). The disease generally progresses at a far slower rate 
than the more severe DMD and muscle degeneration and weakness is limited to muscles 
of the shoulders, hips and proximal limbs; mortality as a consequence of LGMD-1C is 
rare. There are several mutations associated with LGMD-1C, the first two identified were 
a missense mutation that substitutes a proline for a leucine (P104L) in the 
transmembrane domain of caveolin-3 and a micro-deletion of nine base pairs that result 
in the removal of the amino acid sequence of threonine, phenylalanine, threonine (TFT) 
in the scaffolding region of the protein (Minetti et al., 1998). Other mutations identified 
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include a G55S and a C71W (McNally et al., 1998). Oddly, three distinctly separate 
phenotypes can occur as a result of the same mutation in the human CAV3 gene; LGMD-
1C, hyperCKaemia and hereditary muscle rippling disease, suggesting epigenetic factors 
may play a role in the progression of caveolinopathy. 
 
1.2 – Skeletal muscle 
Skeletal muscle accounts for approximately 38 % and 31 % of total body mass for male 
and female adult humans respectively (Janssen et al., 2000). It is a dynamic tissue that 
has the ability to adapt according to the demands placed upon it. Strenuous physical 
exercise, or to be more precise, intense anaerobic exercise such as weight resistance 
training, can result in dramatic increases in muscular size and strength through muscle 
fibre hypertrophy. Conversely, disuse through inactivity results in muscular atrophy; 
which may also occur due to senescence, referred to as sarcopenia and often manifests 
as a result of cancer cachexia (reviewed in (Baracos, 2001; Doherty, 2003)).  
 
Skeletal muscles provide bodily movement through their attachment to skeletal bones 
via tendons of origin and tendons of insertion. It is the bone to which the insertions are 
attached that is moved during muscular contractions. Skeletal muscle is comprised of 
bundles of individual fibres (refer to Figure 1.3), each of which is formed via the fusion 
of multiple myotubes, a process mediated by metalloproteases referred to as meltrins; 
muscle fibres are therefore multi-nucleated (Yagami-Hiromasa et al., 2002). Dystrophin 
and the proteins of the DGC are associated with the plasma membrane of the muscle 
fibre, which is referred to as the sarcolemma by muscle physiologists (Zubrzycka-Gaarn 
et al., 1988; Ervasti and Campbell, 1991).       
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Adapted from MDA Publications 2011 
Figure 1.3 – Diagrammatic representation of the macro-to-micro structure of 
muscle. Skeletal muscles are comprised of bundles of muscle fibres, each fibre resulting 
from the fusion of multiple myotubes. Dystrophin and the proteins of the DGC are 
associated with the sarcolemma of muscle fibres. 
 
1.3 - Dystrophin-associated glycoprotein complex 
Associated with the sarcolemma is a complex of proteins referred to as the Dystrophin-
associated glycoprotein complex (DGC) (Ervasti and Campbell, 1991). The complex 
 (sarcolemma) 
 sarcolemma 
DGC 
9 
 
consists of sarcoglycans, dystroglycans, syntrophins, sarcospan, dystrobrevin and 
dystrophin. The sarcoglycan complex consists of subunits α, β, γ and δ which are 
glycosylated single-pass transmembrane proteins (Ervasti and Campbell, 1991). Their 
function within the complex is to stabilise, along with sarcolemmal bound tetraspanin 
family member sarcospan, the dystroglycan complex and afford the complex protection 
against mechanical stress during muscular contractions. Although absence of any of the 
sarcoglycans results in autosomal-recessive LGMD, sarcospan deficiency has no 
apparent detrimental effect (Lebakken et al., 2000). Dystroglycans α and β are also 
glycosylated, α-dystroglycan, a large extracellular 156 kDa protein, binds laminin-2 of 
the extracellular matrix (Ervasti and Campbell, 1991; Corrado et al., 1994). β-
dystroglycan is a 43 kDa transmembrane spanning glycoprotein that binds dystrophin at 
its C-terminus via a PPxY motif (Jung et al., 1995; Rentschler et al., 1999). Absence of β-
dystroglycan is embryonic lethal, with the embryo reabsorbed by E10.5 (Williamson et 
al., 1997). 
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Figure 1.4 - The dystrophin-associated glycoprotein complex. Rod-like dystrophin, 
via the dystroglycans, anchors the DGC to the sarcolemma affording protection against 
mechanical stress. The proteins of the DGC are believed to be involved in cell-signalling 
and their mutations’ often result in myopathies referred to as muscular dystrophies. 
Caveolin-3 is not an integral protein of the DGC but localises with dystrophin, where 
both bind to β-dystroglycan. 
 
1.3.1 - Dystrophin 
The DMD gene is the largest in the human genome; spanning 2.4 Mb over 79 exons, its 
mRNA is 14 kb in length and takes 16 hours to transcribe (Tennyson et al., 1995). The 
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dystrophin protein accounts for 0.002 % of total skeletal muscle protein and 5 % of 
sarcolemmal protein, consists of 3685 amino acid residues and has a molecular weight 
of 427 kDa (Hoffman et al., 1987; Tennyson et al., 1995). The DMD gene is located on the 
X chromosome; Xp21-Xp223 and was identified as the DMD protein in 1987 by Hoffman 
and colleagues and as its absence or truncation was associated with Duchenne and 
Becker muscular dystrophies respectively, was named dystrophin (Lindenbaum et al., 
1979; Zatz et al., 1981; Murray et al., 1982; Davies et al., 1983). Its four domains consist 
of an N-terminal of 240 amino acids, a second domain of 25 triplehelices, a cysteine-rich 
third domain and a C-terminal of 420 amino acid residues, affording dystrophin a rod-
like structure of 150 nm in length (Koenig et al., 1988). An integral component of the 
DGC, a group of sarcolemmal associated proteins that function in cell signalling 
(reviewed in (Rando, 2001)), dystrophin localises to the sarcolemma, where it binds via 
a WW domain of its C-terminus to a PPxY motif of the β sub-unit of trans-sarcolemmal 
DGC protein dystroglycan (Zubrzycka-Gaarn et al., 1988; Jung et al., 1995). An N-
terminal domain of dystrophin, consisting of 90 amino acid residues, binds to f-actin of 
the cytoskeleton, dystrophin therefore anchors the DGC to the sarcoplasm, to which it is 
believed to afford protection against mechanical stress (Petrof et al., 1993; Corrado et 
al., 1994). The absence of dystrophin results in a breakdown of the DGC, compounding 
its importance in maintaining the integrity of the complex (Ervasti et al., 1990; 
Ohlendieck and Campbell, 1991). 
 
1.3.2 - Caveolin-3 
Associated with, but not an integral DGC protein is caveolin-3 or M-caveolin; the muscle-
specific isoform of the caveolin family is expressed in smooth, cardiac and skeletal 
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muscle (Song et al., 1996; Tang et al., 1996; Crosbie et al., 1998). The CAV3 gene is 
located on chromosome 3p25 in humans and consists of 2 exons spanning 12 kb of DNA, 
which encodes a 1.5 kb transcript translating to a 151 amino acid protein with a 
molecular weight of around 17 kDa (McNally et al., 1998; Minetti et al., 1998). Caveolin-
3 homo-oligomerises and as hydrophobic residues are present within the central region 
of the protein, both N and C terminals position on the sarcoplasmic side of the cell; 
resulting in hairpin-like structures (refer to Figure 1.5 A). Caveolin-3 is an integral 
component of caveolae that form 50-100 nm invaginations within the sarcolemma of 
myofibres, where it acts as a scaffolding protein for lipid-modified proteins (reviewed in 
(Smart et al., 1999)). Caveolins function in cell signalling often playing inhibitory roles; 
and in endocytosis (Hulit et al., 2000; Rodriguez et al., 2009). Caveolin-3 directly 
interacts with neuronal nitric oxide synthase (nNOS) where it inhibits signalling 
(Venema et al., 1997). Mutations in the CAV3 gene result in three distinct pathological 
phenotypes: LGMD-1C, inheritable rippling muscle disease (RMD) and hyperCKaemia 
(Minetti et al., 1998). LGMD-1C is a muscular dystrophy that effects predominantly 
muscles of the hips, shoulders and proximal limbs, although cardiomyopathy is also a 
condition of the disease, it is inherited through the autosomal dominant mode of 
transmission (Minetti et al., 1998). Caveolin-3 initially appears at the sarcolemma during 
the differentiation of myocytes, where it co-localises with dystrophin and via WW 
domains, competitively binds to a PPxY motif located at the C-terminus of β-
dystroglycan, a DGC glyco-protein vital for embryonic survival (Song et al., 1996; 
Williamson et al., 1997; McNally et al., 1998; Rentschler et al., 1999; Sotgia et al., 2000). 
CAV3 is upregulated in DMD and mdx mouse and transgenic mice that over-express Cav3 
exhibit a Duchenne-like phenotype; suggesting caveolin-3 may contribute to the 
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pathogenesis of the disease, although recent data suggests a compensatory rather than 
contributory role to the pathogenesis of DMD (Vaghy et al., 1998; Repetto et al., 1999; 
Galbiati et al., 2000; Merrick et al., 2009). Transgenic mice exhibiting autosomal 
recessive and dominant forms of inheritance, cav3-/- and TgCAV3M1 respectively, have 
been generated as animal models for LGMD-1C (Hagiwara et al., 2000; Ohsawa et al., 
2004).  
 
    
 
Figure 1.5 - Caveolin-3 is an integral protein of caveolae. (A) Caveolin-3 homo-
oligomerises to form hairpin-like structures in caveolae, where it associates with 
cholesterol and sphingolipids. (B) Freeze-fracture electron micrograph of the soleus of a 
WT mouse shows sarcolemmal caveolae.      
 
1.4 - Myogenesis 
The process of muscle generation is referred to as myogenesis and is derived from the 
Greek mys (muscle) and genesis (origin). Although myogenesis is usually used in 
Hagiwara et al. (2000) Hum. Mol. Gen. 9: 3047-33054 
A B 
Razani & Lisanti (2002)Reviews in Undergraduate Research. 1: 44-50 
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reference to the development of the musculature in the embryo, the process is 
recapitulated in postnatal muscle tissue following myotrauma. Following fertilisation, 
cleavage and multiple cell divisions of the mammalian ovum, the blastula undergoes 
gastrulation; establishing the three germ layers and anterioposterior axis of the embryo. 
Epithelialisation of paraxial mesoderm in a rostral to caudal direction results in the 
formation of pairs of mesodermic blocks adjacent to the neural tube, called somites 
(Christ and Ordahl, 1995). Somitic mesoderm differentiates to form the sclerotome and 
the dermomyotome, which as the name suggests, is comprised of dermatomal and 
myotomal cells; it is the myotome from which cells destined for the myogenic lineage 
are derived. Cells of the dermatome give rise to the dermis of the back and those derived 
from the sclerotome the vertebrae and ribs (Christ and Ordahl, 1995). 
 
 
 
Image adapted from  Somitogenesis in Vertebrate DevelopmentYoshiko Takahashi ENCYCLOPEDIA OF LIFE SCIENCES © 2004, John 
Wiley & Sons Ltd. 
Figure 1.6 - Illustrated representation of a transverse view of an early stage 
embryo. Blocks of somites arranged in pairs develop laterally to the neural tube and 
notochord. It is from the myotome that cells destined to form the musculature are 
derived. The image represents a two day old chick embryo. 
Endoderm 
Dermatome 
Myotome 
Sclerotome 
Neural tube 
Notochord 
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Myogenesis is under the control of transcription factors called myogenic regulatory 
factors (MRFs), MRFs are themselves activated by transcription factors which include 
pax-3 and pax-7 (reviewed in (Pownall et al., 2002)). Other regulators essential to the 
myogenic programme include mef2, six, eya, wnt, sonic hedgehog and the notch ligand 
delta-like 1; there is also evidence that micro-RNAs (miRNA) play a role in myogenic 
regulation (Naidu et al., 1995; Cossu and Borello, 1999; Chen et al., 2005; Giordani et al., 
2007; Grifone et al., 2007; Sun et al., 2008). Myogenesis takes place in two stages; 
primary and secondary. Primary myogenesis in the mouse occurs between embryonic 
day (E) 9.5 and E13.5 during which time a scaffold of short thick myotubes is established 
throughout the developing musculature of the embryo. During secondary myogenesis, 
which commences around E11.5 in the mouse and continues into neonatal life, longer 
thinner myotubes are established around the primary myotubes. Primary and secondary 
myotubes not only differ in their morphology but also in the myosin heavy chain (MyHC) 
isoform they express; primary express the slow type 1 and secondary express the fast 
type 2. During the later stages of secondary myogenesis, around E14.5 in the mouse, 
fibre-type switching occurs, where some MyHC-1 switch to MyHC-2 and vice versa, 
resulting in varying mixed fibre-types within muscle groups. The ratio of type 1 to type 2 
MyHC varies dependent on their anatomical position. Fibre-type switching is an 
important process as muscles that are required to contract for longer periods of time e.g. 
soleus, must have a greater ratio of MyHC-1 to MyHC-2 fibres, as although type 2 fibres 
are more explosive, they are not as efficient at continued contractions as the slower 
MyHC-1 fibres. 
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1.5 - Myogenic regulatory factors 
There are four members of the myogenic regulatory factor (MRF) family; Myf-5 
(myogenic factor 5) and MyoD (myogenic differentiation) are expressed in 
undifferentiated myoblasts, whereas Myog (myogenin) and MRF4 (muscle-specific 
regulatory factor 4) are expressed in post-mitotic differentiated myotubes; all MRFs are 
defined by their ability to induce a wide variety of cells into the myogenic programme 
(Davis et al., 1987; Braun et al., 1989; Edmondson and Olson, 1989; Rhodes and 
Konieczny, 1989; Wright et al., 1989; Braun et al., 1990; Choi et al., 1990; Miner and 
Wold, 1990). All MRFs have a basic helix-loop-helix (bHLH) motif and as is typical of 
most transcription factors with this motif, MRFs form heterodimers with enhancer box 
sequences (E-boxes) of gene promoter regions of DNA (reviewed in (Weintraub et al., 
1991; Olson and Klein, 1994)). MRFs are sequentially expressed spatiotemporally 
during embryogenesis with Myf-5 transcripts in mouse somites appearing at E8, 
followed by Myog at E8.5, MRF4 is expressed biphasically, first between E9 and E12 and 
the second wave of expression coinciding with fibre-type specification and innervation 
at E14.5, although work from the Rigby group suggested MRF4 may be 
contemporaneously expressed with Myf-5; the final member, MyoD is expressed at E10.5 
and continues into adulthood (Sassoon et al., 1989; Bober et al., 1991; Ott et al., 1991; 
Summerbell et al., 2002). There has been extensive research employed in an effort to 
ascertain the role each MRF family member plays during myogenesis and to elucidate 
whether any functional redundancy may exist within these transcription factors 
(reviewed in (Arnold and Braun, 1996)). Although MyoD may have some functional 
redundancy, as MyoD-/- mice display no adverse muscle phenotype or aberration in the 
expression of any muscle-specific genes, an increase in Myf-5 expression in these mice 
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suggests a regulatory role for MyoD in the expression of Myf-5 (Rudnicki et al., 1992). 
Skeletal muscle development is also normal in Myf-5-/- mice, although myotomal 
expression of Myf-5 is delayed by two days, E10.5 as opposed to E8.5 in WT, and there 
are distal rib developmental defects; consequently Myf-5-/- mice die shortly after birth, a 
similar phenotype is observed in MRF4-/- mutant-mice (Braun et al., 1992; Braun and 
Arnold, 1995; Patapoutian et al., 1995; Zhang et al., 1995). Initial work with double-
mutant Myf-5-/-/MyoD-/- mice found roles for Myf-5 and MyoD in the specification of 
muscle progenitor cells to the myogenic programme as these mice are amyoplasic, with 
loose mesenchymal tissue and fluid replacing muscle tissue (Rudnicki et al., 1993). More 
recently, it was shown that MRF4 could compensate for the loss of Myf-5 and MyoD as 
long as MRF4 was not compromised, suggesting that rather than functioning only as a 
post-mitotic transcription factor, MRF4 is conducive to inducing myogenic specification 
in the same way as Myf-5 and MyoD (Kassar-Duchossoy et al., 2004). Evidence to 
support the indispensible role myogenin has in completing the process of myogenesis is 
evident in that mutant Myog-/- mice are void of any muscle fibres, instead their 
musculature is comprised of undifferentiated myoblasts; these mice are immobile and 
die soon after birth (Hasty et al., 1993; Nabeshima et al., 1993). 
 
1.6 - Growth factors 
Several growth factors have roles throughout the myogenic programme; fibroblast 
growth factor (FGF) stimulates myoblast proliferation and inhibits differentiation; IGF-2 
establishes the optimum proportion of FMyHC+ve myotubes during fibre-type 
specification and myostatin negatively regulates muscle growth (Moore et al., 1991; 
McPherron et al., 1997; Merrick et al., 2007). The endocrine hormone insulin has roles in 
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glycogenesis, adipogenesis and blood-glucose homeostasis; it also has a profound 
anabolic effect on skeletal muscle. Insulin and insulin-like growth factors (IGF-1 and 
IGF-2) share structural homology and can all mediate signals via insulin-receptors (IR) 
or type-1 IGF receptors (IGF-1R). IR and IGF-1R mediated signalling is attenuated by 
adaptor protein Grb10 (Liu and Roth, 1995; Ooi et al., 1995; Dey et al., 1996), 
conversely, caveolin-3 has been shown to enhance insulin signalling (Oshikawa et al., 
2004). Epidermal growth-factor (EGF) like family member delta-like 1 (Dlk1) has roles 
in cell-cell communication and development and in contrast to Grb10 has a role in IGF-1 
signal amplification (Nueda et al., 2008). Although virtually absent in healthy adult 
muscle, Dlk1 is found in all myopathic muscle tissue (Andersen et al., 2009).  
 
1.6.1 - Insulin-like growth factors 
It has been shown that IGF-2 (insulin-like growth factor 2), is an important peptide in 
the maintenance of MyHC-2 and the switching of MyHC-1 to MyHC-2 during secondary 
myogenesis (Merrick et al., 2007). IGF-2 along with IGF-1 belongs to the insulin-like 
growth factor family (previously called somatomedins) so named for their close 
structural homology with the endocrine hormone insulin. IGF-2 is an imprinted gene, 
with expression from the paternal allele. IGF-2 is primarily produced during 
embryogenesis and unlike IGF-1, which is expressed postnatally; is not regulated by 
growth hormone (GH). IGF-2 signals via the IR and IGF-1R; it also binds the type-2 
insulin-like growth factor receptor (IGF-2R) also referred to as the mannose 6-
phosphate receptor. 
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1.6.2 - Myostatin 
Transforming growth-factor β (TGF-β) super-family member myostatin, or 
growth/differentiation factor-8, is a negative regulator of skeletal muscle growth that 
inhibits myogenesis through repression of myoblast proliferation and downregulation of 
myoD and myogenin; myostatin mutant animals exhibit extreme muscularity (refer to 
Figure 1.7) (McPherron et al., 1997; Thomas et al., 2000; Ríos et al., 2001).  Myostatin 
also has a role in the regulation of a population of skeletal muscle stem cells (SMSc), 
referred to as satellite cells, where via pax7 downregulation, negative regulation of 
satellite cell activation and self-renewal occurs (McCroskery et al., 2003; McFarlane et 
al., 2008). Caveolin-3 negatively regulates myostatin signalling through suppression of 
its type-1 receptor (Ohsawa et al., 2006). Upregulated caveolin-3 is accompanied by 
downregulated myostatin in MD, although there is evidence to refute that there is any 
change in the expression levels of myostatin in dystrophic muscles (Repetto et al., 1999; 
Zhu et al., 2000; Castro-Gago et al., 2006).    
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A, B, G - copyright-free-pictures.org.uk; C-F - (McPherron et al., 1997) 
Figure 1.7 - Myostatin deficiency causes excessive skeletal muscle growth. (A) A 
mutation in the MSTN gene is responsible for the extreme muscularity seen in this dog, 
referred to as a ‘bully whippet’, the usual somatotype for a whippet is shown in B. (C, E) 
Mutant Mstn-/- mice show such extreme muscle hypertrophy it earned them the name 
‘mighty-mice’, the images are of jaw and forelimb muscles; WT littermates are shown in 
panels D and F. (G) Beef cattle farmers unknowingly bred myostatin-deficient double-
muscled mutant the ‘Belgian blue’.   
 
1.7 - Myosin 
Myosins are a family of around twenty cytoplasmic motor proteins that act in concert 
with actin to provide cell motility in processes such as cytokinesis, phagocytosis and 
muscular contractions; they are ubiquitously expressed in all eukaryotic cells (reviewed 
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in (Weiss and Leinwand, 1996)). Each myosin molecule consists of two 200 kDa heavy 
chains and two pairs of 17-23 kDa light chains, the heavy chains consist of a coiled-coil 
rod domain and a globular head domain which binds actin and hydrolyses ATP 
(reviewed in (Weiss and Leinwand, 1996)). There are six myosin heavy chain (MyHC) 
isoforms expressed in skeletal muscle; MyHC-embryonic, MyHC-neonatal (also referred 
to as perinatal), MyHC-β (also referred to as slow or type-1) and three adult fast isoform; 
FMyHC-2a (oxidative), FMyHC-2b (glycolytic) and FMyHC-2dx (oxidative/glycolytic) 
(reviewed in (Weiss and Leinwand, 1996)). During mouse myogenesis the first isoforms 
to be expressed are MyHC-e and MyHC-β between E9 and E10 in the myotome of rostral 
somites, MyHC-neo is expressed at E10.5 and by E15.5 MyHC-neo is the most abundant 
isoform, expressed only in fibres destined to become adult fast-type fibres (Lyons et al., 
1990). Although 70 % of adult skeletal muscle is comprised of FMyHC-2b, it is the loss of 
FMyHC-2dx that presents with the more severe phenotype in FMyHC-2b and FMyHC-2dx 
knockout mice (Acakpo-Satchivi et al., 1997).  
 
1.8 - Satellite cells 
The existence of a population of cells with little cytoplasm, juxtaposed to muscle fibres 
was established in 1961, during electron microscopy of frog tibialis anterior and it was 
proposed that they were responsible for myo-regeneration in all vertebrates; they were 
named ‘satellite’ cells because of their peripheral positions around muscle fibres 
(Mauro, 1961). The theory of mono-nucleated cells fusing to form multi-nucleated fibres 
was first suggested over a century earlier by Theodor Schwann; but as it was fervently 
contested by leading muscle physiologists of the time, was not accepted (reviewed in 
(Schmalbruch, 2006)). Postnatal regeneration of damaged muscle-fibres occurs via the 
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activation of SMSc and subsequent initiation of myogenic processes that recapitulate 
embryonic myogenesis. Satellite cells contribute significantly to this pool of SMSc and 
reside between the sarcolemma and basal lamina of the muscle fibre where they remain 
in quiescence until activated (Mauro, 1961; Schultz et al., 1978). Recent studies suggest 
heterogeneity within the satellite cell population; pax7+/myf5- cells remain 
undifferentiated SMSc thereby maintaining the satellite cell population and pax7+/myf5+ 
cells, committed to become differentiated myoblasts upon stimulation. To which sub-set 
the cell is destined is determined by apical-basal orientation, whereby cells adjacent to 
the basal lamina become pax7+myf5- and those adjacent to the sarcolemma become 
pax7+/myf5+ (Kuang et al., 2007). Satellite cells express specific genes that can be used 
as markers; pax7, a transcription factor of the paired box family of genes is expressed in 
quiescent satellite cells and cell-adhesion molecule M-cadherin, which is expressed in 
both quiescent and activated satellite cells are two used for this purpose (Wernig et al., 
2004). 
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Image from - pimm.wordpress.com  
Figure 1.8 - Schematic illustration showing regneration of a myofibre following 
myotrauma. (Top left of illustration) Activated satellite cells (referred to in the 
illustration as progenitor cells) proliferate and migrate to a damaged myofibre where 
differentiation and fusion occurs. Proliferation ensures the pool of satellite cells are not 
depleted. Satellite cells remain in quiescence until required.         
 
1.9 - Paired box transcription factors 
The importance of pax-3 and pax-7 is illustrated in that cells destined to become 
myoblasts in Pax-3/Pax-7 double-mutant null mice, die or assume a different cell lineage 
(Relaix et al., 2005). Although pax proteins are paralogues of one another as they share 
24 
 
structural homology, their function during myogenesis occurs during different phases of 
development. Pax-3 is expressed predominantly during embryogenesis where it is an 
important migratory factor for myogenic progenitor cells and Pax-7 is expressed in 
satellite cells where it functions in their maintenance. Pax-7 can also substitute 
effectively if Pax-3 is absent (Relaix et al., 2005).  
 
1.9.1 - Pax7 
The transcription factor pax7 is a repressor of myogenesis and is expressed in satellite 
cells where it functions in their maintenance (Seale et al., 2000; Olguin and Olwin, 2004; 
Oustanina et al., 2004). Recent data suggests an age-related dependency for pax7 in the 
maintenance of satellite cells, as Pax7 inactivated satellite cells of adult mice are not 
compromised in their ability to proliferate or regenerate muscle following cardiotoxin 
induced injury (Lepper et al., 2009). Pax7 belongs to a family of nine transcription 
factors necessary for development and along with Pax3, is expressed in muscle and 
neuronal tissues (reviewed in (Buckingham and Relaix, 2007)). Pax7 is a repressor of 
myogenesis, upregulation of Pax7 downregulates MyoD and Pax7 and Myog expression 
have been shown to be mutually exclusive (Seale et al., 2000; Olguin and Olwin, 2004; 
Oustanina et al., 2004).  
 
1.10 - Animal models for DMD 
The use of dystrophic animal models, whether they arose naturally or were developed 
through genetic manipulation, have proven to be invaluable research tools for scientists 
working in the field of muscular dystrophy. If research was reliant solely on human 
subjects, our understanding of the aetiology, molecular mechanisms and natural history 
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of the disease would be incredibly retarded, due to sample size and ethical restrictions.  
A wide range of animals have been used for research including nematodes, zebrafish, 
cats, dogs and rodents; of the mammalian models, the hypertrophic feline muscular 
dystrophy (HFMD) cat has been the least used (reviewed in (Collins and Morgan, 2003)). 
A brief description of the canine and rodent animal models used shall be given.        
 
1.10.1 - Rodent models of muscular dystrophy 
1.10.2 - The dy/dy mouse and cardiomyopathic Syrian hamster 
Prior to the identification of dystrophin as the protein product of the DMD gene in 1987, 
there were three dystrophic rodent strains used as models for DMD; two murine models, 
dy/dy and mdx and a cricetine model BIO.14.6, better known as the cardiomyopathic 
Syrian hamster (Michelson et al., 1955; Hoffman et al., 1987). Of the murine models the 
dy/dy mouse was preferred by some as it presented with a more severe phenotype than 
mdx (Michelson et al., 1955; Bullfield et al., 1984; Dangain and Vrbova, 1984). After four 
decades of use as a model for DMD, the malady of the dy/dy mouse was shown to be 
caused by a deficiency in merosin, due to a mutation in the Lama2 gene; the dy/dy 
mouse was a murine model for merosin deficient congenital muscular dystrophy (Xu et 
al., 1994). In a similar vein to that of the dy/dy mouse, it was shown that the 
cardiomyopathic Syrian hamster’s dystrophy was caused by a mutation in the Sgcd gene, 
which resulted in a deficiency in DGC protein δ-sarcoglycan; this made it a model for 
LGMD-2F (Nigro et al., 1997). The mdx mouse was accepted as the mouse model best 
representative of DMD and has been widely used since. 
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1.10.3 - The mdx mouse 
The mdx mouse has been the preferred animal model of choice for most working in the 
field of muscular dystrophy since its introduction in the mid 1980’s; it arose via a 
spontaneous mutation within exon 23 of the Dmd gene of the WT mouse line C57BL/10 
(Bullfield et al., 1984).  This resulted in a premature STOP codon and subsequent loss of 
the protein dystrophin in the sarcolemma (Sicinski et al., 1989). Testament to its 
unparalleled use as a research model for DMD is evident in the fact that there are 
currently (at the time of writing) 2100 articles on PubMed.gov’s data base relating to the 
mdx mouse (US National Library of Medicine National Institutes of Health) and this is by 
no means exhaustive. When compared to the 44 papers archived for the canine model of 
DMD (GRMD/CXMD), the significance of the mdx mouse cannot be overstated.  
 
Although extensively used as the primary animal model for DMD, the myopathy 
observed in mdx does not accurately represent the pathogenesis and progression that 
manifests with the human form of the disease; mobility is not impaired and life-span is 
not curtailed, although one study found there was an 18 % reduction in mdx lifespan 
(Dangain and Vrbova, 1984; Carnwath and Shotton, 1987; Chamberlain et al., 2007). 
Muscle tissue regenerated in the mdx mouse, although abnormal in architecture; 
variations in fibre sizes and centrally located nuclei, functions perfectly sufficiently and 
is void of the connective and adipose tissue associated with the human form of the 
disease. 
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1.10.4 - The mdx/utrn-/- mouse 
The pathogenesis of the dystrophin/utrophin double-deficient mouse perhaps most 
closely resembles that of DMD. Not only does the histopathogenesis appear more severe 
than that of mdx, but mdx/utrn-/- mice present with pronounced kyphosis, colloquially 
referred to as ‘hunch-back’ and marked muscular impairment when compared to mdx, 
there is also a substantial reduction in their lifespan; death occurring at around twenty 
weeks of age (Deconinck et al., 1997). However, as utrophin is upregulated and not 
absent in DMD muscles, these mice do not provide a true molecular model for the study 
of DMD (Kleopa et al., 2006).    
 
1.10.5 - GRMD dog 
There have been several breeds of dog shown to have canine X-linked muscular 
dystrophy (CXMD) including the Rottweiler, the German short-haired pointer, the Beagle 
and the Golden Retriever (reviewed in (Collins and Morgan, 2003)). It is the Golden 
Retriever muscular dystrophy (GRMD) dog that has been studied most extensively 
(reviewed in (Collins and Morgan, 2003)). The histopathological and physiopathological 
homology between GRMD and DMD makes the GRMD dog the most accurate animal 
model available for the study of DMD (Cooper et al., 1988). The pathogenesis of GRMD 
begins in utero and at birth necrosis of quadrimelic limbs, neck and trunk muscles are 
seen; by the age of six months severe necrosis of muscle tissues are evident with 
carpus/tarsus contractures severely impeding mobility (refer to Figure 1.9) (reviewed 
in (Collins and Morgan, 2003)). As is the case with DMD, premature death of GRMD dogs 
often occurs as a result of respiratory or cardiac failure (reviewed in (Collins and 
Morgan, 2003)). Although a seemingly perfect animal model for DMD, there are several 
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drawbacks to using the GRMD dog. There are great phenotypic variations between 
GRMD dogs of different litters although littermates are phenotypically similar, thus 
trans-litter experiments are more difficult to evaluate (Cooper et al., 1988). Also, the 
comparable size to DMD boys which makes GRMD dogs excellent models for the testing 
of new research strategies and therapies that have shown to be successful in mdx mice, 
makes the practicality of husbandry very difficult (reviewed in (Collins and Morgan, 
2003)).       
 
 
http://www.ncdmd.org/index.cfm National Centre for Canine Models of Duchenne Muscular Dystrophy 
Figure 1.9 - Muscular dystrophy in the Golden Retriever. (A) At three months of age 
the puppy appears to be perfectly normal, with no sign of any dystrophy. (B) The 
aggressive progression of the disease is clearly evident just three months later, the dog 
is no longer able to walk on its toes due to carpus/tarsus contractures and the muscles 
of its hindlimbs appear incapable of supporting its weight for any considerable length of 
time. Young GRMD dogs often succumb to respiratory or cardiac failure.     
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1.11 - Treatments for Duchenne muscular dystrophy  
There are no curative treatments for DMD at the moment, however the administration of 
corticosteroid therapy has helped slow disease progression and along with the 
application of non-invasive ventilation, the life expectancies of DMD patients has been 
prolonged by around a decade (Simonds et al., 1998; Manzur et al., 2008). Although 
these two treatments are the only ones available at the moment, there are new therapies 
that are being developed which look very promising. A brief account of available 
treatments and of some of those being developed shall follow. 
 
1.11.1 - Corticosteroids 
Corticosteroids, notably prednisolone and deflazacort, have been used in the treatment 
of DMD for decades, although the mechanism of action that makes them effective is still 
unknown (reviewed in (Muntoni et al., 2002)). Prolonged use of these drugs is not 
desirable, as side effects including weight gain and growth suppression are common, 
with weight gain more prevalent with prednisolone use (Bonifati et al., 2000). They are 
still the only pharmaceutical treatments available that consistently improve muscle 
strength, muscle functional performance, pulmonary functional performance and if they 
are administered prior to the onset of ventricular dysfunction, have been shown to 
retard the development of this particular cardiac condition (Wong and Christopher, 
2002; Markham et al., 2008). Although boys as young as one year of age have been given 
these drugs, a review of the scientific and clinical evidence conducted in 2002 
recommended corticosteroid treatment between the ages of four and seven years of age 
would be of best benefit and that their administration prolonged ambulation by three 
years (reviewed in (Wong and Christopher, 2002)).          
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1.11.2 - Non-invasive ventilation 
Along with corticosteroid drugs, non-invasive ventilation has increased the life 
expectancies of those with DMD. In a study conducted in 2002, the impact of non-
invasive nocturnal ventilation on the average ages of deaths of patients whose care had 
been managed by the Newcastle Muscle Centre, between the years 1967 and 2002 was 
reviewed. It found the chances of DMD patients surviving to 25 years of age since the use 
of non-invasive nocturnal ventilation had risen by 41 % (Eagle et al., 2002).        
  
 
Figure 1.10 - DMD patient using a non-invasive ventilator. The use of assisted 
ventilation is often necessary as the degeneration of respiratory muscles makes it 
increasingly more difficult for those with DMD to breathe independently. In conjunction 
with corticosteroids, non-invasive ventilation has increased the life expectancies for 
sufferers of DMD by around a decade.     
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1.11.3 - Ataluren (PTC-124) 
Ataluren (formally known as PTC-124) is a therapeutic agent that is in phase two of 
clinical trials. Like the aminoglycoside antibiotic gentamicin, Ataluren promotes 
ribosomal readthrough of premature nonsense stop codons in mRNA, enabling the 
process of translation to continue in diseases such as DMD and cystic fibrosis, where 
premature translational termination results in protein deficiencies and the 
manifestation of their associated diseases (Welch et al., 2007). Like many potential 
therapies, Ataluren has shown promising results in the laboratory when administered to 
mdx mice.  
 
1.11.4 - Exon skipping 
The potential for exon skipping as a therapy for DMD was evident as soon as results 
were shown of dystrophin localisation to the sarcolemma of mdx mice who had been 
administered drugs that promote exon skipping (Mann et al., 2001). Since then it has 
been developed further to enable the skipping of duplicated and deleted exons in human 
DMD subjects, which account for around 80 % of mutations, resulting in the restoration 
of WT dystrophin (Aartsma-Rus et al., 2006 ; Aartsma-Rus et al., 2007). Exon skipping 
employs the use of antisense oligonucleotides (AON), which complement regions of pre-
mRNA upstream or downstream of mutated regions which are subsequently ‘skipped’ 
without affecting the reading frame. This prevents mRNA translation prematurely 
terminating and a truncated, yet functional dystrophin protein is synthesised. This 
results in a milder Becker-like muscular dystrophy. Although this sounds incredibly 
auspicious, exon skipping has been shown to be unsuccessful with multiple exon 
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duplications (Aartsma-Rus et al., 2007).  Clinical trials for exon skipping are now in stage 
three, so treatments should be imminent.   
 
1.11.5 - Myostatin gene therapy 
Ever since the effects of myostatin deficiency on the muscle mass of mutant mice was 
shown, myostatin inhibition as a potential therapeutic treatment for those with muscle 
wasting diseases has been a subject of intense research (McPherron et al., 1997; Ohsawa 
et al., 2006; Cash et al., 2009; Kota et al., 2009; Foley et al., 2010). The pharmaceutical 
company Acceleron Pharma are currently developing a myostatin inhibitor called ACE-
031, it is a soluble form of activin receptor type 2B (ActRIIB), for which myostatin is a 
ligand and recent research has shown ACE-031 to be effective in increasing the strength 
and muscle mass of mdx mice (George Carlson et al., 2011; Pistilli et al., 2011). Phase two 
trials have already been conducted on DMD patients in Canada using this drug.    
 
1.11.6 – Utrophin upregulation 
The autosomal homologue of dystrophin, utrophin, when upregulated in mdx and CXMD 
muscles, has been shown to ameliorate the dystrophic condition and has therefore been 
the subject of extensive research over the past two decades (Tinsley et al., 1996; Tinsley 
et al., 1998; Cerletti et al., 2003). Retro-viral vectors were initially employed to 
introduce Utrn transgenes into the muscle tissues of animal models used for the 
research, but more recently work has progressed with an orally administered drug that 
has been shown to upregulate endogenous utrophin (Cerletti et al., 2003; Tinsley et al., 
2011). The drug is called SMTC1100 and although recent phase one clinical trials 
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produced disappointing results, the drug shows immense promise as a pharmaceutical 
therapy for DMD.  
 
1.11.7 – A matter of time 
The last two decades of research in the field of treatments for DMD have resulted in 
therapeutic agents that could potentially change the prognosis of the disease for those 
affected with DMD in the future. The progressive, debilitating and ultimately lethal 
disease of today could be replaced with one that is manageable, with little impairment to 
the quality of life of those affected. Exon skipping, ribosomal readthrough and utrophin 
upregulation are likely to be ready for general use in the next few years, but the timing 
of administration is of paramount importance for the optimal efficacy of these 
treatments. Speaking to the Times in June of 2011, Professor Dame Kay Davies said, 
“Anyone on these therapies is going to have to be treated more or less from birth to get 
maximum benefit. I’m not sure whether we’re there yet but we need to be ready to 
introduce a screening programme the moment that these treatments start to come 
through...that means piloting and planning now”. 
 
Wales has been screening for DMD for the past 21 years as part of the heel-prick test 
performed on neonates, it is about time we did too.  
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1.12 - Aims and objectives 
1.12.1 – Aim 
The aim of this project was to establish a role for caveolin-3 in the pathogenesis of the 
mdx mouse.  
 
1.12.2 - Objectives 
The first objective was to generate a line of mice that were deficient in both dystrophin 
and caveolin-3, i.e. caveolin-3 deficient mdx mice. Caveolin-3 is upregulated in DMD and 
its mouse model mdx, yet very little work has been done to distinguish between the 
pathogenesis caused by a loss of dystrophin and that caused as a result of an increase in 
caveolin-3. In order to develop a line of mice deficient in dystrophin and caveolin-3, a 
series of crosses were employed beginning with mdx and cav3-/-, with each subsequent 
generation requiring genotyping and careful pairing of offspring to ensure the genetic 
requirements were eventually met. These genetic requirements were mdx with 
hypophysiological levels of caveolin-3 (mdx/cav3+/-) and mdx with a complete deficiency 
in caveolin-3 (mdx/cav3-/-). DNA sequencing of a selected region of the murine Dmd gene 
was used to confirm the presence of the mdx mutation in dystrophin-deficient mutants.   
   
The second objective was to confirm that phenotypes were consistent with genotypes, in 
regards to levels of caveolin-3 in the three dystrophin-deficient mutants, thus western 
blotting and immunohistochemistry (IHC) were used to establish caveolin-3 protein 
levels and localisation.    
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The third objective was to ascertain the effects of reduced caveolin-3 in the musculature 
of developing mdx embryos, in view of establishing a role for caveolin-3 during 
myogenesis. This was achieved through IHC using muscle and muscle cell specific 
antibodies. Caveolin-3 levels were confirmed with western blotting. 
The fourth objective was to correlate observed dystrophic pathogenesis with levels of 
caveolin-3 in postnatal muscles. Aside from examination of the gross histology of muscle 
sections, regenerating areas were calculated as percentages of total areas and 
centronucleated fibres, a hallmark of cumulative regeneration, were counted and 
comparisons made between the three dystrophin-deficient mutants. Haematoxylin and 
eosin (H&E) staining was employed for the histological analysis of postnatal muscle 
tissues.   
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CHAPTER 2 - MATERIALS AND METHODS 
 
2.1 – Introduction 
This chapter contains all of the methodology along with materials that have been used 
during the course of the project. Protocols have been written with enough detail 
included to allow for reproducibility of all experiments. Where the same methodology 
has been used for different protocols, a detailed description of the protocol has been 
written for the first instance and is cross-referenced where used in the remainder of the 
thesis. To avoid repetitious and superfluous text, names of suppliers of any chemicals 
and equipment used have been included when initially mentioned; this also applies to 
the chemical ingredients of any reagents used.      
 
2.2 - Mouse models used 
Three mouse strains were used for all work during this project; wild-type (WT) 
C57BL/10, DMD mouse model mdx and LGMD-1C mouse model cav3-/-. In addition, two 
double-mutant strains were generated for use during this project through crossing mdx 
and cav3-/-; namely mdx/cav3+/- and mdx/cav3-/- (see section 2.3). Throughout the 
remainder of this thesis mdx/cav3+/- (mice with the mdx mutation which are 
heterozygous for Cav3) shall be referred to as double-mutant (DM) hets and mdx/cav3-/- 
(mice with the mdx mutation which are homozygous negative for Cav3) referred to as 
DMs. Animal husbandry was employed at the Biomedical Services Unit (BMSU), 
University of Birmingham. All mouse strains used were isogenic, on a C57BL/10 
background. Cav3-/- were originally generated and provided by Yoshito Hagiwara 
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(Hagiwara et al., 2000) and mdx from the Bullfield laboratory in 1991 (Bullfield et al., 
1984).  
 
Table 2.1 – Mice used and the dystrophic models they represent. Denotations  X – 
WT dystrophin, Xd – mdx mutation, Y – no contribution to the dystrophic genotype, A – 
WT cav3, a – mutant cav3.  
 
Mouse strain Genotype (M/F) Mutated gene Effected 
protein 
Model  
of 
C57BL/10 XYAA/XXAA N/A N/A Wild-type 
mdx XdYAA/XdXdAA Dmd Dystrophin DMD 
cav3-/- XYaa/XXaa Cav3 Caveolin-3 LGMD-1C 
DMhet 
(mdx/cav3+/-) 
XdYAa/XdXdAa Dmd, 
Cav3 (1allele) 
Dystrophin, 
Caveolin-3 (het) 
N/A 
DM 
(mdx/cav3-/-) 
XdYaa/XdXdaa Dmd, Cav3 Dystrophin, 
Caveolin-3 
N/A 
 
2.3 - Generation of DM mice  
Natural matings were set up between cav3-/- males and mdx females. Females were 
checked for vaginal plugs (VP) daily until the presence of a plug indicated a successful 
pregnancy and was taken as embryonic stage 0.5 days (E0.5). This strategy ensured all 
resultant males were hemizygous and all females heterozygous for mdx, as the gene has 
an X-chromosome location; all littermates produced via these crosses were 
heterozygous for Cav3, as it is an autosomal gene. The next stage was to backcross 
DMhet males with mdx females to produce litters that were all dystrophin deficient. 
Approximately half of these were, according to Mendelian principles of genetic 
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inheritance, expected to be DMhets and half mdx. Genotypes of resultant progeny were 
established by polymerase chain reaction (PCR) to identify their neo status. Cav3-/- mice 
were generated through the deletion of exon 2 of the Cav3 gene which was replaced with 
a phosphoglycerate kinase promoter-driven neomycin-resistant cassette (Hagiwara et 
al., 2000), therefore those neo positive mice would be DMhets and those neo negative, 
mdx. The penultimate stage of the breeding programme was to cross DMhet males and 
DMhet females to produce progeny with three possible genotypes; mdx, DMhet and DM. 
In order to identify the genotypes from these crosses, neo and cav3 PCRs were 
performed; mdx would be Cav3 positive/neo negative, DMhets would be positive for 
both genes and DMs Cav3 negative/neo positive. Finally, DMs were crossed to produce 
entire DM litters (Table 2.2). 
 
Table 2.2 - Generation of DM mice. Stage 1: cav3-/- males (XYaa) were crossed with 
mdx females (XdXdAA) to produce F1 DMhet males (XdYAa) and mdx carrier, cav3het 
females (XdXAa) in the Mendelian ratio of 1:1. Stage 2: F1 DMhet males (XdYAa) were 
backcrossed with mdx females (XdXdAA) to produce F2 progeny of two expected 
genotypes (males and females); mdx (XdYAA/XdXdAA) and DMhets (XdYAa/XdXdAa) in 
the Mendelian ratios of 1:1. Stage 3: DMhet males (XdYAa) were crossed with F2 DMhet 
females (XdXdAa) to produce F3 progeny of three expected genotypes (males and 
females); mdx (XdYAA/XdXdAA), DMhets (XdYAa/XdXdAa) and DMs (XdYaa/XdXdaa) in the 
Mendelian ratios of 1:2:1. Stage 4: F3 DM males and females were crossed to produce 
litters of a single genotype, DM (XdYaa/XdXdaa). X – WT dystrophin, Xd – mdx mutation, Y 
– no contribution to the dystrophic genotype, A – WT Cav3, a – mutant Cav3.  
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Stage 1 
 
 XdA XdA 
Xa XdXAa XdXAa 
Ya XdYAa XdYAa 
 
Stage 2 
 XdA XdA 
XdA XdXdAA XdXdAA 
Xda XdXdAa XdXdAa 
YA XdYAA XdYAA 
Ya XdYAa XdYAa 
 
Stage 3 
 XdA Xda 
XdA XdXdAA XdXdAa 
Xda XdXdAa XdXdaa 
YA XdYAA XdYAa 
Ya XdYAa XdYaa 
 
Stage 4 
 Xda Xda 
Xda XdXdaa XdXdaa 
Ya XdYaa XdYaa 
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2.4 - Collection of embryos 
Pregnant female mice of the required gestational stage were sacrificed via cervical 
dislocation (schedule 1 killing) by trained BMSU staff in accordance with the Animal 
Welfare (Scientific Procedures) Act 1986, placed supine and secured to cork dissecting 
boards via quadrupedally inserted hypodermic needles (Terumo). Their abdomens were 
then sprayed with 70 % ethanol (EtOH) for the purpose of sanitisation, opened using 
sterile dissecting tools and their uteri removed (Figure 2.1). Upon removal, the uteri 
were immediately placed into Universal tubes containing sterile phosphate buffered 
saline (sPBS) kept on ice. Embryos were promptly liberated from uteri via the removal 
of deciduas’ and amnion in Petri-dishes (Nunc) under an inverted dissecting Stemi 1000 
microscope (Zeiss) using sterile forceps and processed for either paraffin wax 
embedding (section 2.11) or protein extraction (section 2.15.1). Simultaneous to the 
removal of embryos, the dissected placentas and amnion were placed into eppendorf 
tubes, snap-frozen in liquid nitrogen (LN2) and later stored at -70 °C until required for 
genotyping. All waste uterine tissue was placed into Universal tubes and disposed of 
using specially designated bins at BMSU.  
 
41 
 
 
Adapted from - Cook, M.J. (1965) The Anatomy of the Laboratory Mouse 
Figure 2.1 – Diagram of a pregnant female mouse with opened abdomen prior to 
embryo collection showing bi-lateral uterus. The liver and intestines were either 
excised or moved enough to allow for the removal of the uterus. The uterus lies laterally 
in the mouse abdomen, to prevent mobility problems as gestation progresses and 
contains ‘pods’ of embryos, each embryo having its own placenta.     
 
2.5 - Excision of adult skeletal muscles 
Skeletal muscles and organs were excised from four weeks, nine weeks and nine months 
old mice for the purpose of analysis via immunohistochemistry and western blotting.  
 
Adult mice were sacrificed as described in section 2.4, pinned and sprayed with 70 % 
EtOH to sanitise. Using disposable scalpels (Swann-Morton), fur was removed from 
relevant areas before the commencement of any surgery (as shown in Merrick et al., 
2010). Cutaneous incisions were made using sterilised dissecting scissors and skins 
Liver 
Rectum 
Foetus in 
uterus 
Placenta 
Ileum 
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covering relevant muscles removed, with care taken not to cut into underlying muscles. 
For the removal of triceps and quadriceps, upper proximal limb joints 
humerus/radioulna and femur/tibiofibular were flexed and using sterile dissecting 
scissors, muscles excised. Sections of thoracic cage containing four of five ribs were also 
removed for the purpose of intercostal histological analysis. Samples that were excised 
for the purpose of analysis via immunohistochemistry were fixed in ice-cold 4 % 
paraformaldehyde (PFA) (Sigma-Aldrich) and processed as described in section 2.11; 
samples taken for the purpose of western blotting were snap frozen in LN2 and stored at 
-70 °C until required.  
 
                           
 
Figure 2.2 – Images of skinned fore and hindlimbs. To excise triceps and quadriceps 
from fore and hindlimbs respectively, skinned limbs were first flexed (direction of 
arrows), to allow ease of access to the full length of the muscles. Muscles taken were 
then processed for either protein extraction or paraffin wax embedding.   
 
 
Triceps 
 brachii 
Quadriceps 
femoris 
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2.6 – Extraction of DNA from tissues  
The acquisition of tissue for the purpose of genotyping was a consistent requirement of 
this project. Ear-clips from adult mice and placentas, amnion and tail-clips from 
embryos were used to establish genotypes; tail-clips were also used when genotyping 
neonate mice. Upon their removal, tissues were immediately placed in labelled 
eppendorf tubes, snap-frozen in LN2 and stored at -70 °C until required. There were two 
protocols used for the extraction of DNA; the first used isopropanol as a precipitate and 
the second phenol-chloroform. Of the two methods, phenol-chloroform produced the 
cleanest DNA samples, but as isopropanol was a much simpler and faster method to 
employ, the majority of DNA samples were extracted using this method.   
 
2.6.1 - Isopropanol extraction of DNA 
Tissue samples required for genotyping were removed from storage at -70 °C and 
thawed on ice. To each eppendorf, 200 μL of lysis buffer (100 mM Tris HCl (Fisher 
scientific) pH 8.5; 5 mM EDTA (Fisher scientific); 200 mM NaCl (BDH laboratory 
supplies)) and 5 μL (20 mg mL-1) Proteinase-K (VWR) was added and samples incubated 
for several hours at 50 °C with agitation at 600 revolutions per minute (rpm) using a 
Thermomixer Compact (Eppendorf). The digested samples were then centrifuged at 
13,000 rpm for 60 seconds in a Hettich Mikro 20 centrifuge (DJB Labcare Ltd.) and the 
resultant supernatants transferred to new eppendorf tubes leaving pellets of hair and 
debris (if any) to be discarded. Some embryonic tissues did not require centrifugation as 
the samples were free from hair or debris. Volumes of isopropanol (Fisher Scientific) 
equal to that of the supernatants were then added to the supernatants in each eppendorf 
which were vigorously shaken to precipitate the DNA from their solutions. Using fresh 
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yellow pipette tips (Gilson) for each sample, DNA aggregates were removed from their 
supernatants and placed in fresh labelled eppendorf tubes and placed in a heat block 
(Techne) set at 50 °C for approximately 10 minutes to allow for the evaporation of 
residual isopropanol. If there was no DNA aggregate visible following the addition of 
isopropanol and shaking, the tubes were subjected to centrifugation for 20 minutes at 
13,000 rpm. The supernatants were then carefully aspirated from the eppendorfs which 
were then placed in a heat block set at 50 °C for approximately 10 minutes to allow for 
the evaporation of residual isopropanol. Finally, DNA pellets were re-suspended in 50 – 
100 μL sterile distilled H2O (sdH2O), the volumes of which were dependant on the size of 
the DNA aggregates. The process of re-suspension was hastened via the use of a heat 
block set at 50 °C. Once dissolved the samples were stored at -20 °C until they were 
required for genotyping.  
 
2.6.2 - Phenol-chloroform extraction of DNA 
Although the phenol/chloroform method of DNA extraction from tissues was a more 
onerous process than that of the isopropanol extraction method, the purity of DNA 
attained via this method was far superior. 500 μL of lysis buffer (1 % SDS (Fisher 
Scientific); 50 mM Tris pH 7.5; 50 mM EDTA; 100 mM NaCl) and 5 μL (20 mg mL-1) 
Proteinase-K was added to tissues and samples incubated for several hours at 50 °C with 
agitation at 600 rpm using a Thermomixer Compact, to allow digestion. Once digested, 
samples were removed from the heat block, vortexed thoroughly using a Vortex genie-2 
(Scientific Industries) and centrifuged for 5 minutes at 13,000 rpm to separate hair and 
debris from the supernatants. Eppendorf tubes were tipped and supernatants poured 
into fresh tubes; pouring supernatants from debris pellets was preferred to pipetting 
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supernatants from debris pellets as the latter invariably resulted in disturbance of 
pellets and subsequent supernatant contamination. To each tube, 500 μL of the bottom 
layer of a 1:1 phenol (Sigma-Aldrich)/chloroform (Fisher Scientific) solution was 
aliquoted and tubes once more vortexed thoroughly. The tubes were then centrifuged at 
13,000 rpm for 5 minutes after which upper aqueous phases were removed using wide-
bore yellow pipette tips (200 μL Gilson with tips removed and autoclaved for sterility) 
and added to 500 μL chloroform. Using fresh wide-bore pipette tips once more, upper 
aqueous phases were removed and added to 1 mL 100 % ethanol (EtOH) and left 
overnight at -20 °C in order to precipitate the DNA from their solutions. The following 
day the samples were removed from the freezer and centrifuged at 13,000 rpm for the 
30 minutes at 4 °C after which supernatants were removed and eppendorfs were left un-
capped to allow for the evaporation of residual EtOH from the samples. Once the EtOH 
had evaporated from the samples, DNA pellets were resuspended in 50 μL sdH2O and 
allowed to dissolve for approximately 10 minutes at 50 °C before being stored at -20 °C 
until required for genotyping.  
 
2.7 - Spectrophotometry 
Following all DNA extractions the concentration and purity of DNA in each sample was 
quantified using a double-beamed U-1800 spectrophotometer (Digilab Hitachi) which 
read at λ260 nm and λ280 nm, for DNA and protein absorbency wavelengths 
respectively. For ease of calculation, 5 μL DNA of each sample was added to 95 μL sdH2O 
which meant the resultant reading at λ260 nm equated to the concentration of DNA in 
μg per μL. The concentration of DNA afforded through the use of spectrophotometry 
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would ultimately determine the volumes of DNA aliquoted per PCR mix, with 1 μg DNA 
being the maximum amount aliquoted per reaction mix.    
  
2.8 – Polymerase chain reaction (PCR) 
Several different suppliers’ products of PCR reagents were tried during the course of the 
project including GoTaq (Promega), Amplitaq (Applied Biosystems), Biotherm (Gene 
Craft) and Dreamtaq (Fermentas). The majority of PCR work was employed using GoTaq 
or Amplitaq, of which the preferred buffer of choice was GoTaq flexi green, by virtue of 
the dyes added to the buffer, which negated the need to add loading dyes and therefore 
saved time. All of the DNA polymerases used were of thermophillic bacterium, Thermus 
aquaticus origin. 25 μL of a PCR master mix was added to 0.2 mL nuclease-free PCR 
tubes (ABgene® PCR plates, Thermo Scientific). Each PCR reaction mix consisted of 5 μL 
(5x) GoTaq flexi green buffer; 3 μL (25 mM) magnesium chloride (MgCl2), for a final 
concentration of 3 mM; 0.05 μL (100 mM) of deoxynucleotides dATP, dGTP, dCTP and 
dTTP (Invitrogen), for a final concentration of 200 μM; 1 μL of target-specific primers 
(Alta biosciences) consisting of 10 % forward primer, 10 % reverse primer (stock 
solutions 100 pmol μL-1) and 80 % sdH2O, for a final concentration of 400 nM of each 
primer; sdH2O to 24 μL and GoTaq or Amplitaq polymerase (5 U μL-1), aliquoted at 0.1 
μL per 25 μL reaction mix. All reagents were thawed on ice except for the DNA 
polymerase, which was used directly from -20 °C and returned immediately afterwards. 
Finally 1 μL (200–1000 ng) of sample DNA was added per PCR tube.  
 
All PCRs were performed with the following standard protocol using either Verity 
(Applied Biosystems) or PCR Express (Hybaid) machines. 
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1 cycle  
- 94 °C for 3 minutes 
- Optimal annealing temperature for 45 seconds (dependent on Tm) 
- 72 °C for 45 seconds 
n cycles 
- 94 °C for 30 seconds 
- Optimal annealing temperature for 45 seconds (dependent on Tm) 
- 72 °C for 45 seconds 
 
A further extension of 72 °C for 10 minutes, followed by a period of cooling at 4 °C 
completed the process.  
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Table 2.3 - Primers used for the purposes of genotyping and sequencing. 
Gene target Forward Reverse Amplicon 
length (bp) 
Design Source 
SRY 5’ TCT–TAA–
ACT–CTG–AAG–
AAG–AGA-C- 3’ 
5’ GTC-TTG-CCT-
GTA-TGT-GAT-
GG- 3’ 
 
404 (Kunieda et al., 
1992) 
CAV3 5’ ATT-CCT-GTT-
CGC-CTG-TAT-C- 
3’ 
5’ AGG-ACC-AAC-
CGA-ATC-TTC-
TG- 3’ 
 
670 (Hagiwara et 
al., 2006) 
NEO 5’ GCA-CGC-AGG-
TTC-TCC-GGC- 3’ 
5’ GTC-CTG-ATA-
GCG-GTC-CGC-C- 
3’ 
639 Provided for by 
Craig Hughs 
(UoB medical 
school) 
Dystrophin mdx 5’ CTT-CTG-TGA-
TGT-GAG-GAC-
ATA- 3’ 
5’ CTA-GCT-TTT-
GGC-AGC-TTT-
CC- 3’ 
 
587 Designed by 
myself 
 
2.9 - Gel electrophoresis 
All gel electrophoreses during the course of this project were performed using 
Horizon® Horizontal Gel Electrophoresis apparatus (Life Technologies) and PCR 
products were resolved in 1-1.2 % agarose (Bioline) in 0.5 x TBE (9.3 g EDTA; 55 g Boric 
Acid (Fisher Scientific) and 108 g Tris, made up to 1 L with dH2O to give a 5 x solution). 
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The agarose was dissolved in the TBE via heating in an NN-E442W microwave oven 
(Panasonic) and ethidium bromide (EtBr) (Life Technologies) added to the molten 
agarose gel at a concentration of 1 μL 50mL-1 (0.2 μL mL-1). The gel apparatus was 
pieced together (Figure 2.3) and the molten agarose solution poured into the gel mould 
and allowed to set. Once set, the wedges and gel comb/s were carefully removed, a 
scalpel was used to remove the wedges in order to ensure no tearing of the gel occurred. 
TBE at 0.5 x was then carefully poured into the apparatus chamber, enough to barely 
cover the gel but ensuring wells were free of any air pockets that may have impeded the 
loading of PCR products. 6 μL of a 100 base-pair (bp) DNA ladder (Biolabs) was then 
aliquoted into the first lane of the gel, followed by 10-25 μL of each PCR sample, which 
were aliquoted to subsequent wells. The volume of PCR sample aliquoted was 
dependent on the size of the wells. Once loaded, the apparatus was connected to a power 
source (Hoefer Scientific Instruments) and gels were run at 80-130 V until DNA ladders 
had separated sufficiently enough to identify base-pair graduations. Once the gels had 
been run, they were carefully removed from the electrophoresis apparatus and viewed 
under ultra-violet (UV) light using a Chromato-Vue Transiluminator (UVP). Safety 
precautions regarding UV light exposure and the handling of gels containing EtBr 
required the wearing of a lab coat, gloves and face visa. Images of gels were printed 
immediately and scanned using a CanoScan LiDE 200 (Canon) and saved as JPEG 
computer files. 
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Figure 2.3 - Electrophoresis gel apparatus. Wedges were placed either side of the 
casting tray and molten agarose poured in to a depth of approximately 1 cm, this depth 
would accommodate 25 μL of PCR product per well without spilling over. After pouring 
enough TBE into the filling chamber to barely cover the gel, the gel was run at 80–130 V 
until the ladders’ graduations had separated sufficiently.     
 
2.10 - DNA sequencing 
The application of PCR and visualisation of PCR products via gel electrophoresis was a 
simple and clear method used to identify male from female embryos and cav3-/- from WT 
and cav3hets. However, PCR to identify the mdx point mutation was notoriously difficult 
and was unsuccessful when tried. In order to confirm the presence of the mdx mutation 
in the DM animals that had been generated, DNA sequencing had to be employed; 
therefore primers were designed to amplify the region of DNA containing the C-T base-
pair change that was present in mdx. 2 μL of PCR product from each sample was 
Comb Wedge Gel casting tray 
Buffer 
filling 
chamber 
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aliquoted into a PCR tube, along with 3.2 pmol. dystrophin mdx forward primer (5’ CTT-
CTG-TGA-TGT-GAG-GAC-ATA 3’) and 4.8 μL nuclease-free H2O (Sigma-Aldrich), for a 
total volume of 10 μL. Samples were then taken to the Functional Genomics and 
Proteomics Unit, University of Birmingham for sequencing, where they were run on a 
capillary sequencer ABI 3730 (Applied Biosystems). DNA sequences were analysed 
using Sequence Scanner Software v1.0 (Applied Biosystems). 
 
2.11 - Processing for paraffin wax embedding 
All samples, whether embryonic or muscles from adult mice used for 
immunohistochemical analysis were processed using a 10 step protocol. Once removed 
from uteri (section 2.4) or excised, samples were promptly placed in ice-cold 4 % PFA (4 
g PFA; 100 mL sPBS) for fixing. The fixation time period was dependent on the sample 
being processed (Table 2.4). Following fixation, samples were washed twice for 10 
minutes per wash in sPBS prior to undergoing dehydration in serial EtOH solutions of 40 
%, 70 %, 95 % and 100 % (EtOH diluted with tap water). An additional step of 
decalcification in 0.5 M EDTA pH 7.5 was necessary for E17.5 embryos and sections of 
adult thoracic cages. Decalcification was followed by an overnight wash in dH2O prior to 
dehydration in EtOH. All of the above steps were employed at 4 °C on a gyro-rocker. 
Following dehydration, samples were placed into either 10 or 25 mL glass jars for xylene 
clearing, a process that was undertaken in a fume hood. Following clearing for the 
appropriate time (Table 2.4), the xylene was replaced with molten (60 °C) paraffin wax 
(Paraplast, BDH), with the use of a wax dispenser (Bavimed). Following wax 
dispensation, jars were then placed in a slowly rocking hybridisation oven/shaker SI 
2OH (Stuart Scientific) set at 60 °C for the required duration (Table 2.4). For the final 
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stage of the process, molten wax was dispensed into the bottom of 22 mm x 22 mm 
plastic moulds with peel-away sides (Polysciences Inc.), samples removed from glass 
jars using heated forceps and placed into moulds. Embryos were oriented into the 
moulds right-side down and adult muscle samples carefully placed so that muscles 
fibres would be oriented vertically through the wax to allow for cross-sectional cutting. 
Once the samples were satisfactorily aligned, the moulds were filled with more molten 
wax. Filter paper (Fisher Scientific) labels stating the age of the sample, mouse strain, 
date of sacrifice and if a muscle sample, which particular muscle, were inserted into the 
molten wax of the mould. Blocks were then allowed to solidify at room temperature for 
several hours before being stored at 4 °C until required for sectioning (section 2.12). 
Although processes in the protocol were the same for all stages of mice (additional steps 
for E17.5 and thoracic cages mentioned previously), durations of processes varied 
according to the developmental stage of the mice. Table 2.4 shows a summary of all 
processes and their respective duration for each developmental stage (adapted from 
Deborah Merrick’s 2006 thesis).  
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Table 2.4 - Processes involved in paraffin embedding of embryonic and neonate 
mice and adult muscle samples 
Stage of Process E11.5 E13.5 E15.5 E17.5 Adult muscle* 
4 % PFA  3 h 20 h 20 h 24 h 24 h 
sPBS wash 2x10 m 2x10 m 2x10 m 2x10 m 2x10 m 
0.5 M EDTA pH 7.5 NA NA NA 3 days 3 days 
dH2O  NA NA NA Overnight  Overnight 
40 % EtOH 30 m 1 h 1.5 h 1 day 1 day 
70 % EtOH 30 m 1 h 1.5 h 1 day 1 day 
95 % EtOH 30 m 1 h 1.5 h 1 day 1 day 
100 % EtOH 3x30 m 3x1 h 3x1.5 h 2 days 2 days 
Xylene 3x30 m 3x1 h 3x1.5 h 3 days 3 days 
Paraffin wax 2 in 24 h 2 in 24 h 3 in 48 h 3 in 48 h 3 in 48 h 
 
 
2.12 - Microtome sectioning of paraffin blocks  
A Medax water-bath (Camlab), which was set at 40 °C was filled with tap water and 
allowed to reach the required temperature. Paraffin wax blocks containing embryos or 
muscle samples were selected and removed from cold storage individually for 
sectioning; this ensured the wax remained cold during cutting, making the process of 
sectioning far easier than with a warmer block. Excess wax adjacent to specimens was 
removed using a razor blade and blocks securely clamped in an 1150/Autocut 
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microtome (Reichert-Jung (Figure 2.4)); though care was taken not to damage blocks 
through excessive tightening of the clamp. Blocks were aligned parallel to the blade and 
vertical to the floor and micro-adjustments of the alignment screws of the microtome 
ensured blocks were cut evenly across their surfaces. Wax sections of 20 μm were 
initially cut from fresh blocks which were reduced to 5-8 μm once the samples had been 
reached. When cutting embryos, sagital sections were cut to the mid-line of the sample 
in accordance with The Atlas of Mouse Development (M. H. Kaufmann, 1992, Elsevier 
Academic Press); muscle samples were cut at the muscles’ belly. Cut sections were 
carefully placed on the water’s surface using two artist’s fine paint brushes to allow any 
creases within the wax to unfold. Individual muscle samples did not have to be so 
meticulously aligned as fibre direction was easily ascertained macroscopically and 
sagital and transverse sections cut accordingly. Sections were ‘scooped’ onto 
Superfrost® Plus electrostatically charged microscope slides (VWR) from the water’s 
surface and comprehensively labelled using a pencil. Ink could not be used as it would 
have been washed off during the process of IHC (section 2.13). Any excess water 
trapped between the wax and slides was drained with paper towels and slide mounted 
sections incubated for a minimum of 1 hour or left overnight at 37 °C in a Heraeus 
electronic incubator (Thermo Scientific) to ensure adherence of sections onto slides.  
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Figure 2.4 - Microtome used for the cutting of paraffin wax embedded sections. 
Paraffin wax blocks containing samples were clamped into position and aligned using 
the adjustment screws. Section thickness was selected using the micrometer dial and 
sections were cut with smooth clockwise rotations of the sectioning wheel.   
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2.13 – Immunohistochemistry (IHC) 
Embryos and adult muscle tissues processed for paraffin wax embedding were analysed 
using IHC. The streptavidin/biotin method of signal amplification was employed for all 
IHC performed during the course of this project (as described in Merrick et al., 2007).  
 
2.13.1 - De-waxing, rehydration and antigen retrieval 
Slide mounted sections were placed into metal slide racks and de-waxed with two 
washes in the solvent xylene; one 5 minutes wash and one 10 minutes wash, which were 
performed in the confinements of a fume-hood. Separate glass vessels were used for the 
two washes which were labelled ‘A’ (5 minutes) and ‘B’ (10 minutes). Following de-
waxing of the sections, they were then rehydrated using serial dilutions of EtOH (Fisher 
Scientific), beginning with two x 2 minutes’ immersions in 100 % EtOH, followed by 
further immersions in 95 %, 90 %, 70 %, 50 % and 30 % EtOH solutions, all for a period 
of 2 minutes. EtOH solutions were diluted using tap water. While in the EtOH, the metal 
slide racks were tapped against the bottom of the glass vessels every 30-60 seconds, this 
helped to eliminate any air bubbles from the sections which if left, may have impeded 
the rehydration process. Following rehydration, slides were then washed for 10 minutes 
in PBS using a Gyro-Rocker® STR9 shaker (Bibby Sterlin Ltd.). The next stage involved 
an antigen retrieval step which was necessary to break the amino acid cross-linkage 
bonds that had been made during fixation of the samples in PFA. Without this step any 
antigens of interest in the samples would be unrecognisable to their respective 
antibodies and as a consequence, immunodetection of proteins impossible. A buffer 
consisting of 4.7 g sodium citrate (Fisher Scientific), dissolved in 1.6 L dH2O at pH 6 was 
used for the process of antigen retrieval, which was poured into a Smart-plus pressure 
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cooker (Prestige) and brought to boiling on a hot plate (Russell Hobbs). The slides were 
then placed into the solution, the lid locked and the solution brought to pressure on 
setting II, which was maintained for 90 seconds. The cooker was then promptly removed 
from the heat and cooled under cold running tap water for approximately 3 minutes; 
while cooling, the lid of the pressure cooker was removed upon depressurising of the 
cooker (by releasing steam) as soon as was possible. Slides were then washed for 10 
minutes in fresh PBS as previously.  
 
2.13.2 - Peroxidase quenching, blocking and incubation with primary antibodies 
To enable adjacent sections of slides to be immunolabelled using different antibodies 
without cross-incubation and to contain reagents aliquoted to areas immediately 
surrounding sections, an ImmEdgeTM wax barrier pen (Vector Laboratories) was used to 
draw around each section. Care was taken during this process to ensure sections did not 
dry out, as this would have impaired the quality of staining. Having drawn around each 
section on a slide, the slide was then placed into a separate slide rack in PBS. When all of 
the slides had been completed, they were placed into coplin jars containing 3 % 
hydrogen peroxide (H2O2)(Sigma Aldrich) in tap water for 5 minutes followed by 1 hour 
in 0.5 % H2O2 in 100 % methanol (MeOH)(Fisher Scientific), in order to quench 
endogenous peroxidase activity. Peroxidase quenching was then followed by three 
washes in PBS +0.05 % Tween20 (Sigma Aldrich), 10 minutes per wash. Sections were 
then blocked in TNB (0.1 M Tris pH 7.5; 0.15 M NaCl (BDH); 0.25 g blocking reagent 
(TSA kit Perkin-Elmer)) for 30 minutes, after which the TNB was removed by tapping 
the slides on their sides. For the final stage of day one, sections were incubated in 
primary antibodies; all of which were diluted in TNB. Where possible, one section per 
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slide was aliquoted TNB in place of primary antibody, as a control. Sections were 
incubated with primary antibodies overnight at 4 °C in a humidity chamber, which 
consisted of a lidded tray lined with PBS-soaked filter paper, sealed with masking tape.   
 
Table 2.5 - Antibodies used for IHC during the course of this project. Primary and 
secondary antibodies are listed along with their working concentration and 
immunoglobulin (Ig) isotypes.  
Name Antigen Host Ig class Dilution 
MF20 Pan-myosin Mouse IgG 1/1,000 
MY32 Fast-myosin Mouse IgG 1/1,000 
PAX7 Pax7 Mouse IgG 1/1,000 
CAV3 Caveolin-3 Mouse IgG 1/1,000 
Biotinylated 
anti-mouse 
IgG 
Mouse IgG Goat N/A 1/1,000 
 
2.13.3 - Incubation in secondary antibodies and signal amplification 
Following overnight incubation in primary antibodies, antibodies were carefully 
removed from sections via tapping the slides on the base tray of the humidity chamber. 
To eliminate the possibility of unintentional cross-incubation with neighbouring 
antibodies while washing, slides were individually dipped in fresh PBS before 
commencing with three washes for 10 minutes each in PBS +0.05 % Tween20. Sections 
were then incubated in secondary biotinylated antibodies for 1 hour at room 
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temperature after which they were washed three times for 10 minutes each wash in PBS 
+0.05 % Tween20. Streptavidin conjugated with horse-radish peroxidase (SA-HRP) 
(Perkin-Elmer), diluted 1/100 in TNB was then aliquoted to sections and incubated for 
30 minutes, followed by three more 10 minutes washes in PBS +0.05 % Tween. The next 
stage was signal amplification, which was achieved using biotinyl tyramide (TSA kit, 
Perkin-Elmer), diluted 1/50 with the kit diluent, aliquoted to sections and incubated at 
room temperature for between 8 and 10 minutes (dependent on antibodies used). After 
three more 10 minutes washes in PBS+0.05 % Tween20, sections were incubated for a 
second time for 30 minutes with SA-HRP followed by three final 10 minutes washes in 
PBS+0.05 % Tween20.  
 
2.13.4 - Antigen visualisation, counter staining, dehydration and mounting 
Antigen visualisation was achieved using the chromogen 3, 3’ diaminobenzidine 
tetrahydrochloride (DAB, Dako) at 1 mg ml-1 dissolved in sPBS. To 1 mL of the DAB 
solution, 1 μL of a 30 % H2O2 stock solution was added, to give a working solution of 
0.03 % H2O2.  DAB was then aliquoted to sections using a Pasteur pipette (Sarstedt) and 
incubated for 5-8 minutes, after which slides were washed twice for 5 minutes per wash 
in tap water. DAB is a suspected carcinogen and irritant; therefore its use and disposal 
have strict protocols that must be adhered to. All work involving DAB was carried out in 
a designated foil-lined tray and all equipment that had direct contact with DAB (i.e. 
Pasteur pipette, pipette tips and bijoux tube that contained DAB) were placed into 
sodium hypochlorite (VWR) for 24 hours to de-activate the DAB. Tap water from the 
first wash had sodium hypochlorite (NaClO) added and could be safely disposed of down 
a sink with copious amounts of water after 24 hours; tap water from the second wash 
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was safe to be poured down the sink immediately after use; again with copious amounts 
of water. In addition to a lab coat, two pairs of gloves were also worn and they too were 
soaked in NaClO for 24 hours before being deposited into a specially designated 
hazardous waste bin. Following antigen visualisation, slides were counterstained in 
haematoxylin (Gills) for 2 minutes before being washed in Scott’s tap water (50 μL 10 M 
NaOH (BDH); 400 mL tap water) for a further 5 minutes. Slides were then briefly (<1 
second) dipped in an acid alcohol solution (0.5 % HCl (Fisher Scientific) in 70 % EtOH) 
then immediately washed once more for 5 minutes in Scott’s tap water. The washing 
process was concluded with 5 minutes under running tap water; care was taken during 
this process to ensure sections were not damaged by leaving the lid to the vessel on, but 
open ajar and water delivered to the vessel via a hose connection. Sections were then 
dehydrated with the same serial EtOH concentrations as were used in the rehydration 
process; 30 %, 50 %, 70 %, 90 % and 95 % each for 2 minutes and finally twice for 2 
minutes in 100 % EtOH. Xylene washes for 5 and 10 minutes, using vessels ‘B’ and ‘A’ 
respectively were used to clear the EtOH from sections. Having been cleared, slides 
could now have coverslips mounted on them. DePex mounting medium (Gurr, BDH) was 
used to mount the 22 mm x 64 mm (VWR) coverslips, which after a small amount of the 
medium had been applied, were pressed firmly enough to dissipate the DePex over the 
sections. Both xylene washes and mounting of slides were carried out in a fume-hood; in 
which slides were left to dry overnight before being visualised using an Eclipse E600 
light microscope (Nikon). Images of all IHC runs were taken using an E995 digital 
camera (Nikon) and saved as JPEG files.  
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2.14 - Haematoxylin and eosin staining (H&E) 
Tissue histology was employed on postnatal muscle sections using H&E staining; fibre 
morphology, myonuclei positioning and fibre regeneration were analysed using this 
method of tissue staining. Slide-mounted sections were first de-waxed in xylene and 
rehydrated in EtOH as previously described (section 2.13.1), before being placed in 
haematoxylin for 2 minutes. Slides were then washed in Scott’s water for 5 minutes after 
which they were dipped briefly in acid alcohol and washed once more in Scott’s water 
for 5 minutes. Sections were then partially dehydrated in EtOH solutions of 30 %, 50 %, 
70 % and 90 % for 2 minutes each followed by immersion in eosin (0.5 % eosin (Gurr, 
BDH); 0.5 % acetic acid (Fisher Scientific); 90 % EtOH) also for 2 minutes. The 
dehydration step was completed using a 95 % and two 100 % EtOH solutions, again for 
2 minutes each. Xylene clearing and mounting as has been previously described (section 
2.13.4) completed the process.  
 
2.15 - Protein extraction 
2.15.1 - Protein extraction from embryos 
Embryonic proteins were taken from all mouse strains at E11.5, E13.5, E15.5 and E17.5 
and used for analysis via western blotting. Uteri were removed and embryos liberated as 
previously described (section 2.4), placed in a glass homogeniser and enough RIPA 
buffer (50 mM Tris; 150 mM NaCl; 1 % Nonidet-P40 or Igepal CA-630 (Sigma-Aldrich); 
0.5 % deoxycolic acid (Sigma-Aldrich); to 100 mL with sdH2O) added to barely cover the 
embryos. In order to inhibit endogenous protease activity, 1 protease inhibitor tablet 
(Complete mini, Roche), which had been dissolved in 1.5 mL sdH2O while on ice, was 
added to the RIPA buffer and used at 1.5:8.5, protease inhibitors: RIPA buffer. Embryos 
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were homogenised and poured into 5 mL bijoux tubes, homogenates drawn into 
Plastipak syringes (BD) using 18 gauge hypodermic needles to shear genomic DNA and 
promptly aliquoted into 1.5 mL eppendorf tubes. Tubes were then spun for 30 minutes, 
14,000 RPM at 4 °C in a 5415C centrifuge (Eppendorf) after which the supernatants 
were removed from the debris, aliquoted to fresh labelled eppendorfs and stored at -20 
°C until required. 
 
2.15.2 - Protein extraction from fresh muscle samples and frozen samples 
Adult muscle tissue and all samples that had been snap frozen and stored at -20 °C could 
not be readily homogenised using a glass homogeniser as was used for embryos freshly 
taken from uteri. Instead, samples were ground together with RIPA, using a pestle and 
mortar. The process of grinding was performed on ice to minimise protein degradation 
and was a very time consuming and onerous task. Once ground, homogenates were 
drawn into syringes using 18 gauge hypodermic needles to shear genomic DNA and 
processed as described previously (section 2.15.1).  
 
2.16 - Protein assay 
Once proteins had been extracted from the samples, it was necessary to quantify the 
concentration of protein in each sample, in order to allow for equal loading when 
performing western blotting. Samples were removed from storage at -20 °C and placed 
on ice to thaw (proteins were always kept on ice to prevent degradation). Bovine serum 
albumin (BSA) standards (Pierce) of 1, 2, 5, 10, 15, 25 and 50 μg mL-1 were made from a 
stock solution of 2 mg mL-1 and 100 μL of each was aliquoted in duplicate to the first two 
rows of a 96 well plate (Nunc). Two wells of sterile distilled water (sdH2O) were also 
63 
 
aliquoted as blank controls. The protein samples were diluted to 1/100 and 1/400 with 
sdH2O and 100 μL of each sample were aliquoted in duplicate alongside the blank and 
BSA standards. To which wells standards and samples were aliquoted was recorded. 100 
μL of Coomassie® Protein Assay Reagent (Pierce) was then added to each well and the 
plate left at room temperature for 20 minutes on an SO1 Orbital Shaker (Stuart 
Scientific). Protein concentrations were then calculated using an E max microplate 
reader (Molecular Devices), which read protein concentrations at a wavelength of 595 
nm. Results from the microplate reader were printed using a Laserjet 4ML (Hewlett 
Packard) and loading volumes required for western blotting were then calculated from 
the results provided.  
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Figure 2.5 – Representative illustration of a protein assay plate. Serial dilutions of 
BSA standards were aliquoted in duplicate to the first two rows of a 96 well plate 
(columns 2-8, rows A/B); dH2O was also aliquoted as blank controls (column 1, rows 
A/B). Protein samples were diluted 1/100 and 1/400 and aliquoted also in duplicates; 
1/400 dilutions were aliquoted laterally adjacent to 1/100 dilutions (rows C-H). An 
equal volume of Coomasie assay reagent was added to each well and the plates were 
subjected to colourimetric analysis. The deeper the blue colouration in the illustration is 
indicative of a greater concentration of protein in the sample. Dotted circles represent 
empty wells. The example shown is merely for illustration purposes and does not 
represent any actual protein assay performed during the project.        
 
2.17 - Western blotting  
The quantification of proteins of interest from embryonic, neonatal and adult muscle 
tissue of all murine strains studied was ascertained via SDS polyacrylamide gel 
electrophoresis (PAGE) and western blotting. All western blotting was performed using 
equipment from the mini PROTEAN system® (Bio-Rad Laboratories) using standard 
protocols.  
 
2.17.1 - Gel casting 
Glass plates were selected ensuring that front plates was shorter than outer plates for 
ease of loading and were swilled in hot water and dried with clean paper towel before 
being cleaned using isopropanol. Once residual isopropanol had evaporated, plates were 
clamped into gel casting apparatus (figure 2.6) and a 12 % resolving gel (4 mL 30 % 
Ultra pure ProtoGel® acrylamide (Geneflow); 2.5 mL 1.5 M Tris pH 8.8; 100 μL 10 % 
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SDS; 3.3 mL sdH2O; 100 μL 10 % ammonium persulfate (Sigma-Aldrich); 4 μL TEMED 
(Sigma-Aldrich)) pipetted to approximately ¾ the height of the outer plate. As proteins 
of interest had molecular masses of between 17.5 and 60 kilodaltons (kDa), 12 % gels 
were used for their resolution. Both resolving and stacking gels were made up in 50 mL 
Falcon tubes (BD Biosciences), with ammonium persulfate and TEMED added 
immediately prior to being pipetted between the plates.  The setting of gels in the Falcon 
tubes was indicative that the gels between the plates had also set. A layer of isopropanol 
was then added to the resolving gel solution in order to eliminate any air bubbles from 
the gel’s surface. The gel was then allowed to set. Once set, the isopropanol was carefully 
decanted from the gel and any residual isopropanol removed with the use of filter paper.  
The plates were then clamped back into the gel casting apparatus and the stacking gel 
added (1.4 mL 30 % acrylamide; 100 μL 10 % SDS; 1.2 mL 0.5 M Tris pH 6.8; 5.62 mL 
sdH2O; 85 μL 10 % ammonium persulfate; 8.5 μL TEMED) to the top of the inner plate. A 
comb of the appropriate size (dependent on number of samples being analysed) was 
then carefully inserted between the plates, ensuring there were no bubbles of air 
trapped between the comb and stacking gel. 
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Figure 2.6 - Gel casting. Glass plates were assembled and clamped into casting 
apparatus as shown. Resolving gel was pipetted between the plates to the level indicated 
and setting allowed, after which stacking gel was added to the top of the inner plate and 
a comb carefully inserted between the plates.  
 
2.17.2 - Protein sample preparation, loading and running of gels 
While the gels were setting the protein samples, which had been removed from storage 
at -20 °C and thawed on ice, were prepared. Proteins, unlike DNA are very labile 
molecules and must therefore be kept on ice at all times. Protein concentrations had 
been ascertained prior (section 2.16) and were diluted with sdH2O to 1 μg μL-1, of this 
stock dilution, 7.5 μL of each sample was aliquoted into eppendorfs. An equal volume of 
2x Laemmli sample buffer (Sigma-Aldrich) was also added to the eppendorfs to give a 
Comb 
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total volume of 15 μL and the samples were then boiled for 5-10 minutes in an SBH200D 
digital block heater (Stuart Scientific) set at 95 °C. After boiling, the samples were 
removed from the heating block and placed on ice until required for loading into the gel.  
Once the stacking gel had set, it could be loaded with the protein samples. The gel comb 
was carefully removed from the stacking gel and the gel chamber clamped into the 
electrophoresis apparatus, ensuring the front of the chamber was facing inwards. The 
inner chamber of the electrophoresis apparatus was then filled with running buffer (3 g 
Tris; 14.4 g glycine (Fisher Scientific); 10 mL 10 % SDS; dH2O to 1 L) until it over spilled 
into the outer chamber. Bubbles were then removed from the power filament at the 
bottom of the apparatus through positioning and gently tapping the apparatus on the 
laboratory bench until all visible bubbles were released to the surface. Following this, 
the inner chamber was topped up with running buffer ready for protein loading. Into the 
first lane, 8 μL of a Prestained Broad Range marker (Biolabs) was loaded using long thin 
pipette tips, followed by 15 μL of each of the samples. After checking and filling the inner 
chamber with running buffer, the PS 500X power source (Hoefer Scientific Instruments) 
was run at 100 V. The gel was left to run until the dyes from the Laemmli buffer had 
migrated to the bottom of the gel, upon which the run was terminated.  
 
2.17.3 - Transfer to membrane 
While the run was concluding, items required for the transfer step were prepared. For 
each gel, two sponges and four pieces of filter paper were soaked in transfer buffer (3 g 
Tris; 14.4 g glycine; 200 mL MeOH; to 1 L with dH2O) and a piece of Amersham™ 
Hybond™ - ECL nitrocellulose membrane (GE Healthcare) was soaked in dH2O for 1 
minute before being soaked in transfer buffer. Once the run had been completed, the 
68 
 
plates were removed from the apparatus and separated using a scalpel, which was also 
used to cut the stacking gel from the resolving gel. Transfer cassettes were opened and 
laid clear side down onto a tray. A sponge, two pieces of filter paper, the membrane, gel, 
two more pieces of filter paper and the remaining sponge were placed on the clear side 
of the cassette (Figure 2.7) and a pipette (Costar) rolled across the surface to eliminate 
any bubbles. The cassette was then closed and the ‘sandwich’ placed into the cassette 
holder ensuring the black-side of the cassette faced toward the black-side of the cassette 
holder. An ice block was also added to assist with cooling and the transfer chamber filled 
with transfer buffer. Membrane transfer was performed at 4 °C and run at 100 V for 1 
hour 15 minutes using an EV231 power pack (Consort).  
 
 
 
 
 
 
 
Figure 2.7 - Illustrated representation of cassette ‘sandwich’. Transfer cassettes 
were assembled as shown, starting from the clear side of the cassette and all 
components were soaked in transfer buffer prior. When completed, a pipette was rolled 
across the sandwich to eliminate any air bubbles which could have impeded the transfer 
of membranes from the gel to the membrane. Cassettes were closed and sealed before 
being placed in a cassette holder, ensuring the black side of the cassette was adjacent to 
the black side of the cassette holder.    
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2.17.4 - Membrane probing 
Transfer cassettes were removed from 4 °C and filter paper and gels discarded as non-
hazardous waste. As a means of identifying the side of the membrane onto which the 
proteins had been transferred, the top left corners of the membranes (adjacent to 
marker) were removed and the membranes incubated in blocking buffer (PBS+ 0.1 % 
Tween® 20; 5 % dried skimmed milk, Marvel, Premier International Foods) for 1 hour 
at room temperature with gentle agitation. Following blocking, the membranes were 
incubated in primary antibodies diluted in blocking buffer either overnight at 4 °C, or for 
2 hours at room temperature, both with violent agitation. For economy of antibodies, 
membranes were incubated with primary antibodies in sealed plastic bags, which were 
cut according to the size of the membrane and securely taped to trays.  
 
Table 2.6 - Antibodies used for western blotting during the course of this project.  
Primary and secondary antibodies are listed along with their working concentration and 
immunoglobulin (Ig) isotype.  
Name Host Ig Class Used at 
Anti-pax7 Mouse IgG 1/1,000 
Anti-NTP-2 Rabbit IgG 1/1,000 
Anti- caveolin-3 Mouse IgG 1/500 
Anti-α-tubulin Mouse IgG 1/1,000 
Anti-β-actin Mouse IgG 1/20,000 
Biotinylated anti-mouse IgG Goat N/A 1/1,000 
Biotinylated anti-Rabbit Ig Donkey N/A 1/1,000 
Anti-mouse IgG-HRP Goat N/A 1/1,000 
Anti-rabbit IgG-HRP Goat N/A 1/1,000 
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2.17.5 – Antigen detection 
There were two different methods used for antigen detection; enhanced 
chemiluminescence (ECL) and fluorescence, of which the latter utilised two protocols; 
the first of which employed the use of fluorescently conjugated secondary antibodies 
and the second the biotin/streptavidin system of signal amplification. Both methods 
shall be described separately for ease of reading. 
 
2.17.5.1 - Detection using ECL 
Following incubation in primary antibodies, the membranes were swilled with and then 
washed four times for 5 minutes each wash in PBS + 0.1 % Tween® 20 (PBST) with 
gently shaking. The membranes were then incubated in secondary horse-radish 
peroxidase (HRP) conjugated antibodies diluted in blocking buffer for 1 hour at room 
temperature with violent agitation, again in sealed plastic bags and then swilled and 
washed four times for 5 minutes in PBST. Following washing, the membranes were 
dabbed on tissue paper and incubated in SuperSignal® West Pico chemiluminescence 
substrate (Pierce) for approximately 30 seconds (500 μL of each substrate was mixed 
together immediately prior to use), dabbed dry and placed face down onto cling-film. 
The cling-film wrapped membranes were then taped face up into x-ray cassettes and 
developed onto photographic film (Scientific Laboratory Supplies) using an X-Ograph 
compact X2 (X-Ograph Imaging Systems Ltd). Exposure times ranged from a few seconds 
to several hours.    
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2.17.5.2 - Detection using fluorescence 
Following incubation in primary antibodies, membranes were swilled with and then 
washed four times for 5 minutes in PBST with gently shaking before incubation for 1 
hour at room temperature with Odyssey (LI-COR® Biosciences) secondary antibodies 
diluted in blocking buffer (fluorescence conjugated antibodies are light sensitive, 
therefore incubations were carried out in either LI-COR® dark boxes or wrapped in 
aluminium foil). Following four more 5 minutes washes in PBST, the membranes were 
washed for 5 minutes in PBS before visualisation using the Odyssey Infrared Imaging 
System.  
 
2.17.5.3 - Detection using Streptavidin 
Some proteins were difficult to visualise using fluorescently conjugated secondary 
antibodies alone and in these cases an intermediate step was added to enhance 
signalling. The membranes were washed four times for 5 minutes in PBST following 
incubation in primary antibodies and then incubated for 1 hour at room temperature in 
biotinylated secondary antibodies diluted in blocking buffer. Following four more 
washes for 5 minutes in PBS, the membranes were then incubated in Dylight™ 800 
Conjugated Streptavidin (Thermo Scientific) diluted 1/15,000 in PBS for 30 minutes. As 
was employed for incubation in Odyssey secondary antibodies, incubation with 
streptavidin was performed using LI-COR® dark boxes. Following four final 5 minutes 
washes in PBS, the membranes were visualised using the Odyssey Infrared Imaging 
System. 
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All images were saved as high quality JPEG images on the Odyssey system and 
transferred to a removable storage device.   
 
2.18 - Analysis of regenerating areas in adult muscle 
Quantification of regenerating areas in postnatal derived skeletal muscle tissue was 
calculated with the use of an Eclipse E600 light microscope with a 10 x 10 square grid 
integrated into the eyepiece. The objective of choice utilised for this was x20. The 
numbers of squares covered with areas of regeneration on the grid were counted for 
each section analysed, as were those squares not covered with regenerating areas 
(Figure 2.8). This was repeated across the whole section and regenerating areas 
calculated as percentages of the total area of the section. Grid areas were calculated 
using a 1 mm/100 stage mounted scale micrometer (C. Baker, London).   
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Figure 2.8 - Early stage regeneration at x 20 magnification. Areas of regeneration 
were calculated using an eyepiece integrated 10 x 10 square grid. The numbers of 
squares covered with areas of regeneration on the grid were counted, as were those 
squares not covered with regenerating areas. In the example given for the top row, left 
to right, this would be as follows; square #1, no regeneration; #2, ¾  regeneration; #3, 
whole square regeneration; #4, ¼ regeneration; #5, no regeneration; #6, ⅓ 
regeneration; #7, ⅔ regeneration; #8; #9; #10, no regeneration, for a total of 3 
regenerating squares out of 10. This was repeated across the whole section and 
regenerating areas calculated as percentages of total section areas. Scale bar: 100 μm.  
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2.19 - Statistical analysis 
All statistical analyses were performed using two-tailed student’s t-tests and where 
appropriate asterisks designated as follows; P<0.05 = *, P<0.01 =**, P<0.001 =***. 
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CHAPTER 3 - GENERATION OF DOUBLE-MUTANTS AND CHARACTERISATION OF 
DMHET EMBRYOS 
 
This chapter focuses on the generation of DM (mdx mouse deficient in caveolin-3) and 
DMhet (mdx mouse with reduced caveolin-3) mice, the analysis of which allowed a 
distinction to be made between the pathology caused by the loss of dystrophin and that 
caused by an excess of caveolin-3. Prenatal studies were employed using DMhets due to 
dystrophic phenotypes shown in mdx and cav3-/- embryos.  
 
 
3.1 – INTRODUCTION 
 
The global degeneration of muscle tissue in DMD has long been believed to manifest 
during infancy, although elevated serum creatine kinase levels and abnormalities in 
foetal muscle histology were shown many years ago (Emery, 1977). The DMD mouse 
model, mdx, was thought to initially present with the dystrophic malady at around three 
weeks of age, based on a histopathological phenotype which includes abnormal 
variation in fibre-size, centralised myonuclei, raised levels of serum creatine kinase and 
fibre necrosis (Bullfield et al., 1984; Fletcher et al., 2007). Postnatal phenotypes 
observed in a mouse model for LGMD-1C, cav3-/-, include fibre degeneration between 
five and eight weeks of age, centralised myonuclei and mononuclear cell infiltration, 
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restricted to the muscles of distal hindlimbs, or to be more specific, soleus muscles 
(Hagiwara et al., 2000; Hagiwara et al., 2006). Research from the Smith group 
established that dystrophic phenotypes for both mdx and cav3-/- have embryonic origins; 
with increased cell proliferation and apoptosis evident as early as E11.5 and E15.5 for 
mdx and cav3-/- respectively; perturbations in the SMSc populations of dystrophic 
mutants were also observed (Merrick et al., 2009). These data, pertaining to the onset of 
a dystrophic phenotype in immature muscle, are supported by abnormalities that were 
found in mdx derived undifferentiated myoblasts, where perturbed mitochondrial 
physiology and a reduction in proteins of the mitochondrial respiratory machinery were 
observed (Onopiuk et al., 2009).  
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3.2 – RESULTS 
 
3.2.1 – Generation of DM litters 
3.2.1.1 - Litters produced via mdx and cav3-/- crosses 
Initial matings between cav3-/- males and mdx females resulted in litters in which males 
were hemizygous and females heterozygous for mdx and both males and females were 
heterozygous for Cav3 (Figure 3.1 A). F1 progeny genotypes from these initial crosses 
were therefore mdx/cav3+/- and mdx+/-/cav3+/-, for males and females respectively. Only 
male embryos were required for analysis, thus F1 embryos were sexed from tail-clips, 
placenta or amnion using the following sry (sex-determining region Y) specific primers; 
forward – 5’ TCT–TAA–ACT–CTG–AAG–AAG–AGA-C 3’ and reverse – 5’ GTC-TTG-CCT-
GTA-TGT-GAT-GG 3’. Figure 3.1 E is an image of a gel with EtBr stained products from a 
sry PCR. In the example given, there were three males and five females in the litter; the 
controls’ DNA was extracted from adult tail-clips; ‘m’ and ‘f’ in reference to male and 
female respectively. An additional control consisting of PCR reaction mix minus any DNA 
is labelled as ‘0 DNA’ in the figure.  
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Figure 3.1 
Generation of caveolin-3 deficient mdx mice (DM). (A) Crosses between mdx females 
and cav3-/- males resulted in F1 progeny where all males were hemizygous (XdY) and 
females heterozygous (XdX) for mdx; both males and females were heterozygous for 
Cav3 (Aa). (B) F1 males (DMhets) were backcrossed with mdx females to produce F2 
progeny where 50 % (males and females) were mdx and 50 % (males and females) were 
DMhets. (C) F2 DMhet females were crossed with DMhet males to produce F3 litters 
comprising of three possible different genotypes; mdx (25 %), DMhet (50 %) and DM 
(25 %). (D) Sibling F3 DM males and DM females were then crossed to establish a pure 
F4 DM strain. (E) F1 embryos were sexed using primers to Y-chromosome specific sry as 
only males were DMhets; the gel shown is a typical example. Denotations: X, WT X-
chromosome located Dmd gene; Xd, mutated Dmd (mdx) gene; Y, Y-chromosome; A, WT 
Cav3 autosomal gene; a, mutated Cav3 gene.  
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3.2.1.2 – mdx and DMhet littermates  
F2 litters, resulting from backcrossing DMhet males with mdx females, consisted of two 
possible genotypes; mdx (males and females) and DMhets (males and females), in the 
expected ratios of 1:1 (Figure 3.1 B). F2 embryos’ and adults’ genotypes were 
ascertained via neo PCR using the following primers; forward - 5’ GCA-CGC-AGG-TTC-TCC-
GGC 3’ and reverse - 5’ GTC-CTG-ATA-GCG-GTC-CGC-C 3’. Male and female embryos of both 
genotypes were processed for either paraffin wax embedding for immunohistochemical 
analysis or proteins were extracted to be used for western blotting. Adult DMhets were 
crossed to produce offspring consisting of entire DM litters.     
 
The next stage of the breeding programme involved crossing DMhet males and DMhet 
females (Figure 3.1 C). As there were expected to be three possible genotypes from 
matings between DMhet males and DMhet females; mdx, DMhets and DM, in the 
Mendelian ratios of 1:2:1 or 25 % : 50 % : 25 % respectively; both Cav3 and neo statuses 
of littermates had to be ascertained via PCR. The Cav3 primers used were as follows; 
forward -  5’ ATT-CCT-GTT-CGC-CTG-TAT-C 3’ and reverse - 5’ AGG-ACC-AAC-CGA-ATC-
TTC-TG 3’. Genotyping of the first litter to be born from successfully crossing a DMhet 
male and DMhet female is shown in an image of an electrophoresis gel (Figure 3.2 A). Of 
nine live pups from a litter of ten, one was mdx (#4; Cav3 positive, neo negative), six 
were DMhets (#3, #5-9; Cav3 positive, neo positive) and there were two DM (#1, #2 
Cav3 negative, neo positive), affording ratios of 1:6:2, or 11.1 % : 66.7 % : 22.2 % for 
mdx, DMhet and DM respectively. The genotype of the deceased pre-weaned pup is not 
known, so the ratios and percentages of genotypes stated are not wholly accurate as a 
comparison to the expected. The two DMs were both males and these were paired with 
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DMhet females from which one litter of two DM female pups (#10 and #11) were born 
(sired by DM male #2). These DM females were paired with the DM males; #1 with #10 
and #2 with #11 and a litter of three pups (#12, #13, #14; all Cav3 negative, neo 
positive) born to DM pair #2 and #11. The DM genotypes of pair #2 and #11 were 
confirmed (Figure 3.2 B) and re-confirmed along with their progeny (Figure 3.2 C). 
Samples from WT, mdx, cav3-/-, DMhet and PCR reaction mix only were among those 
used as controls. Subsequent litters proved to be DM (Figure 3.2 D).  
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Figure 3.2 
Genotyping of F2, F3 and F4 litters. F2 litters resulting from crosses between DMhet 
males and mdx females were of two possible genotypes; mdx and DMhet and F3 litters, 
resulting from crosses between DMhet males and females, were of three possible 
genotypes; mdx, DMhet and DM. Genotypes of both were ascertained via establishment 
of Cav3 and neo statuses. The figure shows images of EtBr stained amplicons from Cav3 
and neo PCRs. (A) Electrophoresis gel image of genotyping the first litter to be born from 
successfully crossing a DMhet male with a DMhet female. Of nine littermates, one was 
mdx (#4), six were DMhet (#3, #5-9) and two were DM (#1, #2). From this litter, mating 
pairs were set up with #1 and #2 (both males) and DMhet females resulting in two pups, 
both of which were DM and both of which were female. These DM females were paired 
with DM males #1 and #2 and one litter of three pups was born to pair #2 and #11. (B) 
Confirmation of DM genotypes of pair #2 and #11 shows an absence of Cav3 bands and 
presence of neo bands for both. Controls were provided by WT, cav3-/- and 0 DNA 
samples. (C) Gel showing confirmation of DM genotypes of F3 and F4 mice. Parents (#2, 
#11), progeny (#12-14) and pair #1 and #10 are shown with WT, cav3-/- and 0 DNA 
controls. (D) Genotyping of subsequent litters confirmed the DM line had been 
established. 
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3.2.1.3 – Sequencing to confirm the presence of the mdx mutation 
 The establishment of Cav3 and neo statuses in F2, F3 and F4 mice identified littermates 
that were homozygous positive (cav3+/+), heterozygous (cav3+/-) and homozygous 
negative (cav3-/-) for Cav3; it did not confirm that the mice generated were positive for 
the mdx mutation, i.e. dystrophin deficient. Although it was unlikely that the thymine at 
bp position 3203 of the Dmd gene associated with mdx would have mutated back to WT 
cytosine, DNA sequencing was performed on WT, mdx, mdxhets (F1 females) and DMs. 
Primers; forward - 5’ CTT-CTG-TGA-TGT-GAG-GAC-ATA 3’ and reverse - 5’ CTA-GCT-
TTT-GGC-AGC-TTT-CC 3’ were designed to amplify a 587 bp region that contained the 
mdx C-T point mutation and electrophoresis gels ran to confirm the PCRs had been 
successful in amplifying the target region (Figure 3.3 A). Amplicons were then directly 
aliquoted to reaction mixes for DNA sequencing. Sequence analyses showed the 
expected cytosine, represented by the letter C, was present in WT at bp position 3203 
(Figure 3.3 C), thymine, letter T, was present in DM (Figure 3.3 D) and a letter Y, 
denoting the presence of both cytosine and thymine (Figure 3.3 B), was present in 
mdxhet/cav3het sequences (Figure 3.3 E). Thus, the mdx mutation was confirmed to be 
present in DM mice generated. 
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Figure 3.3 
Sequencing of the Dmd gene to confirm the presence of the mdx mutation in DM. 
PCRs were performed to amplify a 587 bp region of the Dmd gene that contained the 
mdx C-T mutation and electrophoresis gels ran to confirm the PCR had been successful. 
(A) A representative example of a gel showing EtBr stained amplicons; PCR products 
were then directly used for sequencing. (B) Mixed bases diagram (provided by the 
Functional Genomics and Proteomics Unit, University of Birmingham) showing letters 
resulting when two different bases, from homologous alleles occupy the same position 
of DNA; as in the case of an mdx heterozygote. (C) WT DNA sequence showing a cytosine 
(red arrow and red letter) at position 3203. (D) DM DNA showing the C-T mdx point 
mutation. (E) mdxhet showing a Y, denoting both a C and a T at base position 3203.  
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3.2.2 - Caveolin-3 protein levels are reduced in DMhet embryos 
To establish the caveolin-3 protein levels of DMhet embryos in respect to WT and mdx, 
whole embryo protein samples of all four strains, WT, mdx, cav3-/- and DMhet were 
analysed via western blotting. At E13.5 only the increased caveolin-3 of mdx can be 
clearly seen following western blotting but at E15.5 and E17.5 protein levels of all four 
strains, except for cav3-/-, can be seen (Figure 3.4 A). Negative controls were provided 
for by cav3-/- samples, one for each embryonic stage; the very faint E13.5 cav3-/- band 
must therefore be attributed to loading overspill. There is clear upregulation in mdx at 
E17.5 and no protein present in cav3-/- as expected. Although caveolin-3 levels of the 
DMhet appear comparable to WT at E15.5, there is a definite reduction at E17.5 when 
compared to WT and particularly mdx at the same stages; an observation confirmed via 
the β-actin loading control. Although subtle, immunolabelling of E15.5 sagittal wax-
embedded sections with anti-caveolin-3 antibodies shows an increase in staining 
intensity in mdx and a slight reduction in staining intensity of DMhet, when compared to 
WT of the same embryonic stage (Figure 3.4 B). When taken together, these data 
indicate there is a reduction in caveolin-3 protein of developing DMhet embryos. 
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Figure 3.4 
Caveolin-3 probed membranes and sections of WT, mdx, cav3-/- and DMhets. (A) At 
E13.5 a strong band can only be seen in the lane corresponding to mdx but at E15.5 
bands can be seen in all except the lane for cav3-/-. There is very little difference between 
protein levels of WT and DMhet at E15.5, with mdx protein being slightly increased 
when compared to WT at this stage. At E17.5 there is an increase in caveolin-3 protein 
seen in mdx and a decrease in DMhet when compared to WT levels; β-actin served as a 
loading control. (B) 5 μm paraffin wax embedded sections of E15.5 WT, mdx, cav3-/- and 
DMhet intercostals labelled with anti-caveolin-3 antibodies. There is increased intensity 
of staining in mdx and slightly reduced staining in DMhet when compared to WT. The 
apparent staining seen in cav3-/- is due to over-incubation in the tyramide signal 
amplification reagent as there is no sarcolemmal specific staining. 
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3.2.3 - Pax7+ve cells are severely attenuated in DMhets 
Sagittal paraffin wax-embedded WT, mdx, cav3-/- and DMhet sections were 
immunolabelled with anti-pax7 antibodies in order to examine numbers and 
distribution of pax7+ve cells in situ. At E17.5 (Figure 3.5), the number of pax7+ve cells in 
the muscles of the intercostals is reduced in mdx (Figure 3.5 D-F) and DMhets (Figure 
3.5 G-O) when compared to WT (Figure 3.5 A-C).  
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Figure 3.5 
Pax7 labelled intercostal muscles. Paraffin wax embedded E17.5 WT, mdx and DMhet 
5 μm sections were immunohistochemically labelled with anti-pax7 antibodies. At low 
magnification images, pax7+ve cells can be clearly seen in WT (A, B) and mdx (D, E) 
intercostal muscles, but not so clearly in DMhet intercostals (G, H, J, K, M, N). At higher 
magnification, there is no discernible difference in pax7+ve cell staining intensity in mdx 
(F) when compared to WT (C), although there is a greater abundance of pax7+ve cells in 
WT, which is consistent with the greater myofibre density shown. The three DMhets 
have reduced pax7+ve cell abundance when seen at higher magnification (I, L, O).  
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3.2.4 – Reduced fibre-density in dystrophin-deficient intercostal muscles 
Sagittal wax-embedded sections, 5 μm in thickness, were mounted onto slides and 
immunolabelled with anti-pan-myosin MF20 antibodies in order to compare these 
proteins in E17.5 WT, mdx, cav3-/- and DMhets (Figure 3.6). There is an observable 
reduction in fibre-density in the intercostal muscles of mdx (Figure 3.6 E-H) and DMhet 
embryos (Figures 3.6 I-T), when compared to the intercostals of aged matched WT 
embryos (Figures 3.6 A-D); the reduction is evident through areas of white spaces 
located in the centre of the intercostal muscles. Intercostal fibre-density is reduced by 
37.5 % and 71.2 % for mdx and DMhets respectively, when compared to age matched 
WT sections (Figure 3.6 X), n=3 per strain. In contrast, intercostal muscles of age 
matched cav3-/- embryos (Figure 3.6 U-W) show densely packed hypertrophic fibres 
when compared to WT control (Figure 3.6 A-D).  
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Figure 3.6 
E17.5 WT, mdx and DMhet MF20 labelled intercostal muscles. Paraffin wax 
embedded 5 μm sections were labelled with anti-pan-myosin antibody MF20. Reduced 
fibre density in both mdx (E-H) and DMhet (I-T) intercostals can be seen when 
compared to WT (A-D) however, there is no such reduction in the intercostals muscles 
of cav3-/- (U-W). At higher magnification, extra-myonuclei can be seen in DMhet muscle 
(L, P, T), but not in WT (D) or mdx (H). (X) Intercostal muscle-fibre density is reduced 
by 37.5 % and 71.2 % for mdx and DMhet respectively, when compared to WT (graph 
reproduced from Merrick et al., 2009, quantitative analysis performed by Dr Janet 
Smith), n= 3. 
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3.2.5 – MF20 and MY32 labelled diaphragms 
Diaphragm muscles of WT, mdx and DMhets were also examined for myosin content 
using MF20 and MY32 antibodies and there were no discernible difference evident 
between pan-myosin stained and FMyHC stained sections (Figure 3.7). In the lower 
magnification images shown in Figure 3.7, the diaphragms of mdx (Figure 3.7 D, E) and 
DMhets (Figure 3.7 G, H, J, K, M, N) appear substantially reduced in thickness when 
compared to WT diaphragm (Figure 3.7 A, B), but this can be attributed to slight 
differences in the planes at which sagittal sections of the embryos were cut. At higher 
magnification the fibres of DMhets show clustering and increased fibre density (Figure 
3.7 I, L, O) when compared to the WT control (Figure 3.7 C).  Although no pathology 
appears to be present in DMhet or mdx diaphragm at this embryonic stage, there does 
seem to be a greater abundance of extra-myonuclei present in DMhet diaphragms 
(Figure 3.7 I, L, O) when compared to WT (Figure 3.7 C) and mdx (Figure 3.7 F). 
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Figure 3.7 
Diaphragm muscles of E17.5 WT, mdx and DMhets. Sections 5 μm in thickness were 
immunohistochemically labelled using anti-pan-myosin antibody MF20 and anti-FMyHC 
antibody MY32. There is no discernible difference seen between pan-myosin stained (B, 
E, H, K, N) and FMyHC stained (A, D, G, J, M) images. At lower magnification the 
thickness of the diaphragm muscles in mdx (D, E) and DMhets (G, H, J, K, M, N) appears 
reduced when compared to WT diaphragm (A, B). The fibres of DMhets at higher 
magnification show clustering (I, L, O), most evident in I and although the level of 
interstitium is greater in WT (C), there is no clustering of fibres seen. The fibres of mdx 
at higher magnification (F) appear to be more densely packed than those of WT (C). 
Although there appears to be no obvious pathology in the diaphragms of DMhets, there 
seems to be a greater abundance of extra-myonuclei, when compared to both WT and 
mdx. 
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3.2.5 - α-tubulin appears perturbed in dystrophic embryos 
Western blotting was used to examine specific protein levels in all dystrophic strains 
compared to WT in embryonic and adult tissue homogenates and initially α-tubulin was 
used as a loading control for these analyses. Variable lane intensities of α-tubulin on 
western blots indicative of uneven sample loading was reproved when β-actin was used 
as a loading control. Consistent downregulation of α-tubulin can be seen in cav3-/- at 
E13.5, E15.5 and E17.5 when compared to WT at the same stages; conversely, 
upregulation can be seen in mdx and DMhets at the same embryonic developmental 
stages when compared to WT (Figure 3.8 A, B). Densitometric analysis shows α-tubulin 
protein levels in cav3-/- mutants to be between 0.5 and 0.75 of WT levels at all three 
stages, with the greatest difference seen in mdx and DMhets at E13.5, with a 2 and 2.5 
fold increase respectively above that of WT (Figure 3.8 C). As there were no such 
disturbances of β-actin observed in the protein of dystrophic embryos, β-actin was used 
as a reliable loading control. 
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Figure 3.8 
Immunoblots of E13.5 – E17.5 WT, mdx, cav3-/- and DMhet membranes probed for 
caveolin-3, α-tubulin and β-actin. (A) Initial western blot analysis of membranes 
probed for α-tubulin show disturbances in dystrophic embryos consistent throughout 
all stages when compared to WT. (B) Subsequent membrane probing with anti α-tubulin 
afforded similar results, β-actin appeared unaffected in dystrophic mutants. (C) 
Densitometric analysis showed increases of α-tubulin in mdx and DMhet, whereas there 
was a reduction in α-tubulin seen in cav3-/- protein. The graph shows the fold 
increase/decreased compared to WT levels. 
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3.3 – DISCUSSION 
 
3.3.1 - Generation of caveolin-3 deficient mdx mice 
Although breeding programmes do not usually form part of discussions, the generation 
of DM mice was such a time consuming and onerous task that a couple of paragraphs are 
justified.  
 
The initial stage at the commencement of the breeding programme was uncomplicated 
and free from any problems. Female mdx and male cav3-/- mice produced litters that 
were readily sexed using sry specific primers and PCR. There were problems however 
with the next stage of the breeding programme. Although a seemingly straightforward 
process, the genotyping of F2 mice was fraught with PCR inconsistencies (sry 
genotyping presented with no such problems), initially gel electrophoresis of neo PCR 
products resulted in bands which were too faint to make any genotypic identification of 
DNA samples. Later and invariably, there would be no bands at all. This problem 
persisted for a total of seven long, painfully frustrating months and was eventually 
resolved by the use of a different PCR machine. Unfortunately, mice of the required 
genotype (DMhets) required to continue with the breeding programme were by this 
stage too old and as a consequence, DMhet matings did not result in any successful 
pregnancies. The programme had to be started again and in vitro fertilisation (IVF) was 
performed on female mdx and cav3-/- mice using sperm taken from a DMhet male; the 
procedure was performed by BMSU technicians. The decision made by BMSU 
management to use mdx and cav3-/- females, rather than DMhet females further setback 
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the breeding programme. However, a litter of nine re-derived mice were born to an mdx 
female of which two males, # 1 and # 2, which were positive for neo and negative for 
Cav3 were crossed with DMhet females and a litter of two pups were born; genotyping 
showed these two females were DM. These two females were backcrossed with males # 
1 and # 2 and a litter of three pups were born to male # 2 and female # 11. The DM line 
had been established. 
Had I have been aware that a line of mice deficient in both dystrophin and caveolin-3 
had already been generated; I could have looked at acquiring these mice which would 
have saved hundreds of laboratory hours that could have been used in generating data. 
Given the opportunity to choose the line of caveolin-3 deficient mice to use, I would 
prefer the TgCAV3M1 line over the cav3-/- line as the P104L mutation of the former 
results in the autosomal dominant transmission of the disease, rather than recessive 
transmission (Hagiwara et al., 2000; Ohsawa et al., 2006). The use of the TgCAV3M1 
mouse model would not only have saved time in the generation process, but as a model 
for LGMD-1C it is more akin to the human caveolinopathy than the cav3-/- mouse.     
 
3.3.2 - Embryonic phenotype of DMhets 
3.3.2.1 - Attrition of pax7+ve cells in DMhets 
It has been shown that both pax7 protein and pax7+ve cell numbers are reduced in mdx 
and cav3-/- late gestation embryos (Merrick et al., 2009). In DMhet embryos, the attrition 
of pax7+ve cells is even more severe than that which is seen in mdx, with evidence of 
pax7+ve cell fragmentation suggesting increased apoptosis of pax7+ve cells in these 
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mutants. The reduced levels of caveolin-3 in late stage (E17.5) DMhet embryos as is 
shown in western blots could have a detrimental effect on the numbers of pax7+ve cells, 
through a reduction in the embryonic growth factor Igf-2. A reduction of Igf-2 has been 
shown previously in cav3-/- embryos (unpublished data) and Igf-2 has been shown to 
have an inhibitory effect on apoptosis of dystrophic SMSc (Smith et al., 2000; Merrick et 
al., 2007). Pax7 is detected in WT mouse at E11.5, as is caveolin-3; mdx and cav3-/- both 
have delayed pax7 expression and towards late gestation, pax7 protein levels and 
pax7+ve cells are significantly reduced in both mutants, although caveolin-3 is increased 
in mdx late gestation embryos; as it is in adult mdx and DMD (Vaghy et al., 1998; Repetto 
et al., 1999; Merrick et al., 2009). This suggests caveolin-3 has a role in the maintenance 
of pax7 expression and subsequently pax7+ve satellite cells and that dystrophin may 
compensate for the absence of caveolin-3. In the absence of dystrophin, with reduced 
levels of caveolin-3, the attrition of pax7+ve cells is exacerbated in the DMhet. Through 
which signalling pathway caveolin-3 may mediate pax7 maintenance, if it does at all, 
needs to be elucidated, but evidence suggests that transforming growth-factor β  (TGF-
β) super-family member myostatin may have a role. The reduction of pax7 protein and 
attrition of pax7+ve cells in cav3-/- mutants complies with data that showed caveolin-3 
negatively regulates myostatin signalling through suppression of its type-1 
(ALK4/ALK5) receptor (Ohsawa et al., 2006; Merrick et al., 2009). Interestingly, 
myostatin negatively regulates the expression of Igf-2 (Lalani et al., 2000; Miyake et al., 
2010). Taken together these data infer a very real involvement for caveolin-3 in the 
maintenance of pax7, an inference compounded in that upregulated caveolin-3 is 
accompanied by downregulated myostatin in DMD  (Repetto et al., 1999; Zhu et al., 
2000). 
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3.3.2.2 - Fibre loss in intercostal muscles of dystrophin-deficient mutants 
It has been shown that FMyHC can be detected in WT at E11.5, whereas there is a delay  
in mdx, this suggests a temporal role for dystrophin in the optimisation of FMyHC 
expression as although FMyHC is not detected in cav3-/- at E11.5, its levels are above that 
of WT by E13.5 (Merrick et al., 2007). The reduced fibre-density shown in the 
intercostals of mdx is consistent with this developmental delay. DMhet embryos have a 
greater reduction in intercostal fibre-density than in age matched mdx embryos and as 
no such reduction is present in cav3-/-, this suggests a compensatory role for caveolin-3 
in the maintenance of dystrophin deficient mdx intercostal muscles. Myostatin, of the 
TGF-β family of growth factors, negatively regulates myoblast proliferation and 
differentiation through suppression of Igf-2 and research has shown that caveolin-3 
inhibits myostatin via binding of its type-2 receptor (Lalani et al., 2000; Thomas et al., 
2000; Ríos et al., 2001; Ohsawa et al., 2006; Miyake et al., 2010). The more severe 
phenotype seen in the DMhet is consistent with these data. It has been shown that 
FMyHC+ve fibres are depleted in DMD and mdx, with a virtual total loss of FMyHC-2dx+ve 
and FMyHC-2b+ve fibres along with a concomitant 7-fold increase of SMyHC in 
diaphragm muscle of 22 to 24 month mdx (Petrof et al., 1993). The loss of FMyHC-2dx 
presents a more severe phenotype than the loss of the more abundant FMyHC-2b, 
including kyphosis, a condition common in DMD and LGMD-1C (Acakpo-Satchivi et al., 
1997). The global-loss of FMyHC, when taken with the intercostal fibre-reduction in mdx 
is significant, as more than 70 % of skeletal muscle is comprised of FMyHC-2b and 30-60 
% of diaphragm MyHC is the FMyHC-2dx isoform. Understanding the molecular 
aetiology of respiratory muscle degeneration is crucial to the understanding of the 
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pathogenesis of DMD, as 56 % of mortalities (Figures for England and Wales) are 
attributed to respiratory failure (Calvert et al., 2006). 
 
3.3.3 - Tubulin upregulation 
The upregulation of α-tubulin seen in mdx and in the DMhet concurs with microarray 
analysis results which found a 2.7 fold increase in the expression of α-tubulin in DMD 
muscle biopsies compared to healthy muscle biopsy expression of the same gene 
(Haslett et al., 2002). Results obtained from colleagues using lysates of dystrophic cell-
lines also showed α-tubulin to be an unreliable house-keeping protein when analysing 
proteins from these sources. The molecular mechanisms responsible for the increased 
protein levels of α-tubulin seen in dystrophin-deficient muscle and the reduction seen in 
cav-3-/- embryos although interesting are beyond the scope of this thesis, but as the 
increase of α-tubulin seen in mdx is echoed in DM, it suggests the involvement of the 
DGC and not the increase in caveolin-3 as a possible causal factor. Interestingly, α-
tubulin is shown to be increased, as opposed to decreased, in postnatal muscle of cav3-/- 
mice so this may infer a role for caveolin-3 in the temporal expression of α-tubulin.  
 
Table 3.1 - Summary of results. The two embryonic dystrophin-deficient mouse 
strains used along with the results are summarised. All results are compared with WT, 
therefore – denotes < WT and + denotes >WT. 
Mouse Caveolin-3 Pax7+ve 
cells 
Intercostal 
fibre density 
α-tubulin 
mdx + - - + 
DMhet - -- -- + 
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CHAPTER 4 - CORRELATION OF CAVEOLIN-3 TO THE OBSERVED PATHOLOGY IN 
POSTNATAL DYSTROPHIN-DEFICIENT MICE 
 
This chapter looks at the musculo-histopathology of the three dystrophin-deficient 
mouse strains used during the course of this study, mdx and the two double-mutants 
generated, namely the DM (mdx/cav3-/-) and DMhet (mdx/cav3+/-); with a view to 
correlate observed pathology with levels of caveolin-3 protein. Data pertaining to three 
postnatal time points; four weeks, nine weeks and nine months, shall be presented 
herein.       
 
4.1 – INTRODUCTION 
The mdx mouse has been the preferred animal model of choice for most working in the 
field of muscular dystrophy since its introduction in the mid 1980’s (Bullfield et al., 
1984). Although extensively used as the primary animal model for DMD, the myopathy 
observed in mdx does not accurately represent the pathogenesis and progression that 
manifests with the human form of the disease as mobility is not impaired and life-span is 
comparable to that of WT mice. Muscle tissue regenerated in the mdx mouse, although 
abnormal in architecture as there are variations in fibre sizes and centrally located 
nuclei, functions perfectly sufficiently and is void of the connective and adipose tissue 
associated with the human form of the disease.  
The loss of dystrophin from the DGC has a profound effect on the complex’ integrity and 
results in its eventual breakdown, there are many genes that have been found to be 
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differentially expressed in dystrophin-deficient muscle (Ervasti et al., 1990; Haslett et 
al., 2002; Porter et al., 2002; Noguchi et al., 2003; Turk et al., 2005). DGC associated 
protein caveolin-3 is one that is upregulated in DMD and mdx and it has been suggested 
that the increase protein content of caveolin-3 may contribute to the pathogenesis 
observed in mdx and DMD (Vaghy et al., 1998; Repetto et al., 1999; Galbiati et al., 2000). 
The histological analyses of mdx, DM and DMhet mice, in essence all dystrophin-deficient 
mice with hyperphysiological levels of caveolin-3, mdx; hypophysiological/WT levels of 
caveolin-3, DMhet; and a deficiency of caveolin-3, DM would allow for a correlation to be 
made between varying levels of caveolin-3 and the associated pathology.     
The decision to use mice of four weeks, nine weeks and nine months of age was dictated 
by the progression of the dystrophic condition previously observed in mdx. Proximal 
limb muscles, or to be more specific, triceps brachii and quadriceps femoris, were 
chosen by virtue of their mixed fibre content and comparative associated workload, as 
there is a correlation between mechanical stress and muscle degeneration, with no 
degeneration present in denervated hindlimb muscles (Karpati et al., 1988; Petrof et al., 
1993).  
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Figure 4.1 – Stages of muscle regeneration in mdx. (A) Following degeneration of 
fibres, infiltration of muscle tissue interstitium with muscle progenitor (satellite) cells, 
fibroblasts and leukocytes occurs resulting in areas of hypercellularity. (B) Newly 
regenerating fibres are identified via their large centrally located single nuclei; the 
numbers of interstitial cells has diminished. (C) Regenerating fibres are now larger, with 
smaller centrally located nuclei; of which there may be more than one per fibre. (D) 
Regenerated fibres are of a round morphology and are heterogeneous in size. The 
retention of central nuclei is indicative of a fibre having regenerated and can be used to 
assess the level of regeneration in a section of muscle.   
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4.2 – RESULTS 
 
4.2.1 – IHC and western blotting confirms the loss of caveolin-3 in the DM 
Proteins were extracted from triceps and quadriceps muscles, separated via PAGE, 
transferred onto nitrocellulose membranes and probed with anti-caveolin-3 antibodies. 
Detection was enhanced through the use of biotinylated secondary 
antibodies/streptavidin and membranes visualised  using the Odyssey Infrared Imaging 
System. Caveolin-3 is shown to be absent in all mice identified as DM, thus the 
phenotypes were confirmation of the genotypes (Figures 4.2 B). The levels of caveolin-3 
in the muscles of DMhet mice is slightly variable, but similar to that of WT, it is always 
reduced when compared to mdx (Figures 4.2 B; 4.3 A), which when analysed using 
densitometry gave a P value of 0.007154 with n=4 using a two-tailed student’s t-test 
(Figure 4.2 C). Caveolin-3 in mdx is shown to be increased by as much as seven fold 
when compared to WT (Figure 4.2 C). These observations are consistent with all ages of 
mice analysed (Figures 4.2 A; 4.3 A). As was seen with western blotting performed with 
embryos, there are perturbations in α-tubulin shown in all dystrophic mutants (Figure 
4.2 A), with the greatest disturbances seen in mdx and DM which when compared to WT 
afford P values of 0.000565 and 0.009145 respectively with n=4 using a two-tailed 
student’s t-test (Figure 4.2 B). Imperial protein stain was used as a loading control, 
which proved to be reliable (Figure 4.2 A; 4.3 A). To establish the levels of caveolin-3 
localised to the sarcolemma, IHC was performed on 5 μm sections of paraffin wax 
embedded nine weeks old triceps muscles (Figure 4.3 B). The increased levels are 
clearly seen in the muscle of mdx, evident by the intense brown staining around the 
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periphery of the muscle fibres which is less intense in WT and DMhet muscle sections. 
The complete lack of staining in the DM once more establishes the caveolin-3 deficiency 
in the DM; cav3-/- samples were included as controls. The presence of centrally nucleated 
fibres can be seen in all three of the dystrophin-deficient mutants (Figure 4.3 B).   
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Figure 4.2 
Membranes probed with antibodies to caveolin-3 and α-tubulin (A) As was 
demonstrated with embryos, α-tubulin protein levels appear to be disrupted in mdx, 
DMhet and DM postnatal proximal limb muscle tissue, with an increase in levels of the 
protein shown when compared to WT. Imperial protein stain provided a more reliable 
method of protein loading control. (B) Bar graph showing densitometric analysis of α-
tubulin/Imperial protein stain from western blots of nine weeks old proximal limb 
muscle tissue samples. There is an increase of α-tubulin in all mutants when compared 
to WT; the greatest seen in mdx and DM where P=0.000565 and P=0.009145 
respectively. (C) Densitometry of caveolin-3/Imperial protein stain shows nearly a 
seven fold increase in the caveolin-3 protein of mdx when compared to WT, there is no 
difference between WT caveolin-3 and DMhet, confirmed qualitatively by the western 
blot (A). There is a statistically significant difference in caveolin-3 protein levels of mdx 
and DMhet, where P=0.007154; n=4, error bars: s.d. Asterisks’ denotations ** = P<0.01, 
*** = P<0.001. 
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Figure 4.3 
Caveolin-3 protein levels and localisation in WT, mdx, cav3-/-, DMhet and DM. (A) 
membranes probed with anti-caveolin-3 antibodies show upregulation in mdx and an 
absence of caveolin-3 in DM and cav3-/- at all stages; DMhets at nine weeks and nine 
months show levels comparable to WT but reduced when compared to mdx. (B) 
Caveolin-3 labelled paraffin wax embedded triceps muscles of nine weeks old WT, mdx, 
cav3-/-, DMhet and DM show peripheral staining around fibres of WT, mdx and DMhet, 
the more intense staining seen in mdx; there is an absence of staining in both cav3-/-  and 
DM sections. The staining shown in the DMhet is comparable to WT but reduced when 
compared to mdx.  Note the centrally located nuclei present in fibres of mdx, DMhet and 
DM muscle tissues. 
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4.2.2 – Macroscopic analysis of the DM 
The DM mice generated display no signs of obvious pathogenesis while alive; they are 
indistinguishable from their WT and mdx counterparts, although WT animals appear to 
be slightly slimmer in comparison to the dystrophic mutants (Figure 4.4 A). There are 
no real differences between the live bodyweights of all four strains used although there 
is less variation shown between females than males (Figure 4.5). Their inquisitiveness 
and mobility around the cages is as would be expected for healthy mice and this does 
not appear to change as they age. In order to conduct a comparable examination of the 
muscularity of DM mice; WT, mdx and cav3-/- specimens around nine months of age, 
were culled and their skins removed along with DM animals. With their skins removed, 
differences in the muscularity of all strains can be seen. Both mdx and DM display 
hypertrophy of all viewable skeletal muscles when compared to WT and cav3-/-; which 
can be clearly seen in both the distal and proximal parts of the hindlimbs, where 
quadriceps, tibialis anterior, gluteal and biceps femoris display increased muscle mass 
(Figure 4.4 B). When skins of the dorsa are removed from mdx, cav3-/- and DM, an 
excess of subcutaneous adipose tissue can be seen in cav3-/-, particularly on the flanks 
and scapular regions, mdx and DM do not display this level of adiposity (Figure 4.4 C). 
When venters are viewed of mdx, cav3-/- and DM, the increased adiposity that is seen on 
the back is consistent on the abdomen of cav3-/-, mdx appears to be the leanest and the 
DM intermediate between mdx and cav3-/- (Figure 4.4 D).  The lumbodorsal fascia of 
cav3-/- also appears to be thicker than that of mdx and DM (Figure 4.4 C). 
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Figure 4.4 
Macroscopic analysis of nine month old WT, mdx, cav3-/- and DM somatotypes. (A) 
All strains appear of a similar body size, the WT specimen being slightly slimmer than 
the others. (B) Dorsal view of skinned hindlimbs showing comparable muscle mass of all 
strains. When compared to WT, mdx and particularly DM show hypertrophy of all 
viewable proximal and distal hindlimb muscles, including gluteal muscles. There 
appears to be no discernible difference between cav3-/- and WT hindlimbs’ muscle mass. 
(C) Skinned mdx, cav3-/- and DM dorsa showing subcutaneous adipose deposition; cav3-/- 
mutants show the highest level of subcutaneous fat, with larger depositions on the 
flanks and scapular regions than mdx and DM. The lumbodorsal fascia in cav3-/- also 
appears thicker than in mdx and DM. (D) Images of skinned venters show a greater 
degree of abdominal adipose tissue present in cav3-/-, the least in mdx and an 
intermediate degree exhibited by the DM. An excess of adipose tissue can also be seen 
on the underside of skin lying bilaterally to the lower abdomen of cav3-/-; with very little 
present in mdx and once more the DM exhibiting an intermediate amount. 
 
119 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
0 20 40 60 80
w
e
ig
h
t 
in
 g
ra
m
s
age in weeks
WT
mdx
cav3
DM
0
5
10
15
20
25
30
35
40
45
0 20 40 60 80
w
e
ig
h
t 
in
 g
ra
m
s
age in weeks
WT
MDX
CAV-3
DM
0
5
10
15
20
25
30
35
40
45
50
0 10 20 30 40 50
w
e
ig
h
t 
in
 g
ra
m
s
age in weeks
WT
mdx
cav3
DM
A 
B 
C 
 
♂ 
♀ 
120 
 
Figure 4.5 
Line graphs showing live bodyweights of adult WT, mdx, cav3-/- and DM colonies. 
(A) Weights of both males and females were pooled resulting in a curve showing great 
variation in bodyweights. (B) Male bodyweights. The greatest variation of bodyweights 
is seen in males. (C) There is less variation seen between the bodyweights of females. 
The number of mice per strain used to generate data for each age group was between 
one and six (males and females separately). 
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4.2.3 - Regeneration of dystrophin-deficient proximal limb muscles 
Paraffin wax embedded triceps and quadriceps muscles excised from WT, mdx, cav3-/-, 
DM and DMhets of four weeks, nine weeks and nine months of age were cut into 5 μm 
sections, mounted onto slides and processed for staining using H&E. Muscle tissue stains 
pink and nucleic acids and therefore nuclei, stains blue/purple. Regeneration, due to the 
abundance of infiltrative cells associated with the process; which include myocytes, 
fibroblasts and monocytes, is easily identified using H&E staining as the regenerative 
areas exhibit extensive regions of blue/purple stained nuclei. 
 
4.2.3.1 – Histology of four weeks triceps and quadriceps 
At four weeks of age the extent of regeneration shown in mdx and DM, in both triceps 
and quadriceps is such that it is clearly observable at low magnification (Figures 4.6 A-
E; 4.7 A-C, F, G). There are no extensive areas of regeneration, in either triceps or 
quadriceps, visible at low magnification in the four weeks old DMhet analysed (Figures 
4.6 F; 4.7 H) and one of the DMs was seen to have no observable areas of regeneration 
in quadriceps analysed (Figure 4.7 E) . Analysis of triceps muscle taken from the same 
DM (Figure 4.7 E) was not possible due to the poor quality of the sections obtained.  
When viewed at higher magnification (Figures 4.8; 4.9), areas of concentrated 
hypercellularity, indicative of the initial stage of muscle regeneration, can be seen in mdx 
(Figures 4.8 E, F; 4.9 F), DM (Figures 4.8 L; 4.9 J, L) and DMhet (Figure 4.9 M, O). 
Areas of regenerated muscle tissue can also be identified via the presence of centrally 
located myonuclei, which are shown in mdx (Figures 4.8 D-F; 4.9 D, E), DM (Figures 
4.8 J-L, O; 4.9 J-L) and DMhet (Figures 4.8 M, N; 4.9 N) sections. There are no 
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hypercellular areas or centrally nucleated fibres shown in WT triceps or quadriceps 
muscle; the nuclei of WT are seen to locate to the peripheries of the muscle fibres’ 
(Figures 4.8 A-C; 4.9 A-C), as do the myonuclei of cav3-/- (Figures 4.8 G-I; 4.9 G-I). Of 
the images presented of cav3-/, only one fibre exhibits central myonucleation (Figure 
4.8 G). N=4 per strain except DMhet where n=1. Images shown are of n=3, except where 
stated in the figure legend 
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Figure 4.6 
H&E stained four weeks old triceps.  Transverse sections 5 μm in thickness, were cut 
from paraffin wax embedded triceps muscles of four weeks old mdx, DM and DMhet 
mice and processed for H&E staining. Areas of regeneration are stained purple/blue. 
Gross histology shows regeneration in both mdx (A-C) and DM (D, E), but not in the 
DMhet (F). Images taken are of different mice. Only one DMhet was available at four 
weeks of age.  
 
125 
 
 
 
126 
 
Figure 4.7 
H&E stained four weeks old quadriceps.  Transverse sections 5 μm in thickness, were 
cut from paraffin wax embedded quadriceps muscles of four weeks old mdx, DM and 
DMhet mice and processed for H&E staining. (A-C) mdx; (D) DMhet; (E-H) DM. Areas of 
regeneration are stained purple/blue. At low magnification only mdx (C) shows obvious 
areas of regeneration, although regeneration can be seen in mdx (A,B) and DM (F,G). 
Images taken are of different mice. Only one DMhet was available at four weeks of age. 
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Figure 4.8 
Images of four weeks old H&E stained triceps muscles. Transverse sections 5 μm in 
thickness, were cut from paraffin wax embedded triceps muscles of four weeks old WT, 
mdx, cav3-/-, DM and DMhet mice and processed for H&E staining. (A-C) WT fibres are of 
a uniform size with myonuclei positioned at the fibres’ peripheries; cav3-/- fibres appear 
morphologically identical to those of WT (G-I). Centrally located myonuclei and 
heterogeneity of fibre sizes are shown in mdx (D-F), DM (J-L, O) and DMhet (M, N). 
Areas of regeneration (characterised by hypercellularity) are evident in mdx (E, F) and 
DM (L, O). All images shown are of three different mice per strain, except for DMhet 
where only one was available. Scale bar = 40 μm. 
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Figure 4.9 
Images of four weeks old H&E stained quadriceps muscles. 5 μm thick transverse 
sections  were cut from paraffin wax embedded quadriceps muscles of four weeks old 
WT, mdx, cav3-/-, DM and DMhet mice and processed for H&E staining. (A-C) WT fibres 
are of a uniform size with myonuclei positioned at the fibres’ peripheries; cav3-/- fibres 
appear morphologically identical to those of WT (G-I). Centrally located myonuclei are 
shown in mdx (D, E), DM (J-L) and DMhet (N). Areas of regeneration (characterised by 
hypercellularity) are evident in mdx (E, F), DM (J, L) and DMhet (O). All images shown 
are of three different mice per strain, except for DMhet where only one was available. 
Scale bar = 40 μm. 
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4.2.3.2 – Histology of nine weeks triceps and quadriceps 
At nine weeks of age areas of regeneration in triceps and quadriceps of mdx (Figures 
4.10 A-C; 4.11 A-C), DM (Figures 4.10 D-F; 4.11 D-F) and DMhets (Figures 4.10 G, H; 
4.11 G, H) can be seen in images taken at low magnification. There does not appear to be 
any discernible differences at nine weeks when compared to triceps and quadriceps of 
mdx, DM and DMhet at four weeks of age (Figures 4.6; 4.7); neither is there any obvious 
observable differences in the level of regeneration between the three dystrophin-
deficient mutants. 
Higher magnification images show areas of hypercellularity and many centrally located 
nuclei in triceps and quadriceps of mdx (Figures 4.12 D-F; 4.13 D-F), DM (Figures 4.12 
J-L; 4.13 I-K) and DMhets (Figures 4.12 M-O; 4.13 L, M), neither of which are present 
in the same muscles of WT (Figures 4.12 A-C; 4.13 A-C) or cav3-/- (Figures 4.12 G-I; 
4.13 G, H) at nine weeks of age.  
Many of the muscle fibres seen in DM and DMhet triceps and quadriceps are of a 
rounded morphology, in contrast to the fibres of WT and cav3-/- muscle, which have a 
more angular morphology (Figures 4.12 A-C, G-I; 4.13 A-C, G, H). This phenotype is 
also shown in mdx (Figures 4.12 D-F; 4.13 D-F). Fibres of mdx, DM and DMhets also 
exhibit heterogeneity within their fibre sizes, with hypertrophic fibres juxtaposed next 
to very small fibres; the nuclei of which may or may not be centrally located (Figure 
4.12 D, J, M). Fibres of WT and cav3-/- appear to be of a more uniform size, although 
cav3-/- fibres are seen to be less dense than those of WT.  N=3 per strain, except for 
DMhet where n=2. Images shown are of n=3, except where stated in the figure legend. 
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Figure 4.10 
H&E stained nine weeks old triceps.  Transverse sections 5 μm in thickness, were cut 
from paraffin wax embedded triceps muscles of nine weeks old mdx, DM and DMhet 
mice and processed for H&E staining. Areas of regeneration are stained purple/blue. 
Gross histology shows regenerative areas in mdx (A-C), DM (D-F) and DMhet (G, H). 
Images taken are of different mice. 
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Figure 4.11 
H&E stained nine weeks old quadriceps.  Transverse sections 5 μm in thickness, were 
cut from paraffin wax embedded quadriceps muscles of nine weeks old mdx, DM and 
DMhet mice and processed for H&E staining. Areas of regeneration are stained 
purple/blue. Gross histology shows regeneration in all mutants; mdx (A-C), DM (D-F) 
and DMhet (G, H). Images taken are of different mice. 
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Figure 4.12 
Images of nine weeks old H&E stained triceps. 5 μm thick transverse sections were 
cut from paraffin wax embedded triceps muscles of nine weeks old WT, mdx, cav3-/-, DM 
and DMhet mice and processed for H&E staining. WT fibres are of a uniform size with 
myonuclei positioned at the fibres’ peripheries (A-C). The fibres of cav3-/- muscle 
although uniform in size as in WT, appear less dense than those of WT (G-I). Centrally 
located myonuclei and heterogeneity of fibre sizes are shown in mdx (D-F), DM (J-L) and 
DMhet (M-O). Areas of regeneration (characterised by hypercellularity) are evident in 
mdx (E, F), DM (K, L) and DMhet (M-O). Images taken of two different WT and DMhets 
and three different mdx, cav3-/- and DM. Scale bar = 40 μm. 
 
 
 
 
 
 
138 
 
 
 
 
139 
 
Figure 4.13 
Images of nine weeks old H&E stained quadriceps. 5 μm thick transverse sections  
were cut from paraffin wax embedded quadriceps muscles of nine weeks old WT, mdx, 
cav3-/-, DM and DMhet mice and processed for H&E staining. (A-C) WT fibres are of a 
uniform size with myonuclei positioned at the fibres’ peripheries; cav3-/- fibres appear 
morphologically identical to those of WT, with no signs of any pathogenesis (G, H). 
Centrally located myonuclei are shown in mdx (D-F), DM (J, K) and DMhet (L, M). Areas 
of regeneration (characterised by hypercellularity) are evident in mdx (D, F), DM (I) and 
DMhet (L, M). Variations in fibre sizes can be seen in mdx (D), DM (I, J) and DMhet (L, 
M). Images were taken from three WT, three mdx, two cav3-/- , three DM and one DMhet. 
Scale bar = 40 μm. 
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4.2.3.3 – Histology of nine months triceps and quadriceps 
Triceps muscles at nine months of age show no regenerative areas that can be seen at 
low magnification in any of the dystrophin-deficient mutants, WT or cav3-/- sections 
(Figure 4.14). In muscles of the quadriceps, small areas of hypercellularity can be seen 
in a single mdx (Figure 4.15 B) and a single DM section (Figure 4.15 D). There were no 
mdx sections of sufficient quality to photograph.  
Images that were taken at higher magnification show that there are regenerative areas 
present in mdx (Figure 4.17 C), DM (Figure 4.17 F) and DMhet (Figure 4.16 F) 
sections. Many of the fibres of mdx (Figure 4.17 B, D), DM (Figures 4.16 E, F; 4.17 F-H) 
and DMhets (Figures 4.16 G, H; 4.17 I-K) at this age have centrally located nuclei and 
are hypertrophic, although there is an observable heterogeneity of fibre sizes in all of 
the dystrophin-deficient mutants (Figures 4.16 E-H; 4.17 B-D, F-K). WT and cav3-/- 
fibres are shown to be of a uniform size (Figures 4.16 A, C, D; 4.17 A, E). In both triceps 
and quadriceps of DMhet sections there are clusters of non-muscle cells that may be 
adipocytes (Figures 4.16 F; 4.17 J), but as appropriate labelling was not performed to 
ascertain the identity of the cells, this is purely speculative. A smaller number of what 
appears to be the same cell type can be seen in a DM section image (Figure 4.16 E). N=1 
WT, n=2 cav3-/-, n=3 mdx, DM, DMhet.      
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Figure 4.14 
H&E stained nine months old triceps. 5 μm thick transverse sections were cut from 
paraffin wax embedded triceps muscles of nine months old WT, mdx, cav3-/-, DM and 
DMhet mice and processed for H&E staining. At this low magnification there appears to 
be no obvious signs of pathogenesis in any of the dystrophic mutants. Images taken are 
of different mice. 
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Figure 4.15 
H&E stained nine months old quadriceps muscles.  Transverse sections 5 μm in 
thickness, were cut from paraffin wax embedded quadriceps muscles of nine months old 
mdx, DM and DMhet mice and processed for H&E staining. Areas of regeneration are 
stained purple/blue. There appears to be small regenerative areas in mdx (B) and DM 
(D). Images taken are of different mice. 
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Figure 4.16 
Images of nine months old H&E stained triceps. 5 μm thick transverse sections were 
cut from paraffin wax embedded triceps muscles of nine months old WT, cav3-/-, DM and 
DMhet mice and processed for H&E staining. WT fibres are of a uniform size with 
myonuclei positioned at the fibres’ peripheries (A); there is no discernible difference 
seen in cav3-/- when compared to WT, although there are a couple of centrally located 
myonuclei shown in the images presented (B,C). Hypertrophic fibres when compared to 
WT are seen in DM and these fibres display centrally located myonuclei (D) as do DMhet 
fibres (E-G). Areas of regeneration (characterised by hypercellularity) are evident only 
in DMhet (F). Non muscle cells can be seen in DM (D) and in particular DMhet (E), these 
cells may be adipocytes, not usually present in muscles of the limbs of mdx. Images were 
taken from one WT, one cav3-/-, one DM and two DMhets. Scale bar = 40 μm.  
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Figure 4.17 
Images of nine months old H&E stained quadriceps. Transverse sections  5 μm in 
thickness were cut from paraffin wax embedded quadriceps muscles of nine months old 
WT, mdx, cav3-/-, DM and DMhet mice and processed for H&E staining. WT fibres are of a 
uniform size with myonuclei peripherally positioned within the fibres’ (A). There 
appears to be no histopathology in cav3-/- tissue, however there does appear to be a 
greater degree of interstitium between cav3-/- fibres (E) when compared to those of WT 
(A). Centrally located myonuclei are shown in mdx (B, D), DM (F-H) and DMhet (I-K). 
Areas of regeneration (characterised by hypercellularity) are evident in mdx (C) and DM 
(F), but not in DMhet (I-K). Variations in fibre sizes can be seen in mdx (B, D), DM (F, G) 
and DMhet (K). There are also non muscle cells shown in DMhet (J), which may be 
adipocytes. Images were taken from one WT, two mdx, one cav3-/-, two DMs and three 
DMhets. Scale bar = 40 μm. 
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4.2.4 - Respiratory muscles 
4.2.4.1 - intercostals 
Sections of thoracic cages were excised from WT, mice at four weeks, nine weeks and 
nine months of age and embedded in paraffin wax. Sections 5 μm thick were cut, 
mounted and processed for staining with H&E. 
When seen at low magnification, there appears to be no discernible differences in any of 
the strains at four weeks (Figure 4.18 A1-E1), nine weeks (Figure 4.18 F1-J1) or nine 
months of age (Figure 4.18 K1-O1) and as the quality of the sections shown varies, 
accurate analyses of these data is difficult. However, there are no obvious signs of 
pathogenesis seen in any of the dystrophic mutants, i.e   mdx (Figure 4.18 B1, G1, L1), 
cav3-/- (Figure 4.18 C1, H1, M1), DM (Figure 4.18 D1, I1, N1) or DMhet (Figure 4.18 
E1, J1, O1) when compared to WT images of the same ages (Figure 4.18 F1, K1).  
At higher magnification (Figure 4.18 A2-E2, F2-J2, K2-O2), areas undergoing 
regeneration are shown in mdx (Figure 4.18 B2) and DMhet (Figure 4.18 E2) at four 
weeks of age; mdx (Figure 4.18 G2), DM (Figure 4.18 I2) and DMhet (Figure 4.18 J2) 
at nine weeks of age and DM only (Figure 4.18 N2) at nine months of age. Centrally 
located myonuclei can be seen in a few fibres of mdx (Figure 4.18 B2), DM (Figure 4.18 
D2) and DMhet (Figure 4.18 E2) at four weeks, but as centrally nucleated fibres are also 
present in WT of the same age (Figure 4.18 A2), this phenotype cannot be attributed to 
their dystrophic condition. There are many more centrally located myonuclei seen at 
nine weeks of age in mdx (Figure 4.18 G2), DM (Figure 4.18 I2) and DMhet (Figure 
4.18 J2) and at nine months of age in mdx (Figure 4.18 L2) and DMhet (Figure 4.18 
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O2), but as they are more numerous than that which was shown at four weeks of age, 
are indicative of regenerated fibres 
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Figure 4.18 
H&E stained intercostal muscles. 5 μm thick sections of paraffin wax embedded 
thoracic cages from four weeks, nine weeks and nine months old WT, mdx, cav3-/-, DM 
and DMhet were processed for H&E staining. At low magnification there appears to be 
no discernible differences in any of the strains at four weeks (B1-E1), nine weeks (F1-
J1) or nine months of age (K1-O1). Higher magnification images show areas undergoing 
regeneration (areas of hypercellularity) in mdx (B2) and DMhet (E2) at four weeks of 
age; mdx (G2), DM (I2) and DMhet (J2) at nine weeks of age and DM (N2) at nine months 
of age. Central nucleation of fibres can be seen in very few fibres at four weeks in mdx 
(B2), DM (D2) and DMhet (E2; there are also a couple of centrally nucleated WT fibres 
shown at four weeks of age (A2). There are many more centrally located myonuclei seen 
at nine weeks in mdx (G2), DM (I2) and DMhet (J2); and at nine months of age in mdx 
(L2) and DMhet (O2) images. 
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4.2.4.2 - Diaphragm 
Diaphragm muscles were removed from WT, mdx, cav3-/-, DM and DMhet mice at four 
weeks and nine weeks of age and embedded in paraffin wax. 5 μm thick sections were 
cut, mounted and then processed for staining with H&E. 
Areas of regeneration are shown in mdx (Figure 4.19 B), DM (Figure 4.19 D) and 
DMhet (Figure 4.19 E) at four weeks of age; cav3-/- (Figure 4.19 C) diaphragm appears 
as WT (Figure 4.19 A) at the same age. At nine weeks of age hypercellularity is shown in 
mdx (Figure 4.19 I) and DMhet (Figure 4.19 L, M) diaphragm muscles, although the 
cells seen in DMhet muscle are spread evenly throughout the muscle fibres’ interstitium 
rather than aggregated as in mdx. Most of the fibres shown in DMhet have centrally 
located myonuclei. The most severe diaphragmatic pathogenesis is shown in the DM 
where adipocytes appear to be seen within the section (Figure 4.19 K).  
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Figure 4.19 
H&E stained diaphragm muscle. 5 μm thick sections of paraffin wax embedded 
diaphragm muscles from four weeks, nine weeks and nine months old WT, mdx, cav3-/-, 
DM and DMhet were processed for H&E staining. At four weeks of age, areas of 
regeneration (hypercellular regions) are shown in mdx (B), DM (D) and DMhet (E). At 
nine weeks of age hypercellularity is obvious in mdx (I) and although not aggregated as 
shown in mdx, extra-myonuclei can be seen in DMhet (L, M); there is also an abundance 
of centrally located myonuclei seen in DMhet. The most severe diaphragmatic 
pathogenesis is shown in the DM where there appears to be adipocytes within the 
section (K). 
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4.2.5 - Fibre diameter variation in dystrophin-deficient mutants 
Following histological analyses of sections from WT, mdx, cav3-/-, DM and DMhets, it was 
noted that all three dystrophin-deficient mutants exhibited heterogeneity of fibre sizes, 
whereas their WT and cav3-/- age matched counterparts, possessed fibres that were of a 
more uniform size. With the use of a stage mounted scale micrometer, diameters of nine 
weeks old WT, mdx, cav3-/-, DM and DMhet triceps muscle fibres were measured. Nine 
weeks was chosen as there appeared to be greater variation in fibre sizes at this age and 
triceps were chosen as the quality of the sections cut from these muscles were better 
and this would allow for more accurate measurements to be taken.  
 
WT fibres range between 15 μm and 85 μm in diameter (Figure 4.20 A), the modal size 
being 30 μm and 85 % ranging between 25 μm and 55 μm (Figure 4.21 A). The fibres of 
mdx, although showing a greater range, 10 μm - 100 μm (Figure 4.20 A-C), like WT have 
a modal diameter of 30 μm, with 62 % of these fibres ranging between 25 μm and 55 μm 
(Figure 4.21 B). Both DM and DMhets have approximately 50 % of their fibres between 
25 μm and 55 μm (Figure 4.21 C, D), with ranges of 10 μm -125 μm and 10 μm -115 μm 
for DM and DMhets respectively (Figure 4.20 A-C). The modal size for DM is 60 μm and 
for DMhets 40 μm. The fibres of cav3-/- triceps range between 20 μm -95 μm (Figure 
4.20 A), 71 % of these fibres are between 25 μm and 55 μm in diameter (Figure 4.21 E), 
cav3-/- fibres have a modal size of 40 μm. All four dystrophic mutants exhibit 
hypertrophic fibres; 26 % of mdx and cav3-/- fibres have diameters between 60 μm and 
125 μm and 42 % and 40 % of fibres are within this range for DM and DMhets 
respectively. Fewer than 10 % of WT fibres are of this size. Not only do dystrophin-
deficient mutants possess larger fibres than WT or cav3-/-, they also have a higher 
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proportion of small sized fibres too. Around 11 % of fibres in mdx and DMhet and 7 % in 
DM have diameters between 10 μm and 20 μm (Figure 4.21 B, C, D), compared to WT 
where 5 % of fibres are within this range (Figure 4.21 A). 3 % of cav3-/- muscle fibres 
are 10 μm - 20 μm in diameter (Figure 4.21 E). 
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Figure 4.20 
Graphical representation of fibre diameter sizes of nine weeks triceps muscles. 
(A) Line graph showing fibre diameter sizes of WT, mdx, cav3-/- DMhet and DM. Fibre 
sizes range between 15 - 85 μm for WT, 10 - 100  μm for mdx, 20 - 95 μm for cav3-/-, 10 - 
125 μm for DM and 10 - 115 μm for DMhet. 85 % of WT fibres are between 25 μm and 
55 μm in diameter; DM and DMhets have approximately 50 % of their fibres between 
these measurements whereas 62 % and 71 % of fibres are between these sizes for mdx 
and cav3-/- respectively. A higher percentage of fibres are seen between 15 μm and 40 
μm in mdx than in any of the other strains and there are more fibres between 45 μm and 
100 μm (with the exception of those measuring 75 μm) in DM than mdx. (B,C) The same 
data comparing the three dystrophin-deficient mutants (B) and WT, mdx and DM (C). 
WT n=2, mdx n=3, cav3-/- n=3, DM n=3, DMhet n=2. 
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Figure 4.21 
Pie charts showing proportions of small, medium, large and extra-large muscle 
fibres in nine weeks old WT, mdx, cav3-/- and DM triceps muscles. (A) WT triceps 
consisted of 5.3 % small fibres (10 μm – 20 μm), 85.3 % medium fibres (25 μm – 55 μm) 
and 9.4 % large fibres (60 μm – 95 μm). (B) mdx triceps consisted of 11.7 % small fibres, 
62.3 % medium fibres, 24.9 % large fibres and 1 % extra-large fibres. (C) cav3-/- 
consisted of 3 % small fibres, 71 % medium fibres and 26 % large fibres. (D) DM 
consisted of 7.2 % small fibres, 50 % medium fibres, 38.7 % large fibres and 4.1 % extra-
large fibres. DMhet consisted of 11 % small fibres, 49 % medium fibres, 38.3 % large 
fibres and 1.7 % extra-large fibres. 
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4.2.6 - Quantification of muscle regeneration 
4.2.6.1 - Hypercellular aggregation 
In order to quantify the level of regeneration occurring in dystrophin-deficient mutants, 
regenerating regions were calculated as percentages of the sections’ total areas. H&E 
stained sections were used for the analyses, as regenerative areas stain a deep 
blue/purple and are therefore easily identifiable. Newly regenerating fibres, 
characterised by large centrally located nuclei, were not included in the counts, only the 
initial hypercellular regions, which contain leukocytes, fibroblasts and myocytes, were 
counted (Figure 4.22 A). H&E stained triceps and quadriceps sections of mdx and DM at 
four weeks and nine weeks of age were used for the analyses.     
 
The levels of regeneration, as percentages of total areas, appear to be greater in mdx 
than in DM at both four weeks and nine weeks of age. This trend is seen in triceps 
muscles and quadriceps muscles (Figure 4.22 B, C); although error bars attest to the 
huge variation observed between mdx triceps sections of four weeks of age (Figure 4.22 
B). At nine weeks of age, differences seen between the levels of regeneration in mdx and 
DM triceps is just outside of statistical significance, with a P value of 0.053578. Based on 
bars of the graph (Figure 4.22 B) representative of averages, both dystrophin-deficient 
mutants exhibit similar temporal patterns of muscle regeneration; the greater 
regeneration occurring at four weeks of age. The opposite is seen in quadriceps muscles, 
where the bars show the greater average levels of regeneration at nine weeks of age 
(Figure 4.22 C). Although none of these data are statistically significant, there does 
appear to be a trend where there is more regeneration occurring in mdx than in DM.      
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Figure 4.22 
Regeneration in mdx and DM triceps and quadriceps muscles. (A) Areas showing 
concentrated extra-myonuclei hypercellularity associated with regeneration. These 
areas are graphically represented as percentages of total sections’ areas. (B) Bar graph 
showing percentage area of triceps undergoing regeneration at four weeks and nine 
weeks of age. At both stages the level of regeneration is greater in mdx than DM; 
although there is a huge variation seen at four weeks in mdx. At nine weeks the 
difference between regeneration in mdx and DM falls just outside statistical significance, 
with a P value of 0.053578. Both mdx and DM exhibit very similar temporal patterns of 
regeneration with more extensive areas of regeneration seen at four weeks than at nine 
weeks. (C) Bar graph showing percentage area of quadriceps undergoing regeneration 
at four weeks and nine weeks of age. As with triceps muscles, there appears to be more 
regeneration in mdx than DM, although the greater regeneration is shown at nine weeks 
as opposed to four weeks in both mutants. The difference shown between mdx and DM 
was not statistically significant, with a P value of 0.131729. Error bars s.d. n=3 per 
strain. Student’s t-test used.  
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4.2.6.2 - Centrally located myonuclei  
To further access any differences pertaining to the regeneration of muscle tissue in mdx 
and DM mice, muscle fibres with centrally located nuclei and extra-myonuclei were 
counted in mdx and DM triceps muscles. Sections taken from four weeks and nine weeks 
old mice were analysed; three different mice from each strain and age being used for the 
analyses.  
 
At four weeks of age there is no difference observed in the percentage of fibres with 
centrally located nuclei (Figure 4.23 A), with 28 % and 34 % of fibres having centrally 
located nuclei, for mdx and DM respectively. At nine weeks of age there is an increase 
seen in the central nucleation of myofibres, whereby 85 % of mdx and 75 % of DM fibres 
are centrally nucleated (Figure 4.23 A), this equates to an approximate fold increase of 
three and two, for mdx and DM respectively. Although a 10 % difference is shown 
between mdx and DM at nine weeks of age, this difference is not statistically significant, 
with a P value of 0.077256.    
 
4.2.6.3 - Extra-myonuclei in dystrophin-deficient mutants  
Aside from the increased, aggregated cellularity observed in regenerative areas of 
muscle tissue, an increase in the numbers of interstitial cells was seen in mdx and DM 
(Figure 4.23 B). Between 5 % and 10 % of the total cells in WT and cav3-/- triceps at 
four weeks and nine weeks of age are interstitially located, compared to 24 % – 34 % for 
mdx and DM respectively; many of which are located in areas of regeneration. There is 
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no difference in the extra-myonuclei content shown between four weeks and nine weeks 
mdx and DM muscle. 
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Figure 4.23 
Graphical representation of central nucleated myofibres and extra-myonuclei.  
(A) Bar graph showing percentages of centrally located myonuclei in four weeks and 
nine weeks old mdx and DM triceps. Although no real difference can be seen between 
mdx and DM at four weeks, there appears to be a difference at nine weeks; although 
this difference is not statistically significant, with a P value of 0.077256. A greater 
percentage of centrally located nuclei are seen in fibres at nine weeks of age than at 
four weeks of age; n= 3 per strain. (B) Bar graph showing percentages of extra-
myonuclei as percentages of total nuclei in triceps muscles of four weeks and nine 
weeks old WT, mdx, cav3-/- and DM. There are no differences seen in the percentages of 
extra-myonuclei at four weeks and at nine weeks of age. At both ages, there are greater 
percentages of extra-myonuclei seen in mdx and DM, between 24 % and 34 %, when 
compared to WT and cav3-/-, where between 5 % and 10 % of nuclei are interstitially 
located. No statistical significance was shown at four weeks and as only one WT was 
used at nine weeks, statistical analysis could not be applied; n= 3 for four weeks; n=1 
WT, mdx, n=3 cav3-/-, DM for nine weeks. Error bars s.d. Student’s t-test. 
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4.3 – DISCUSSION 
 
The generation of DM and DMhet mice enabled direct comparisons to be made between 
mdx mice with varying levels of caveolin-3 and thus establish a role, if any, that 
caveolin-3 may have in the pathogenesis of the mdx mouse. A line of mice deficient in 
both dystrophin and caveolin-3 had been developed previously by a group researching 
the expression levels of Opn (osteopontin) in dystrophic mice (Hagiwara et al., 2006). 
Although the pathology of the muscles of the different dystrophic models wasn’t 
studied extensively, they did make some observations regarding the 
degeneration/regeneration of tibialis anterior muscles in mdx and DM, or double-
deficient mice, as they were referred to.  
 
4.3.1 – The macroscopic analysis of DM mice 
4.3.1.1 – Mobility and general appearance 
It is known that the malady of the mdx mouse does not impair the mobility of the 
animals in any way and their movement is indistinguishable from that of WT mice; 
Hagiwara’s group reported that the movement of DM mice was akin to mdx, as was 
their lifespan (Dangain and Vrbova, 1984; Tanabe et al., 1986; Hagiwara et al., 2006). 
Although observations pertaining to the mobility of our DM mice concur with that 
which has been previously published, i.e. no impairment, no definitive concurrence or 
disputation can be given regarding their longevity, as our line was not established long 
enough for senescence to occur.  
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4.3.1.2 – Muscle mass 
An increase in muscle mass is a phenotype obvious to anybody who has ever worked 
closely with mdx. This increase, compared to WT controls, has been previously 
documented to be between 9 % and 42 %, dependent on age (Lynch et al., 2001). 
Although there is an increase in the cross-sectional areas of mdx muscles, the force of 
contractions when normalised to areas are no greater than that of WT animals; thus, 
muscle hypertrophy is believed to occur as a compensatory mechanism for the loss of 
contractile force generated by mdx muscles, which is around 20 % lower than that of 
WT (Coulton et al., 1988; Williams et al., 1993; Lynch et al., 2001; Chan et al., 2007). 
There has been uncertainty as to whether the increased muscle size observed in mdx is 
due to muscle hypertrophy or hyperplasia, yet Lynch found a 35 % increase in the 
numbers of fibres in soleus and extensor digitorum longus (EDL) mdx muscles when 
compared to age matched controls, but these data may have included branched fibres 
which have been found to increase with ageing in mdx (Lynch et al., 2001; Chan et al., 
2007). The DM mice generated for this study showed profound muscle hypertrophy, 
even when compared with mdx of similar ages, though their bodyweights were no 
heavier than that of mdx or WT; this is consistent with data pertaining to the 
bodyweights of mdx in relationship to the less muscular WT animals (Tanabe et al., 
1986). Interestingly, the caveolin-3 null mice we used for our work, cav3-/-, did not 
appear to be any less muscular than WT animals, in contrast to the caveolin-3 null mice 
(TgCAV3M1) generated and used by the Sunada group of Japan, which exhibited a 
marked reduction in hindlimbs muscle mass when compared to WT controls (Ohsawa 
et al., 2006). The difference in the generation of these two murine models for LGMD-1C 
being that cav3-/- had the region of DNA encoding the scaffolding and membrane 
 171 
 
spanning domains of exon 2 replaced with a neo cassette, while TgCAV3M1 mice had 
the P104L mutation, shown to result in the human myopathy LGMD-1C, trangenically 
inserted. Whether or not the methods used to generate these two models for LGMD-1C 
resulted in any phenotypic difference regarding the pathogenicity of their myopathies 
is open to debate, but the mode of inheritance for the two models shows that cav3-/- 
mice transmit the disease in a manner associated with a type-2 LGMD, i.e. recessively, 
whereas TgCAV3M1 transmit in the dominant manner of a type-1 LGMD (Minetti et al., 
1998; Hagiwara et al., 2000; Sunada et al., 2001).  
 
The pronounced skeletal muscle hypertrophy exhibited by the DM mice generated for 
this study, could be seen as contradictory to data suggesting that caveolin-3 inhibits 
myostatin signalling, a negative regulator of skeletal muscle mass; a consequence of 
which sees mice lacking caveolin-3 present with atrophied skeletal muscles, which can 
be rescued by myostatin inhibition (McPherron et al., 1997; Ohsawa et al., 2006). The 
effects of increased myostatin signalling on the muscle mass of DM mice, assuming data 
presented by Ohsawa et al. to be correct, appears to be of no consequence, the only 
variable being the absence of dystrophin. This suggests that dystrophin or any one of 
the proteins of the DGC, may be required by myostatin to optimally convey its signal, or 
required for Mstn be optimally expressed. Another reason for the observed 
hypertrophy could be due to an increase in the growth factor Igf1, which unlike Igf2 is 
not affected by the upregulation of Mstn and has been shown to be upregulated in 
regenerating mdx muscle fibres, having a hypertrophic effect on skeletal muscle mass 
(De Lucca et al., 1999; Lalani et al., 2000; Miyake et al., 2010; Shavlakadze et al., 2010). 
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Whatever the reason for the observed muscle hypertrophy of DM mice, it is beyond the 
scope of this project, but may provide the basis for some interesting future work.      
 
4.3.1.3 – Fat deposition  
Although fat deposition has not been studied in murine models of MD, observed 
differences between mdx, cav3-/- and DM mice regarding subcutaneous levels of fat 
warrant a brief mention. Fat deposition of nine month old cav3-/- mice used in this 
study was by far in excess to that of WT, mdx and DM mice of similar ages. These 
observations are consistent with a study that found cav3-/- mice developed insulin 
resistance in their skeletal muscles; they concluded that caveolin-3, unlike other 
caveolins which are signal suppressors, enhances insulin signalling (Hulit et al., 2000; 
Oshikawa et al., 2004; Rodriguez et al., 2009). Insulin resistance invariable results in an 
increase in adipogenesis and consequently, increases in fat deposition (reviewed in 
(Holland et al., 2007)). One possible explanation for the leaner somatotypes of DMs 
over that of cav3-/- mice, is the signalling of Igf1 through insulin receptors (IR); though 
not its cognate receptor, Igf1 can bind to and convey a signal via the IR (Gauguin et al., 
2007). This hypothesis is backed up in that DM mice are not as lean as their mdx 
counterparts; who have increased Igf1 expression and by virtue of increased levels of 
caveolin-3, (possibly) have enhanced insulin signalling also.       
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4.3.2 – Muscle regeneration in DM mice     
4.3.2.1 – Cell infiltration into regenerating areas 
During the initial stages of muscle regeneration in mdx mouse there is an infiltration of 
various cell types, including resident satellite cells and extravasated leukocytes, into 
the regenerating areas; a process that begins with the apoptosis of muscle fibres 
(Carnwath and Shotton, 1987; Smith et al., 1995; Tidball et al., 1995). When sections of 
muscles are stained with haematoxylin, these infiltrated hypercellular areas appear 
blue/purple in colour and due to the concentrated numbers of cells, are easily 
identified as areas of regeneration. Muscle regeneration is invariably preceded by 
muscle degeneration, thus an area of regeneration conversely, is representative of an 
area of degeneration. It has been well documented that episodes or ‘bouts’ of 
degeneration followed by regeneration begin at around three weeks of age and 
continue until around twelve weeks of age, at which point they occur less frequently; 
maximal regenerative activity occurs around eight weeks of age when many 
regeneration associated genes also peak (Bullfield et al., 1984; Tanabe et al., 1986; 
Porter et al., 2004; Turk et al., 2005). It should be noted however that three weeks of 
age signals the onset of the dystrophic condition regarding observable 
degeneration/regeneration, as phenotypic differences in dystrophic embryos when 
compared to WT have been presented in this study (Chapter 3) and previously 
(Merrick et al., 2007; Merrick et al., 2009).  
 
Cell infiltration and therefore regeneration observed in DMs during this study were 
akin to that of mdx at the three ages studied, i.e. four weeks, nine weeks and nine 
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months, at which point hypercellularity was only observable (with the exception of two 
quadriceps sections, mdx and DM) at higher magnification. This observation is 
consistent with that of Hagiwara’s group, who concluded there were no differences in 
the patterns of degeneration and regeneration between  their double-deficient mice 
and mdx (Hagiwara et al., 2006). As there was an absence of any areas of gross 
regeneration at four weeks in DMhet it would be easy to grasp at this as a real piece of 
data. However, as only one DMhet was available at this age, it would not be prudent to 
view this as a phenotypic difference, as higher magnification images showed that there 
were indeed areas that were regenerating and areas that had regenerated as the 
presence of centrally located nuclei attested to. When hypercellular areas were 
quantified, there appeared to be a trend (P value of 0.053578 for nine weeks triceps) 
suggesting a greater level of regeneration in mdx than in DM, this was consistent for 
four weeks and nine weeks of age in both muscles analysed. Given a greater sample 
size, this difference may well have been significant and as such would have fitted in 
with data regarding the increased expression levels of Opn (osteopontin) in mdx. Opn 
has been shown to be secreted by many cell types, including macrophages where it may 
have chemotactic properties, attracting inflammatory cells to areas of muscle 
degeneration (Weber et al., 1996; Barbosa-Souza et al., 2011). It has been shown that 
muscle fibres of mdx, express greater levels of Opn than do those of DM; this would 
affect the numbers of mononuclear cells infiltrating areas of degeneration, i.e. there 
would be more infiltration in mdx muscles (Hagiwara et al., 2006). Independent studies 
regarding OPN expression in DMD muscle have shown increases of 46 fold and 146 
fold; another study showed that in WT mouse TA muscle, an increase of 118 fold, 48 
hours following cardiotoxin induced injury was observed (Haslett et al., 2002; Porter et 
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al., 2002; Hirata et al., 2003). DMD subjects using the anti-inflammatory drug 
prednisolone exhibited no increase in the expression of OPN ('t Hoen et al., 2011).      
 
4.3.2.2 – Centrally nucleated fibres are more prevalent in mdx 
The central positioning of nuclei in regenerating mdx muscle fibres persists with the 
fibres’ maturity and thus centronucleation can be used as a cumulative index for 
muscle regeneration, although the validity of its use has been disputed (Karpati et al., 
1988; Williams et al., 1993; Totsuka et al., 1998). Centronucleation in mdx mouse has 
been well documented and re-confirmed by those generating various mdx crosses 
(Bullfield et al., 1984; Tanabe et al., 1986; Carnwath and Shotton, 1987; Deconinck et 
al., 1997; Hagiwara et al., 2006). It has been shown that centrally nucleated fibres are 
more resistant to mechanical stress than mdx fibres with peripherally located 
myonuclei, suggesting centronucleation occurs as a compensatory mechanism in 
dystrophic muscle fibres, although there are no differences in the contractile properties 
of the two (Williams et al., 1993; Narita and Yorifuji, 1999). 
 
The progressive increase of centrally nucleated fibres shown in mdx and DM mice used 
in this study is typical of what has been shown historically. With 85 % of mdx fibres and 
75 % of DM fibres centronucleated at nine weeks, these figures concur with previously 
published data that showed 80 % of mdx fibres at 60 days of age had centrally located 
nuclei (Karpati et al., 1988). Although not statistically significant, with a P value of 
0.077256 using a sample size of n=3, the 10 % increase shown in centronucleated mdx 
fibres over those of DM, could be an important observation regarding the involvement 
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of caveolin-3 in dystrophin-deficient muscle regeneration. When taken together with 
data pertaining to cell infiltration into regenerating areas (section 4.3.2.1), the 
increased centronucleation seen in mdx suggests a greater occurrence of regeneration 
and therefore preliminary degeneration in dystrophin-deficient muscle in the presence 
of caveolin-3.  
An elevation in muscle fibre degeneration in mdx may be caused by an increased 
autoimmune response due to the supraphysiological levels of caveolin-3 present. 
Caveolin-1 has 65 % identity and 85 % similarity to caveolin-3 and has been shown to 
play a role in the activation of CD26+ T-cells through their interaction with the lipid 
rafts of caveolae; moreover, satellite cells have been shown to express Cav-1 (Smart et 
al., 1999; Ishii et al., 2001; Volonte et al., 2005; Ohnuma et al., 2006). It could be 
postulated that the increased levels of caveolin-3 and caveolae in mdx muscle along 
with an abundance of caveolin-1+ve satellite cells , at a time when an infiltration of 
leukocytes are prevalent, provide an abundance of lipid rafts with which to interact, 
thus prolonging the regenerative process. It has also been shown that HLA class I 
antigens, though usually absent from muscle fibres, are expressed on muscle fibres of 
DMD, targeting them for destruction by cytotoxic T-lymphocytes, it has been suggested 
that this may exacerbate the dystrophic condition  (Arahata and Engel, 1984; 
Appleyard et al., 1985). When the chemotactic properties of osteopontin, which is 
increased in mdx when compared to DM, is taken together with the interaction of 
CD26+ T-cells with caveolin of lipid rafts and data presented in this study regarding the 
observed increases in regeneration and centronucleation, it could be suggested that the 
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increased levels of caveolin-3 in mdx muscle may impede regeneration through an 
increased and prolonged inflammatory response.   
 
4.3.3 – The histopathogenesis of respiratory muscles in dystrophin-deficient 
mutants 
Perhaps the most important muscles in terms of the pathology of mdx are the 
respiratory muscles. It is the degeneration of the intercostals and diaphragm and the 
resultant respiratory failure that is the main cause of death for DMD patients (Calvert 
et al., 2006). There have been conflicting reports as to whether the dystrophic 
condition of the diaphragm precedes or begins contemporaneously with that of the 
limbs, where unlike muscles of the limbs, degenerated fibres are replaced with fibrous 
connective tissue; this results in a collagen content that is ten times greater than in that 
of the limbs (Stedman et al., 1991; Deconinck et al., 1997).  
 
The severely reduced intercostals muscle fibre density that was shown in late gestation 
embryos of DMhet mice and to a lesser degree in mdx (Chapter 3), was not evident in 
adult animals. The sections obtained from the intercostals of most of the mouse strains 
were of insufficient quality to enable accurate analyses to be performed, but those that 
were obtained appeared to be similar in all three of the dystrophin-deficient mutants.  
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4.3.4 - Muscle fibre calibre variations in dystrophin-deficient mutants 
Regenerated mdx muscle-tissue invariable consists of fibres of varying sizes, which may 
or may not be centronucleated (Bullfield et al., 1984; Tanabe et al., 1986). As previously 
mentioned (section 4.3.1.2), mdx muscles are larger but their overall contractile force 
is no different to that of WT muscles (Coulton et al., 1988; Williams et al., 1993; Lynch 
et al., 2001). It has also been shown that the contractile properties of individual mdx 
fibres when compared to WT fibres are surprisingly similar, with a statistically 
significant reduction seen only in the fibres of soleus muscles, these experiments were 
performed on single unbranched fibres and fibre-branching has been shown to reduce 
the force of contractions (Williams et al., 1993; Chan et al., 2007).  
 
The DM and DMhet mice showed the same heterogeneity of fibre sizes that have been 
previously reported with mdx and mdx crosses (Bullfield et al., 1984; Tanabe et al., 
1986; Deconinck et al., 1997; Anderson et al., 2006). However, the absence of caveolin-
3 in DM muscle resulted in a 14 % increase above that of mdx in fibres with calibres 
above 60 μm and a four-fold increase in fibres with calibres over 100 μm in diameter; 
the differences in DMhet were more subtle. It has been suggested that fibres with 
calibres of less than 20 μm are not subject to necrosis as are larger fibres (based on the 
centronuclear index) and this could be the reason for the small calibre fibres seen in 
mdx and other dystrophic myopathies; it has also been shown that although most 
regenerated fibres have larger diameters than non-regenerated fibres, they are not 
prone to repeated bouts of necrosis (Karpati et al., 1988; Massa et al., 1997). The data 
presented in this study showed the proportions of small calibre fibres were 11.7 %, 7.2 
% and 11 % and for fibres above 100 μm, 1 %, 4.1 % and 1.7 % for mdx, DM and DMhet 
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respectively; it also showed a correlation between caveolin-3 levels and fibre-size in 
the absence of dystrophin, whereby a reduction of caveolin-3 results in an increase in 
the percentages of large fibres and a reduction in the percentage of small fibres. 
A recent paper showed that caveolae act as stress sinks to buffer membrane tension 
caused by mechanical stresses, when membrane tension increased, the caveolae would 
disassemble to effectively increase the surface area of the membrane and relieve 
tension. In cells which were deficient in caveolin and thus caveolae, there was no 
buffering and as a consequence, their membranes were ruptured (Sinha et al., 2011). 
The upregulation of caveolin-3 in mdx muscle fits in with this model rather well, as it 
has been shown that the lack of dystrophin in contracting mdx muscle results in 
sarcolemmal ruptures that are directly proportionate to the magnitude of the applied 
stress (Petrof et al., 1993). The increased caveolae would help to buffer this stress to 
some extent. The DM mice do not have the luxury of the buffering system afforded by 
caveolae, so they may compensate by growing larger muscles. Larger muscle fibres are 
less likely to have sarcolemmal ruptures than smaller calibre fibres as they are capable 
of more forceful contractions and therefore increased workloads. The intermediate 
fibre size of the DMhet adds validity to this hypothesis. The extreme hypertrophic 
phenotype of the DM could also be attributed to an increased fusion of myoblasts 
during the regenerative process as it has been shown that in myoblasts deficient in 
caveolin-3 there is an increase in myotube fusion, conversely in the same report it was 
shown that myoblasts that overexpressed Cav3 showed a reduction in myotube fusion 
(Volonte et al., 2003).  
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Whatever the reason for the differences observed, it is beyond the scope of this report 
to elucidate. But the data collected herein suggests that caveolin-3 has a role in 
determining sizes of regenerated fibres in dystrophin-deficient muscle and may in fact 
exacerbate the inflammatory response in leukocyte infiltrated regenerating 
dystrophin-deficient muscle tissue.      
Table 4.1 – Summary of results. The four dystrophic mouse strains along with the 
most significant results are summarised. All results are compared with WT, therefore – 
denotes < WT; +- denotes =WT; + denotes >WT; n/d denotes no data.    
 
Mouse 
strain 
Caveolin-3 
protein 
Muscle  
mass 
Sub-cut. 
adiposity 
Fibre  
size 
Central 
nuclei 
mdx + + - ++ 85 % 
cav3-/- 0 +- ++ + n/d 
DMhet +- n/d n/d +++ n/d 
DM 0 ++ + ++++ 75 % 
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CHAPTER 5 - CONCLUSIONS AND FUTURE WORK 
 
5.1 - Conclusions 
5.1.1 - Caveolin-3 in embryonic myogenesis 
Although the increased caveolin-3 protein in DMD and the mouse model of the disease, 
mdx has been known of for more than a decade, there has been very little research into 
how this may affect the pathogenesis observed in these dystrophinopathies (Vaghy et 
al., 1998; Repetto et al., 1999). The data presented in this thesis has shown that in the 
skeletal muscles of the developing mdx embryo the affect of reduced levels of caveolin-
3 is profound. The global attrition of pax7+ve cells in DMhet embryos, when taken with 
the more severe reduction of intercostals muscles fibre-density, strongly suggests the 
increased protein levels of caveolin-3 in mdx may occur as a compensatory mechanism 
in the absence of dystrophin, which may help ameliorate the dystrophic condition of 
mdx. This appears to contradict data which showed transgenic mice that overexpress 
Cav3 have a more severe DMD-like phenotype than mdx, although this particular study 
was conducted using adult mice (Galbiati et al., 2000). This implied that it was the 
increase in caveolin-3 rather than the deficiency in dystrophin that was the primary 
cause of the pathogenesis observed in dystrophin-deficient muscle.  
 
5.1.2 – Caveolin-3 in adult myoregeneration 
However, the contradiction leans towards concurrence with the pathogenesis of adult 
muscle tissue. Based on the initial gross histological analysis of both triceps and 
quadriceps muscles, whether caveolin-3 is increased compared to WT, as in mdx; at WT 
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levels, as in DMhet; or completely absent, as in DM; the histopathogenesis of 
dystrophin-deficient muscles it seems is neither exacerbated nor ameliorated to a 
statistically significant extent. The quantitative data, although not significant, did show 
a trend in that there was a greater level of regeneration, assessed by the area of tissue 
with aggregated hypercellularity and centronucleated fibres, in mdx muscles. This 
suggests that the increased levels of caveolin-3 do in fact contribute slightly to the 
dystrophic phenotype of mdx. As discussed in chapter 4, this could be due to an 
increased inflammatory response.         
 
5.1.3 – Heterogeneity of muscle fibre calibres 
The greater variation in the sizes of muscle fibres shown in DM muscle would suggest 
that caveolin-3 has a role in the regulation of muscle fibre calibre size. However, as all 
three dystrophin-deficient mice present with the same phenotype and all have different 
levels of caveolin-3, it is very difficult to draw any conclusions. There was a correlation 
between caveolin-3 levels and fibre-size in that a decrease in caveolin-3 was 
accompanied by an increase in fibre sizes. As mentioned in the discussion of chapter 4, 
this does support Volonte’s paper which showed caveolin-3 deficient myoblasts 
exhibited an increase in fusion, the bouts of regeneration and lack of dystrophin would 
possibly disrupt the process somewhat but the correlation is seen in the three 
dystrophin-deficient mutants (Volonte et al., 2003).   
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5.2 - Future work 
The following section briefly describes work that would have been conducted if given 
considerably more time.   
 
The late acquisition of DM mice did not allow for the analysis of DM embryos, so the 
effect of a caveolin-3 deficiency in dystrophin-deficient embryonic muscle 
unfortunately could not be ascertained. This is an area of work that if given 
considerably more time I would have pursued.    
With the DM line established during the final six months of the project, the sample sizes 
available were limited. The quantitative data shows that several analyses were just 
outside of statistical significance; given more samples these data would more than 
likely have been significant. In the samples that were analysed there were great 
degrees of variation regarding regenerating areas exhibited by all of the dystrophin-
deficient mutants. A fixed section of muscle tissue is merely a snapshot of what was 
occurring in a microscopic area of muscle at a precise time-point. The same muscle, if 
cut just a couple of millimetres further up or down could produce an entirely different 
set of results. The only way to be sure of any slight difference there may be would be to 
section entire muscles, from insertions to origins, of at least ten different mice of each 
dystrophin-deficient mutant. Although very onerous and time consuming, the data 
generated would be robust.  
I find it extremely difficult to believe that the increased levels of caveolin-3 in mdx 
mouse have no functional purpose, particularly in light of recent data regarding 
caveolae as plasmalemma stress reservoirs (Sinha et al., 2011). Given time I would 
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have generated exercised induce muscle damage on all dystrophin-deficient strains 
along with WT controls. Downhill treadmill running would be employed to induce a 
greater degree of muscle damage and repeated grip strength tests would be performed 
too as a form of anaerobic eccentric exercise and to evaluate muscle strength. 
Following injections with Evans blue dye, muscles would be eventually excised and 
histologically examined. 
Finally, it would be worth establishing a DM cell line derived from muscle explants, in 
vitro experiments could be performed and cell signalling pathways elucidated in a 
dystrophin and caveolin-3 deficient cell-line.  
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APPENDICES 
 
APPENDIX 1 – Suppliers of Chemicals and Equipment 
 
Alta Biosciences (Building Y10, University of Birmingham, Edgbaston, 
Birmingham, B15 2TT, UK).  
Primers: 
CAV3: F (D72502DL) – 5’ ATT-CCT-GTT-CGC-CTG-TAT-C- 3’ R (D72501DL) – 5’ AGG-
ACC-AAC-CGA-ATC-TTC-TG- 3’ 
Dystrophin mdx: F (D71047DL) – 5’ CTT-CTG-TGA-TGT-GAG-GAC-ATA- 3’ R 
(D71048DL) – 5’ CTA-GCT-TTT-GGC-AGC-TTT-CC- 3’ 
NEO: F – 5’ GCA-CGC-AGG-TTC-TCC-GGC- 3’ R – 5’ GTC CTG ATA GCG GTC CGC C- 3’  
SRY: F (D64053DL) – 5’ TCT–TAA–ACT–CTG–AAG–AAG–AGA-C- 3’ R (D64054DL) – 5’ 
GTC-TTG-CCT-GTA-TGT-GAT-GG- 3’  
 
Applied Biosystems (Life Technologies Corporation (Headquarters), 5791 Van 
Allen Way, PO Box 6482, Carlsbad, California 92008, USA). 
Capillary Sequencer ABI 3730 
Sequence Scanner Software v1.0 
 
BD Biosciences (Edmund Halley Road - Oxford Science Park, Oxford, OX4 4DQ) 
50 mL Falcon tubes (Cat. No. 352070) 
 
BDH 
Eosin Yellowish (Cat. No. 341972Q) 
Sodium Hydroxide Pearl (Cat. No. 104384F) 
 
Bibby Scientific Limited, Beacon Road, Stone, Staffordshire ST15 0SA, UK 
Digital block heater (Cat. No. SBH200D) 
Techne DB-2A Dri-Block Heater (Cat. No. FDB02AD) 
 
BioLine Ltd (Unit 16, The Edge Business Centre, Humber Road, London, NW2 
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6EW, UK) 
Agarose Molecular Grade (Cat. No. BIO-41025) 
 
 
Bio-Rad Laboratories Ltd (Bio-Rad House,  
Maxted Road, Hemel Hempstead, Hertfordshire, HP2 7DX, UK) 
Mini Protean II Electrophoresis Cell (Cat No. 165-3301) 
Mini Trans-blot blotting Cell (Cat No. 170-3930) 
 
Carl Zeiss Ltd. (15-20 Woodfield Road, Welwyn Garden City, Hertfordshire, AL7 
1JQ, UK) 
Stemi 1000 dissecting microscope 
 
Dako UK Ltd (Cambridge House, St Thomas Place, Ely, Cambridgeshire, CB7 4EX, 
UK) 
DAB Chromogen (Cat. No. S3000) 
 
Developmental Studies Hybridoma Bank (University of Iowa, Department of 
Biology, 028 Biology Building East, Iowa City, Iowa, 52242-1324, USA) 
Mouse monoclonal anti-pax7 antibody 
Mouse monoclonal anti-pan myosin antibody (MF20) 
 
DJB Labcare Ltd. (20 Howard Way, Interchange Business Park, Newport Pagnell, 
Buckinghamshire, MK16 9QS, UK.) 
Hettich Mikro 20 centrifuge 
 
Eppendorf UK Ltd (Endurance House, Chivers Way, Histon, Cambridge, CB24 9ZR, 
UK) 
Centrifuge (Cat. No. 5415 C) 
 
Fisher Scientific UK Ltd (Bishop Meadow Road, Loughborough, Leicestershire, 
LE11 5RG, UK) 
Boric acid (Cat. No. B/3800/53) 
Chloroform (Cat. No. C/0354/17) 
Diaminoethanetetra-acetic acid disodium salt (Cat. No. D/0700/53) 
Ethanol, absolute (Cat. No. E/0650DF/17) 
Glacial acetic acid (Cat. No. A/0360/PB17) 
Glycine (Cat. No. G/P460/53) 
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Hydrochloric acid (Cat. No. 101252F) 
Methanol (Cat. No. M/4000/17) 
Propan-2-ol (Cat. No. P/7490/17) 
Shandon Histoplast paraffin wax (Cat. No. SD6774006) 
Sodium Chloride (Cat. No. S/3160/53) 
Sodium dodecyl sulphate (Cat. No. S/5200/53) 
Stirring hotplate (Cat. No. 11-503-50SH) 
Tri-Sodium Citrate (Cat. No. S/3320/53) 
TRIS (hydroxylmethyl methylamine; Cat. No. T/P630/53) 
Xylene, (Cat. No. X/0250/17) 
 
GE Healthcare UK Ltd (Amersham Place, Little Chalfont, Buckinghamshire HP7 
9NA, UK) 
Amersham™ Hybond™ - ECL Nitrocellulose membrane. (Cat. No. RPN203D) 
Goat-anti-mouse IgG biotinylated whole antibody (Cat. No. RPN1177V1) 
 
Geneflow Ltd (Fradley Business Centre, WoodEnd Lane, Fradley, Staffordshire, 
WS13 8NF, UK) 
Protogel, 30% Acrylamide, 0.8% (w/v) Bis-Acrylamide Stock Solution (37.5:1)  
 
Gilson Inc. (3000 Parmenter Street, P.O. Box 620027, Middleton, WI 53562-0027, 
USA) 
Pipette tips 
 
Grants Instruments (Cambridge) Ltd, UK (29 Station Road, Shepreth, 
Cambridgeshire, SG8 6GB, UK) 
Water bath 
 
 
 
Jenkons Scientific Ltd. (Cherrycourt Way, Stanbridge Road, Leighton Buzzard, 
Bedfordshire, LU7 4UA, UK) 
U-1800 Spectrophotometer, DigLab, Hitachi 
 
Kendro Laboratory Products Plc (Stortford Hall Park, Bishop’s Stortford, 
Hertfordshire, CM23 5GZ, UK) 
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Heraeus Incubator  
 
Leica Microsystems Ltd, UK (Davy Avenue, Knowlhill, Milton Keynes, MK5 8LB, 
UK) 
Inverted microscope - Leica DMIRB 
1150/Autocut Microtome 
 
Premier International Foods (UK) Ltd (Bridge Road, Long Sutton, Spalding, Lincs, 
PE12 9EQ, UK) 
Marvel dried skimmed milk  
Merck (Boulevard Industrial Park, Padge Road, Beeston, Nottingham, NG9 2JR)  
Haematoxylin solution modified acc. To Gill III (Cat. No. 1.05174.0500) 
 
Molecular Devices Ltd. (135 Wharfedale Road, Winnersh Triangle, Winersh, 
Wokingham, RG41 5RB, UK) 
Emax microplate reader 
 
Nikon UK Ltd (380 Richmond Road, Kingston Upon Thames, Surrey, KT2 5PR, UK) 
Nikon Eclipse E600 Microscope 
 
 
Novocastra Laboratories Ltd (Balliol Business Park West, Benton Lane, Newcastle 
upon Tyne, NE12 8EW, UK) 
Anti-developmental Myosin Antibody (Cat. No. NCL-MHCd) 
 
Nunc Plasticware (Life Technologies Ltd, 3 Fountain Drive, Ichinnan Business 
Park, Paisley, PA4 9RF, UK) 
96-well plates (Cat No. 167008A) 
Petri-dishes 
 
Panasonic UK Ltd. (Panasonic House, Willoughby Road, Bracknell, Berkshire, 
RG12 8FP, UK) 
Microwave oven 
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Pechiney Plastic Packaging (Menasha, WI 549252, USA) 
Parafilm, laboratory Film (PM-996) 
 
Perkin Elmer (Saxon Way Bar Hill, Cambridge, Cambridgeshire, CB23 8SL, UK)  
Biotinyl Tyramide solution plus amplification diluent (Cat. No. SAT700001EA) 
Streptavidin-HRP (Cat. No. NEL 750001EA)  
 
Pierce (Perbio Sciences UK Ltd, Century House, High Street, Tattenhall, Cheshire, 
CH3 9RJ, UK) 
Albumin Standard Ampules (Cat. No. 23209) 
Coomassie® Protein Assay Reagent (Cat. No. 1856209) 
Supersignal® West Pico Chemiluminescent substrate kit (Cat. No. 34080) 
 
Polysciences Inc. (Park Scientific Ltd., 24 Low Farm Place, Moulton Park, GB-NN3 
6HY, Northampton, UK) 
Peel-A-Way® Disposable Embedding Molds (Cat. No. 18646A-1) 
 
Reichert-Jung (Germany) 
1150/Autocut microtome 
 
Roche Diagnostic Ltd (Charles Avenue, Burgess Hill, RH15 9RY, UK) 
Complete mini Protease Inhibitor Cocktail tablets (Cat. No. 11836153001) 
 
Santa Cruz Biotechnology, Inc (Bergheimer Str. 89-2 69115, Heidelberg, 
Germany) 
Anti-rabbit IgG-HRP (Cat no. sc-2004; Lot No. K159) 
Goat anti-mouse IgG-HRP (Cat No. sc-2005; Lot No. J1802) 
 
Sigma-Aldrich (Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BD12 
4QH, UK) 
Anti-fast skeletal Myosin primary antibody (Cat No. M-4276; Clone MY-32)) 
Anti-tubulin primary antibody (Cat No. T9026) 
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Ammonium Persulfate (APS) (Cat No. A3678; Lot No. 022K1258) 
Bromphenol Blue (3’,3”,5’,5” Tetrabromophenolsulfonephthalein) (Cat No. B-5525; Lot 
No. 47H3638) 
Deoxycolic Acid (Cat No. D-6750; Lot No. 110K0192) 
Diaminoethanetetra-acetic acid disodium salt (Cat No. D/0700/53; Lot No. 0113456) 
Dimethyl Sulfoxide (DMSO) (Cat. No. D2650) 
Ethidium Bromide (E-1510) 
Hydrogen Peroxide 30 wt.% sol. In water (Cat. No. H1009) 
Paraformaldehyde (Cat No. EC-890; Lot No. 10-02-29) 
Potassium Chloride KCl (Cat No. P9333; Lot No. 7447407) 
SDS Sample buffer , Laemmli (Cat No. S-3401; Lot No. 20K9342) 
0.0075 M Potassium Chloride (KCl) solution (Cat No. P9327; Lot No. 22K2424) 
TEMED (Cat No. T-9281; Lot No. 38H0438) 
Tween® 20 (Cat. No. P7949) 
 
Sony (Pipersway, Thatcham, Berkshire RG19 4LZ, UK) 
Gel imaging camera, video graphic printer (UP-860LE) 
 
Stuart Scientific Co Ltd (Holmethorpe Industrial Estate, Redhill, Surrey RH1 2NB, 
UK) 
Gyro-Rocker® Shaker (STR9) 
Hybridisation oven/shaker S12OH 
 
Swann-Morton Ltd, UK (Owlerton Green, Sheffield, S6 2BJ, UK) 
Sterile Scalpels. 
 
Tefal (PO Box 467; Slough PDO, Berkshire SL3 8WD, UK) 
‘Kwisto’ Pressure cooker 
 
Terumo UK Ltd. (3 Unily Grove, Off School Lane, Knowsley Industrials Park, 
Knowsley, Merseyside, L34 9GI, UK) 
18 gauge needles (Cat No. NN-1838R) 
 
Upstate Biotechnology Incorporated (199 Saranac Avenue, Lake Placid, New 
York, 12946, USA) 
Anti-Igf2 IgG1. Mouse Monoclonal. (Cat Number 05-166; Lot No. 05166) 
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Vector Laboratories Ltd (3 Accent Park, Blakewell Road, Orton Southgate, 
Peterborough, PE2 6XS, UK) 
ImmEdge Hydrophobic Barrier Pen™ (Cat. No. H-4000) 
 
VWR International (Merk Ltd, Hunter Boulevard, Magna Park, Lutterworth, Leics, 
LE17 4XN, UK) 
Depex Mounting medium ‘Gurr’ (Cat No. 361252B; Lot No. OB327384) 
Eosin (Cat No. 341972Q; Lot No. K28531926205) 
Glass Coverslips 22 x 64 mm (Cat No. 406/0188/52) 
Glass Homogeniser (1-5 ml; Cat No. 409/1435/09) 
Paramat, wax (Cat No. 36/144V; Lot No. 114080) 
Sodium Hypochlorite Solution (Cat. No. 301696S) 
Sodium dodecyl sulphate (Cat No. S/5200/53; Batch No. 0398855) 
Superfrost Plus Microscope Slides (Cat No. 406/0179/00) 
X-Ograph Imaging Systems Ltd (Xograph House, Hampton Street, Tetbury, 
Gloucestershire, GL8 8LD, UK) 
X-Ograph X2 machine 
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CHEMICAL SOLUTIONS 
 
 
4% Paraformaldehyde (PFA) 
4 g Paraformaldehyde (Sigma-Aldrich, UK) – weigh with care, wearing a facemask 
100 ml PBS (see above) 
Heated to 70˚C, in a fumehood, to allow powder to go in to solution, ensuring 
temperature did not go above 70˚C, as PFA is explosive at high temperatures. 
 
0.5 M EDTA 
16.4 g EDTA (Fisher Scientific Ltd, UK) 
100 ml dH2O 
pH 7.5 with concentrated HCl (Fisher Scientific Ltd, UK) 
 
Immunohistochemistry (IHC)  
Sodium Citrate Buffer 
4.7 g Sodium Citrate (Fisher Scientific Ltd, UK) 
1.6 L dH2O 
pH 6 with Conc HCl (Fisher Scientific Ltd, UK) 
 
Washing Buffer (PBS + 0.05%Tween20) 
2 l PBS (See above) 
1 ml Tween20 (Sigma-Aldrich, UK) 
 
TNB 
0.61 g TRIS (Fisher Scientific Ltd, UK) in 100 ml dH2O, pH 7.5 
0.44 g NaCl (Fisher Scientific Ltd, UK) 
0.25 g Blocking Reagent (TSA Kit, PerkinElmer Life Sciences) 
 
DAB 
1 x 10 mg DAB tablet (DAKO, UK) 
10 ml PBS (See above) 
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Allowed to dissolve (on ice). 
(All work involving DAB was carried out in the confines of a tray covered in aluminium 
foil. Two pairs of gloves were worn at all times. Anything that came in contact with DAB 
(i.e. pipette tip) was placed in bleach overnight.  After overnight exposure to bleach at 
room temperature, the DAB was safe and was flushed down the sink with copious 
amounts of water (half life of DAB in solution at RT is <20 minutes). The content of the 
tray was then autoclaved). 
 
Scott’s Water 
50 μl 10 M Sodium Hydroxide (Fisher Scientific, UK) 
400 ml tap water 
 
Acid-Alcohol 
400 ml 70 % Ethanol (Fisher Scientific, UK) 
2 ml concentrated HCl (Fisher Scientific, UK) 
 
Protein Extraction and blotting 
Lysis Buffer (850 μl) and Protease inhibitors (150 μl) (RIPA Buffer) 
Lysis Buffer (store at 4˚C for 2-3 months) 
50 mM Tris (Fisher Scientific, UK) 
150 mM NaCl (Fisher Scientific, UK) 
1% Nonide-P40 (Roche Diagnostic Ltd, UK) 
0.5% deoxycolic acid (Sigma Aldrich, UK 
Made up to 100 ml with sterile dH2O 
Protease Inhibitors (store at -20˚C for 2-3 months) 
1 protease inhibitor tablet (Roche Diagnostic Ltd, UK) 
1.5 ml sterile H2O 
 
Running Buffer 
3 g TRIS (Fisher Scientific Ltd, UK) 
14.42 Glycine (Fisher Scientific Ltd, UK) 
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1 g SDS (Fisher Scientific Ltd, UK) 
Made up to 1 litre with dH2O 
 
Transfer Buffer 
3.03 g TRIS (Fisher Scientific Ltd, UK) 
14.4 g Glycine (Fisher Scientific Ltd, UK) 
200ml Methanol (Fisher Scientific Ltd, UK) 
Made up to 1 litre with dH2O 
pH to 8.5 with Conc HCl (Fisher Scientific Ltd, UK) 
 
1.5 M TRIS-HCl 
18.17 g TRIS (Fisher Scientific Ltd, UK) 
Made to 100 ml with dH2O 
pH to 8.8 with concentrated HCl (Fisher Scientific Ltd, UK) 
 
0.5 M TRIS-HCl 
6.05 g TRIS (Fisher Scientific Ltd, UK) 
Made up to100 ml with dH2O 
pH to 6.8 with concentrated HCl (Fisher Scientific Ltd, UK) 
 
10% SDS 
10 g SDSMade up to100 ml with dH2O 
 
10X TBS 
24.2 g TRIS 
80 g NaCl 
Made up to100 ml with dH2O 
pH to 7.6 with Conc HCl (Fisher Scientific Ltd, UK) 
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Blocking Buffer 
15 ml 10X TBS (see above) 
135 ml dH2O 
7.5 g non-fat dry milk (Marvel, UK) 
0.15 ml Tween20 (Sigma-Aldrich, UK) 
 
Stripping Buffer 
7.5 g Glycine (Fisher Scientific Ltd, UK) 
Made up to 1 litre with dH2O 
pH to 2.5 with Conc HCl (Fisher Scientific Ltd, UK) 
 
Wash Buffer (TBS/T) 
100 ml 10X TBS (see above) 
900 ml dH2O 
1 ml Tween20 (Sigma-Aldrich, UK) 
 
Primary Antibody Dilution Buffer 
2 ml 10X TBS 
18 ml dH2O 
1 g BSA (Sigma-Aldrich, UK) 
20 μl Tween20 (Sigma-Aldrich, UK) 
 
6X loading buffer 
30% glycerol (Sigma-Aldrich, UK) 
0.25 % Xylene cyanole (Sigma-Aldrich, UK) 
0.25 % Bromphenol blue (Sigma-Aldrich, UK) 
 
 
 
